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ABSTRACT
Immunotherapy is a complementary or alternative approach to current 
treatment strategies for cancer. The clinical goal of tumour immunotherapy is to elicit 
either active or passive immunity directed against tumour antigens by harnessing the 
immune system to target tumours and thereby break tolerance and improve survival 
and quality of life of cancer patients. There is a need to identify and target clinically 
relevant antigens for immunotherapy which could be used to treat a greater proportion 
of cancer patients. We studied the immunotherapeutic potential of EN2, HOXAl and 
H0XB13 (members of the HOX family) as vaccine targets in this project.
Homeodomain-containing proteins (HOX) are transcription factors that 
regulate the co-ordinated expression of multiple genes involved in development, 
differentiation and malignant transformation. Immunohistochemical studies on high- 
density melanoma, breast and ovarian cancer tissue arrays (to assess EN2, HOXAl 
and H0XB13 expression respectively) showed a large proportion of cancer cores 
over-expressing these antigens compared to normal tissues. Moreover, the 
autoantibody response to these antigens was examined in cancer patients using ELISA 
assays. Further to this, we used a reverse immunology strategy to identify several 
immunogenic HLA-A2 restricted EN2, HOXAl and H0XB13 epitopes which were 
observed to generate peptide specific immune responses in the majority of donors 
tested. This was done by repeated peptide stimulation of PBMC from healthy donors 
and screening against T2 cells loaded with or without the relevant peptide in IFN-y 
ELISPOT assays. Alongside this, HOXAl-specific T cells were tested against breast 
cancer cell lines, suggesting these epitopes are naturally processed and presented. Our 
findings suggest EN2 and HOXAl as potential promising targets for vaccine therapy 
to treat melanoma and breast cancer patients respectively.
Although peptide-based cancer vaccines are capable of eliciting measurable 
immune responses in various types of cancer, objective clinical responses remain 
infrequent and transient. One explanation for this tumour escape is 
immunosuppression mediated by a subset of T cells known as T regulatory cells 
(Treg) that can block effective anti-tumour immune responses.
Ill
We have developed a peptide (HWFT) that blocks the interaction between the 
Treg specific transcription factor, F0XP3 and its co-factor NFAT. Upon treatment of 
sorted murine splenocyte populations with HWFT we showed specific apoptosis of 
Tregs compared to non-Tregs as assessed by annexinV/7AAD FACS analysis. 
Furthermore, it was observed that HWFT inhibits murine Treg suppressive function in 
proliferation assays as well as inhibiting the production of the IL-10 suppressive 
cytokine. However, in humans, HWFT inhibits Treg suppressive capacity without 
killing. In addition, we assessed the effects of HWFT on immune responses against 
common recall antigens in in vitro assays using the PBMC of healthy individuals and 
cancer patients. This was compared with anti CD25 depletion as an alternative Treg 
targeting method. The results showed enhanced immune responses against common 
recall antigens upon HWFT treatment in cancer patients.
In both systems non-Treg cells are spared, suggesting that our peptide 
represents a more specific and potentially less toxic method for targeting Tregs to 
relieve immune suppression than any other current treatment. Consequently, we 
believe the pre-clinical development of our peptide will lead to a safer and more 
effective modulation of Treg across a range of different cancers as a combination 
therapy with vaccines or other treatment modalities.
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Chapter 1
Introduction
1. INTRODUCTION
1.1 Prevalence of cancer
Cancer is a class of diseases characterized by dynamic changes in the genome. 
Cellular transformation as a result of mutations is caused by activation of oncogenes 
and/or inactivation of tumour suppressor genes. There is now considerable evidence 
indicating that during tumorigenesis which is a multistep process, normal human cells 
progressively transform into highly malignant derivatives. Cancer has been proved to 
be the second cause of death in the world (Zingde, 2001; Hanahan and Weinberg, 
2000). More than 1 in 3 people will develop some form of cancer during their 
lifetime. Many types of human cancers have been revealed to be an age-dependent 
incident. The incidence of cancer worldwide is 10.9 million people with 6.7 million 
deaths from the disease each year. In the last five years the prevalence of cancer 
worldwide has been estimated to be 24.6 million people of whom 45% live in Asia 
and around half of these people live in Europe and North America (Table 1.1) (Ferlay 
et al 2002).
Country Number % of total
Africa 649,800 6
Asia 4,876,900 45
Europe 2,820,800 26
Latin America & the Caribbean 833,000 8
Northern America 1,570,500 14
Oceania 111,500 1
Developed Countries 5,016,100 46
Developing Countries 5,827,500 54
World 10,862,500 100
Table 1.1 Table showing the prevalence of cancer in different countries
The types of cancer being diagnosed vary enormously across the world. 
However, lung, breast, bowel, stomach and prostate cancers generally account for half 
of all cancer diagnosed. Lung cancer with 18% mortality is the most common type of 
cancer. Breast cancer incidence worldwide is one in ten of all new cancers diagnosed 
and almost one in four cancers diagnosed in women. It is the main cause of death 
from cancer in women globally with more than 1.1 million women diagnosed
annually. The frequency of various cancers in UK is listed in Table 1.2. (http://www- 
dep.iarc.fr/; CIS).
cancer Number
Breast (female) 550,000
Large bowel 250,000
Prostate 215,000
Lung 65,000
Other 920,000
All cancers 2,000,000
Table 1.2 Table show ing the num ber of c a se s  of different can cers  in UK in 2008. These 
figures are based on diagnosis in 1971-2001 which are applied to 2008 population, Thames 
Cancer Registry 2008.
In 2006 in the UK 293,601 people were diagnosed with cancer which accounts 
for a person to be diagnosed with cancer every two minutes. It has been estimated that 
currently 2 million people in the UK survive from cancer which is approximately 
equivalent to 3.3% of the population of the UK. The cancer mortality statistics in 
2007 show figures of 155,484 deaths from cancer which is around 24% of all deaths 
in the UK (Table 1.3). Thus, despite treatments for cancer there is still high mortality. 
Consequently, taking into account the seriousness of cancer as a disease as well as 
limitations of the current treatments in use proves an urge for alternative therapies 
(ISD, ONS).
Incidence Mortally
UK incKjcnce 2000 Cancws v.K<h co«fitn.ic one pe* cw l (X n o 'c  to to tj u k  V onahly  2002  C an c e rs  whsch a>ntf>buie o n e  p er cen t
canc<*f burden ^  m ore to  total ca n ce r mortality
am I.
I
no*.
O mça*?.
^  l i .v  
V.V.,
CW.,f
KC--'; .
*.VSCt
' c n c ,16 33 600 ,2 2 -.,
jüüC Be .vet 16 220 ,1 0 -.,
3i30C ■ly. B’-as' 12 3% ÿ-.i
1 7 ' iO m y I H H B H I 9 '--to 16%'
■ ■ ■ ■  0 -  - .'250
9 « 0 •4-.'
9 ' X ,3-. "3 3 ^ 4 ' . '
7W~. ,r. 4 9' .7 i3*..
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7C.-K 4 esc
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Table 1.3 Table showing UK cancer incidence and mortality. This table was adapted from 
http://cancerresearchuk.ora/aboutcancer/statistics/.
Cancer is a collection of diseases characterised by a dynamic genome which 
leads to uncontrolled cell proliferation and the ability to invade and metastasise 
(Zingde, 2001; Hanahan & Weinberg, 2000). In normal cells growth is tightly 
controlled by the cell cycle; a four stage process which receives inhibitory or 
stimulatory signals provided by cell-cell contact and the cellular environment 
(Weinberg, 1994). Checkpoints after each step of the cycle allow for the detection of 
alterations or DNA damage. If this is detected the cycle is halted allowing for either 
the repair of damage or for programming the cell to die (apoptosis). In a tumour cell 
this regulation is bypassed; the cell evades programmed cell death (apoptosis) and 
continues to proliferate. The tight controls on a cell are regulated by two categories of 
genes; oncogenes and tumour suppressor genes (Zingde, 2001). For a tumour to 
develop it is necessary for a number of alterations to occur in these key genes 
(Zingde, 2001). The initial mutations lead to excessive proliferation that in turn can 
lead to further mutations in these genes. This is illustrated in the classical case of 
colon cancer where as the cell proliferates the incidence of mutations increases
leading to the development of the disease. As a tumour develops the six essential 
alterations that are required for continued tumourigenesis are as follows:
• Self-sufficiency in growth signals
• Insensitivity to growth inhibitory signals
• Evasion of apoptosis
• Limitless replicative senescence
• Sustained angiogenesis
• Tissue invasion and metastasis
As mentioned there are two broad categories of genes essential in 
tumourigenesis i.e. oncogenes and tumour suppressor genes (TSG) (Diamandis, 1997; 
Weinberg, 1994). Mutations in these cause either a gain or loss of function, leading to 
evasion of normal control of cellular growth and homeostasis. Oncogenes are one 
class of genes which are significant for tumourigenesis. These are formed from their 
normal cellular counterparts; proto-oncogenes, which encode for proteins that regulate 
cellular responses to external stimuli (Zingde, 2001). In a normal cell these proteins 
form a complex biochemical network allowing the cell to gain information about its 
environment and then initiate an appropriate response. However, in a cancer cell these 
genes are mutated and express proteins which permanently activate downstream 
signalling pathways, without any external stimuli. Ultimately this leads to activation 
of genes involved in a number of cellular activities including growth. Oncogene 
activation, unlike TSGs, is a dominant process as only one allele of the gene needs to 
be altered for its abnormal expression to occur (Diamandis, 1997). Many oncogenes 
have been described, coding for either ‘abnormal’ protein or overexpressed ‘normal’ 
protein (Franks & Teich, 1991).
The best example of an oncogene is the signal transduction molecule Ras 
which is activated by mutations in a wide range of different cancers at different 
incidence levels i.e. 90% in pancreatic cancer, 50% in colon cancer and 30% in lung 
cancer (Bos, 1989). This activation occurs as a result of a point mutation, which is in 
either codon 12, 13 (GTP-binding domain) or 61 (GTPase domain). Normally ras 
binds GTP, causing a conformational change therefore allowing interactions with 
downstream signalling molecules. When mutated, ras can no longer release the bound
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GTP and so remains constantly activated meaning downstream pathways are 
permanently switched on (Bertram, 2001). This activation allows for cells to 
overcome normal cellular controls, one of the initiating factors in the development of 
cancer.
The second class of genes involved in the development of cancer are TSGs. In 
normal cells TSG products function by regulating cell growth in an inhibitory manner 
to prevent a cancer phenotype. If genetic damage causes the loss or inactivation of a 
TSG a cell is deprived of its innate inhibition to proliferate thereby allowing the 
transformation towards a cancer phenotype. For this loss or inactivation to occur both 
copies of the TSG must be altered i.e. recessive (Diamandis, 1997). There are a 
variety of mechanisms for this including the loss of heterozygosity (LOH), 
méthylation, cytogenetic aberrations, genetic mutations, gain of autoinhibitory 
functions and polymorphisms (Zingde, 2001; Sager, 1992). The most well known of 
these is P53, termed the ‘guardian of the genome’ (Bertram, 2001). It is found on the 
short arm of chromosome 17 and encodes for a transcription factor which is involved 
in cell cycle regulation. Expression of P53 is induced after a cell incurs DNA damage, 
hypoxia or oncogene activation and then it initiates an appropriate response by 
inducing either apoptosis or cell cycle arrest. In cancer cells P53 is often mutated or 
deleted leading to loss of these functions, so cells rapidly accumulate genetic damage 
and avoid apoptosis allowing for continued tumourigenesis (Bueter et al, 2006). The 
importance of p53 is illustrated by the fact that up to 50% of all human tumours have 
mutations in this gene (Bueter et al, 2006; Hanahan & Weinberg, 2000).
Homeobox (HOX) genes are a large group of regulatory genes which encode 
transcription factors involved in developmental processes (Abe et al, 2006). In 
humans there are 39 HOX genes which are divided into four genomic clusters A, B, C 
and D. During embryonic development these genes are expressed to varying degrees 
however the majority of them are then subsequently down-regulated throughout ‘adult 
life’ (Lappin et al, 2006). Re-expression of some of these HOX genes in adults has 
been shown to be linked to the development of tumours. These antigens which can be 
potential tumour targets will be fully introduced in results chapters.
1.1.1 Cancer therapy
Four main types of treatment have been developed and are currently being 
used. These include: (i) Surgery; to remove the tumour burden whenever possible, (ii) 
Chemotherapy; involving administration of cytotoxic drugs. Various combinations 
can be used depending on the type of cancer, (iii) Radiotherapy; involving an energy 
beam of radiation directed to the site of the tumour (Franks and Teich, 1991), (iv) 
Hormone ablation; for example for the treatment of prostate cancer.
Combinations of the first three treatments are generally used, for example a 
primary tumour may be removed by surgery then be followed by chemotherapy or 
radiotherapy to eradicate any residual cancer cells. (Berzofsky et al, 2004). 
Alternatives to these traditional treatments include gene therapy, (to replace, block or 
correct abnormal genes) and immunotherapy, which aims to stimulate the body’s 
immune system to attack the cancer cells. Types of therapies and the use of 
immunotherapy will be discussed later in more detail.
1.1.2 Evidence for tumour immunity
Alternative therapies such as the use of immunotherapy have been shown to be 
promising in treating cancer. However, what is the evidence that the immune system 
can control cancer? In fact, several convincing lines of evidence of the involvement of 
the immune system in cancer have been demonstrated. These include the evidence 
that individuals with underlying primary or secondary immune deficiencies, such as 
chronic infection i.e. AIDS, or an autoimmune disease are specifically at increased 
risk of malignancy (Penn, 1999; Sheil et al, 1997). Also, prolonged consumption of 
immunosuppressive medications, previous viral infections, such as HIV, Epstein Barr 
virus, hepatitis or herpes virus infections as well as genetic susceptibility to cancer 
and extreme of age, are all correlated with the progress of certain types of cancer 
(Penn, 1999; Sheil et al, 1997).
Another line of evidence is that in an extensive survey by Emerson, it was 
shown that spontaneous regression occurred in some cancers such as 10% of
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carcinomas and 15% of nodular lymphomas in addition to other cases from another 
studies including melanoma, breast and lung cancers (Sell and Max, 2001). Further 
examples of evidence which show the involvement of the immune system in tackling 
tumours are summarised in Table 1.4. In summary, an immune response is generated 
against tumours; however, the involvement of immunity in regression of inoperable 
primary tumours remains circumstantial.
1.2 Generation of an immune response
The immune system has two major components, an innate arm and an adaptive 
arm. Innate immunity is the first line of defense in confronting infections and foreign 
antigens, while adaptive immunity is more specific against any foreign substances 
including cancer cells, auto-antigens, etc (Figure 1.1).
1.2.1 Innate immune system
Innate immunity (natural or native immunity) is instant, immediate, initial 
nonspecific response, induces adaptive immunity and integrates with adaptive 
immunity. It comprises four types of defensive barriers such as anatomic, physiologic, 
phagocytic and inflammatory. There are different elements of innate immunity with 
different roles and functions such as neutrophils, mast cells, basophils, eosinophils, 
natural killer cells macrophages and dendritic cells (Janeway et al, 2001).
Natural killer (NK) cells target and kill rapidly and non-specifically aberrant 
cells such as tumorigenic and virally infected cells. NK cells mediate killing through 
cytotoxic molecules which are stored within lysosomes. A lytic immunological 
synapse between the NK cell and its target is formed upon target cell recognition 
which occurs through lack of major histocompatibility complex (MHC) (Topham and 
Hewitt, 2009).
Dendritic cells (DCs) are specialized antigen presenting cells (APCs) that 
orchestrate innate and adaptive immune responses. There are different DC subsets
8
with different surface molecules and receptors which express different sets of 
cytokines/chemokines, leading to distinct immunological outcomes (Banchereau et al, 
2009). Upon continuous antigen sampling immature DCs start to mature and get 
activated and up-regulate chemokine receptors, which guide them to draining lymph 
nodes where they become capable of inducing primary T cell responses due to their 
high levels of MHC, adhesion and co-stimulatory molecule expression. DCs are able 
to present and cross-present the antigenic peptides in the context of both MHC Class 
II and Class I molecules unlike other APCs such as B cells, monocytes and 
macrophages (Rock and Clark, 1996; Rock et al, 1990). Therefore, they can prime 
CD4+ T helper cells, as well as CD8+ cytotoxic T cells (Clarke, 2000; Van Gool et al, 
2009).
Macrophages are a major component of innate immune defence that express a 
large repertoire of various classes of pattern recognition surface antigens and other 
receptors which determine the homeostatic and immunologic potential of these 
versatile cells. Tumour associated macrophages (TAMs) have a range of functions 
including modulation of tumour cell growth (enhancement and inhibition), 
angiogenesis and vascularization, stroma formation and dissolution. Upon activation, 
they can induce apoptosis and/or elicit tumour destructive reactions through 
alterations of the tumour microvasculature (Siveen and Kuttan, 2009). Furthermore, 
macrophages are APCs as well.
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Figure 1.1 A schematic diagram of the lineage of immune cells. Different cells of the 
immune system and their involvement in innate (rapid non-specific response) and adaptive 
(slow highly specific response) immunity.
1.2.2 Adaptive immune system
The adaptive immune system is comprised of two broad classes of immune 
responses, antibody responses (humoral immunity) and cell-mediated immune 
responses that are carried out by B and T lymphocytes, respectively and express 
receptors with remarkable diversity to recognize particular antigens. B and T 
lymphocytes circulate in the blood and lymphoid organs such as the spleen and lymph 
nodes.
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1.2.2.1 Humoral immunity
One major arm of the lymphoid network consists of B lymphocytes whose 
major function is to provide humoral immunity by secreting antibodies (Abs) which 
are proteins called immunoglobulins and are specific for antigen. All 
immunoglobulins have common structural features which enable them to recognize 
and bind specifically to epitopes on antigens and perform a further function after 
combining with the antigen. Abs are combined of heavy and light chains that include 
constant and variable regions (Figure 1.2). The variable regions contain six 
complementarity determining regions (CDRs) which compose the antigen (Ag) 
binding-site (Alzari et al, 1988). The interaction of Abs with antigens may result in a 
variety of important biological consequences including neutralization of toxins and 
viral activity, immobilization of bacteria, agglutination of antigenic particles, 
opsonisation to engulf microorganisms, antibody-dependant cell-mediated 
cytotoxicity (ADCC) to destroy antigens through binding with target cells and specific 
receptors on NK cells and finally activating serum complement to facilitate 
phagocytosis (Gabrielli et al, 2009).
After triggering the B cell antigen-specific receptor, immunoglobulin, an 
activation cascade occurs in B cells. Upon antigen binding to variable regions at the 
cell surface, a signal is transmitted into the cell through the associated Ig a and 13. The 
antigen also induces receptor cross-linking resulting in more than one Ig receptor 
molecule in the cell membrane. Therefore, Ig a and 13 play the same role in signal 
transduction for the B cell receptor as CD3 plays for the T cell receptor (Kuby, 1993). 
The B cell surface molecules CD 19, CD20 and CD21 also play a role in signalling 
after antigen binding by enhancing the signal transmitted through Ig. Following this 
sequence of activation events, transcription factors such as NF-AT and NF-kB enter 
the nucleus of the B cell and promote the transcription of specific genes such as 
immunoglobulin and cytokine receptor genes. Consequently, 12 hours after antigenic 
stimulation, the B cell increases in size and if it receives appropriate signals, generally 
from Th cells, the B cell blast proliferates and differentiates into a cell that synthesizes 
and secretes immunoglobulin (Benjamin! et al, 1996).
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Figure 1.2 Schematic representation of the structure of an immunoglobulin molecule
The complement system
The complement (C) system as a crucial constituent of innate immunity is 
actively involved in the host protection against infectious elements, removal of 
apoptotic cells and immune complexes (Walport, 2001) as well as cancer cells (Figure 
1.3). Findings suggest that terminal C complex and activated C components are 
deposited on tumour cells i.e. in thyroid carcinoma and breast (Niculescu et al, 1992; 
Lucas et al, 1996). Release of the biologically active products from the C system 
adequate to recognize and invade tumour cells needs an activation process. Tumour 
cells can directly activate the C system through the alternative (Fujita et al, 1995; 
Budzko et al, 1976; Matsumoto et al, 1997) or the lectin pathway (Fujita et al, 1995; 
Ma et al, 1999). Nevertheless, the most effective means to target C activation 
products to tumour cells in order to generate cell destruction is through the Ab-
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mediated activation of the classical pathway. It has been proven that the humoral 
response in cancer patients is not very sufficient due to the generation of only low- 
affmity and low-titer Abs against tumour antigens in tumour-bearing patients. 
Moreover, observations have demonstrated that these Abs are usually poor activators 
of C system, hence are unconvincing to modulate C-dependent cytotoxicity (CDC) of 
tumour cells (Matsumoto et al, 1997).
Classical pathway Mannan-binding lectin pathway Alternative pathway
Antigen antibody complexes 
(pathogen surface)
Mannan-binding lectin binds 
mannose on pathogen surfaces
Pathogen surfaces
1 1
C1q, C1r, (:1s, C4, 02 MBL, MASP-1, MASP-2, 04, 02 03, components B and D
C3 convertase
1 1
Peptide mediators of inflammation, 
phagocyte recruitment
Binds to complement 
receptors on phagocytes
1
Opsonization of pathogens
(04a)" Terminal complement
03a, 05a 03b components:
05b, 06, 07, 08, 09
Membrane-attack complex, lysis 
of certain pathogens and cells
Removal of immune complexes
Figure 1.3 The relationship between pathways of complement activation. MASP, 
mannan-binding lectin-associated serine protease; MBL, mannose-binding lectin.
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1.2.2.2 Cell-mediated adaptive immunity
In cell-mediated immune responses, activated T lymphocytes, B lymphocytes, 
eosinophils, neutrophils, macrophages, DCs and NK cells of the appropriate 
specificity respond robustly to the antigen, and either kill the pathogen directly or 
secrete cytokine mediators that promote a B lymphocyte response. CD4 T cells within 
the adaptive immune network provide regulatory effects that have a key role in 
controlling the majority of immune functions and memory cells that enhance host 
protection. Through the release of cytokines, hormones that replenish hematopoietic 
elements and promote inflammation, many of the regulatory effects are mediated. 
CDS T cells also known as cytotoxic T lymphocytes (CTLs) function as crucial parts 
of the host defence against intracellular pathogens such as viruses and tumour cells 
(Fleisher, 1997).
1.2.2.2.1 Generation of effective CTL responses
The activation and development of an adaptive immune response originates 
from the involvement of a T-cell antigen receptor (TCR) with a short antigenic 
peptide bound to MHC-I and/or MHC-II. Co-stimulation and co-inhibition serve as 
positive and negative signals, which are mainly induced by the interaction between 
the B7 family and their receptor CD28 family and determine the outcome of this 
engagement (Zang and Allison, 2007).
CD4^ T cells, based on their cytokine secretion profile, are classified into T 
helper I (ThI) cells that provide help to prime CD 8  ^T-cell responses and Th2 cells 
that activate B cells to become antibody-secreting plasma cells (Morel and Oriss, 
1998; Old, 1996; Glennie and Johnson, 2000). Elimination of CD4^ T cells in CD4- 
knockout animals or by the use of anti-CD4 antibodies has shown the necessity of 
CD4^ T cells in the generation of antigen-specific CD8^ T lymphocytes (Hung et al,
1998). CD4"^  Th cells and CD8  ^T cells require antigen recognition and presentation 
on the same APC, in order to provide help to CD4"^  T cells to prime naive CD8  ^T-cell 
responses and activate memory CD8^ T cells. It has been proposed by several studies 
that DCs as specialized professional APCs, are activated for effective initial priming
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and activation of CD8  ^ T cells through CD40-CD40 ligand (CD40L) interactions 
between CD4^ T cells and DCs (Schoenberger et al, 1998; Bennett et al, 1998; 
Banchereau and Steinman, 1998). Upon activation, DCs become capable of priming 
CTLs that distinguish an MHC-I component on the same APC. Lack of co­
stimulatory molecules in non-professional APCs such as cancer cells prevents 
induction of immune responses from naive T cells (Houghton and Guevara-Patino, 
2004). Consequently, tolerance rather than activation of CTLs can be induced in the 
absence of CD4^ Th cells which results in the lack of properly activated DCs (Wang, 
2001).
Furthermore, CTLs play an important role in the induction of tumour-specific 
CD4+ T cells to help CD8+ responses, as well as mediation of antitumor effector 
functions through induction of eosinophils and macrophages to produce superoxide 
and nitric oxide (Berzofsky et al, 2004). High levels of co-stimulatory molecules such 
as members of the extended family of B7 genes (B7-1 (CD80), B7-2 (CD86), 
B7h/B7RP-1 and B7-H1) are expressed by antigen presenting cells (i.e. DCs) as well 
as secretion of critical cytokines such as IL-12 and lL-15 that contribute to CTL 
activation and memory. Although the expression of B7-1 or B7-2 on the surface of 
tumour cells enhances immunity against various types of tumours, it has been shown 
that in poorly immunogenic tumours B7-1 or B7-2 expression alone is not effective 
enough to generate an immune response (Zang and Allison, 2007). B7-1/B7-2 
pathways act mainly on naive lymphocytes, whereas B7h/B7RP-1 and B7-H1 have 
effects on antigen-experienced T cells (Bugeon and Dallman, 2000). T-dependent 
antibody isotype switching and expansion of effector cells is promoted by the 
inducible costimulatory molecule (lC0S)-B7h. Effector T cells then interact with 
antigen-presenting cells in sites of inflamed tissues and are regulated by PD-1 and its 
ligands. The interaction between the peripheral tissues and effector T cells can be 
controlled by B7-H3 and B7x (Loke and Allison, 2004).
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1.2.2.2.2 Cell-mediated cytotoxicity
Effector cells of the immune system such as NK cells, CTLs and cells 
mediating antibody-dependent cellular cytotoxicity (ADCC) modulate direct killing to 
erradicate infected cells and tumour cells. CTL effectors as crucial elements of the 
host adaptive immune response to intracellular pathogens are mainly 
CD3^CD8^TCRa(3^ T cells (Doherty and Christensen, 2000; Russell and Ley, 2002). 
Improving the frequency and activity of these CTL effectors is the essential objective 
of immune interventions and several vaccines (Me Michael, 1998; Parmiani et al, 
2002). There are two main mechanisms through which CTL-mediated killing occurs: 
(a) direct interaction between Fas receptor (Fas R), also known as CD95, on the target 
cell and Fas ligands (FasL), also known as CD 178, on the CTL (b) the release of 
granzymes and perforin from the granules of CTLs (Clark et al, 1995; Barry and 
Bleackley, 2002; Kagi et al, 1996). In both pathways, ultimately, induction of 
apoptotic cell death caused by the activation of the caspase cascade results in the 
killing of target cells.
Considerable evidence has shown that DNA fragmentation in target cells of 
granzyme B knock-out mice is not induced due to an impaired ability of CTLs. In 
addition, several data obtained from perforin knock-out mice have demonstrated 
delayed tumour clearance and an increased vulnerability to viral infection (Doherty 
and Christensen, 2000; Russell and Ley, 2002). Moreover, in humans the interruption 
of CTL pathways results in severe disease and often death such as deficit of CD95 or 
CD 178 in autoimmune lymphoproliferative syndrome (Chun and Lenardo, 2001; 
Fisher et al, 1995) and deficit of perforin in familial hemophagocytic
lymphohistiocytosis (Stepp et al, 1999). As a result of interaction between CTL and
target cell the substances of the cytotoxic granules are released and consequently
perforin binds to the target cell membrane. Following this, CTL-released granzymes 
penetrate the target cell cytosol and induce the activation of the apoptosis machinery 
through cleaving a variety of caspases. Upon cleavage, cellular proteins cleaved by 
activated caspases then reveal the phenotypic characteristics of apoptosis, such as 
membrane blebbing, cytoplasmic shrinkage, chromatin condensation, and DNA 
degradation (Chahroudi et al, 2003). It has been shown that in the early stages of the
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immune response, the CTLs are constituted mainly of lymphoblastoids expressing 
both FasL and perforin. However, as antigen and cytokines become limiting factors 
upon progression of the immune response, the CD8  ^ cells gradually shift killing 
phenotype from mostly a fast-acting perforin-based to a slow-acting FasL-based 
killing mechanism (Meiraz et al, 2009).
1.3 Recognition of cancer by the Immune system
There is convincing evidence that cellular and humoral immune recognition is 
elicited by many human tumours (Dranoff, 2009). Most of the antigens that are 
expressed by human cancer cells and are recognized by host antibodies and T cells are 
non-mutated self antigens that are also expressed on the surface of normal cells. 
Studies of spontaneous tumours in mice have also shown the relevance of T cell 
recognition of non-mutated self-antigens (Houghton and Guevara-Patino, 2004). 
However, from another perspective, one explanation for the difficulties in 
immunization against human cancer could be that these antigens are ineffective at 
triggering immune responses against cancer cells which might be due to tolerance. 
Although these tumours are weakly immunogenic, they have been considered as 
representative of most human cancers compared to the strongly immunogenic 
mutagen-induced tumours (Prehn and Main, 1957; Hewitt et al, 1976). Figure 1.4 
shows an example of induction of immune response and infiltration of CDS T cells     • ■   X   ------------------------  . JL
towards prostate specific tumour antigen, AMACR.
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■Figure 1.4 Immunogold/fluorescent staining of AMACR/CD3 on prostate cancer 
biopsies. Silver staining of AMACR marker showed the cytoplasmic staining of the neoplastic 
glands (black). CDS" T cells infiltrating intra-tumoral and peri-tumoral regions were detected 
using an Alexa fluor 488 (green) secondary antibody (Ismail and Bokaee et al] 2009).
Regarding this view, cancer antigens that are recognized by the immune 
system are eonsidered as self or mutated self-antigens (Houghton et al, 2001). 
Mutations in proto-oncogenes and tumour suppressor genes which are normal eellular 
genes and have control over cell growth and survival (Hahn and Weinberg, 2002) 
contribute to the emergence of cancer. The genetic alterations in proto-oncogenes and 
tumour suppressor genes promote profound changes in normal host cells such as a 
block in terminal differentiation, immortality, angiogenesis, and potential metastasis 
(Hahn and Weinberg, 2002). Therefore, cancer eells employ the same crucial cellular 
molecules as healthy cells to modulate growth and survival (Houghton and Guevara- 
Patino, 2004).
In the thymus more than 90% of immature T cells with high-affmity TCRs for 
a self-antigen are eliminated during their early development and are then replete with 
mature, naive, self-reactive T cells that have relatively low affinity TCRs for self­
antigens. Therefore, auto immunity is avoided through essential eradication of these 
high-affmity T eells (Bowne et al, 1999). These weak self-antigens are unable to 
generate immune responses. However, through vaceination or other means, activation
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of T cells against these ineffective self-antigens can result in rejection of tumours 
presenting these antigens (Naftzger et al, 1996; Weber et al, 1998; Gold et al, 2003).
1.3.1 Tumour antigens
The identification of antigens associated with tumour destruction is a major 
goal of cancer immunology. The amplification of gene products selectively or 
preferentially transcribed in the tumour allows accelerated molecular identification of 
tumour antigens. Because MHC restriction of T cells necessitates that for any newly 
defined antigen, it is crucial to determine the potential immunogenicity of such gene 
products. Therefore, immunogenicity will have to be defined for any individual MHC 
haplotype.
There are two main considerations regarding the choice of tumour antigens for 
an adoptive transfer of T cells or a vaccine, namely: specificity of tumour antigens 
and sufficient expression at the surface of the tumour cells for T cell recognition 
(Lucas and Coulie, 2008). In cases when potential tumour antigens are not expressed 
on the surface of tumour cells and are thus inaccessible to antibodies, proteosomes 
cleave a sampling of all proteins synthesized in the cell into short fragments (peptides) 
that are loaded onto newly synthesized MHC-1 molecules; i.e. HLA-A, -B, and -C. 
The peptide-MHC complexes are transported to the cell surface to be recognised by 
the TCRs of CD8+ T lymphocytes at the molecular level (Figure 1.5). It has been 
established that specific CTLs recognize 8-10 amino acid-long peptides that arise 
from the proteasomal degradation of intracellular proteins and are able to bind to the 
groove of surface class I HLA molecules. Therefore, CTLs are not only restricted to 
tumour antigens expressed intact on the cell surface but also any abnormal protein 
synthesized in the cell can be detected by them.
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Figure 1.5 A diagram showing the basic composition of the MHC molecule.
Tumour antigens are mainly mutated self-proteins (undergone as many as 
10,000 mutations/cell), which are exuberant in cancer cells due to genomic instability 
(Stoler et al, 1999). The number of tumour antigens, MHC and co-stimulatory genes 
are all crucial factors in T cell priming in immunotherapy. Findings have shown that 
for an effective antitumor response a 1% antigen-specific CTL level of the effector 
CD8^ cells are needed (Walker and Disis, 2003), while levels of less than 0.01% have 
been obtained from most vaccine strategies in patients (Tomasi et al, 2006).
Using transfection of genomic tumour DNA into target cells expressing 
adequate MHC has revealed most of the common tumour antigens detected by T cells. 
Upon transfection the target cells become sensitive to killing by CTLs with specific
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antitumor reactivity. Weak immune responses raised by these antigens can be due to 
absence of tumour-specific CD4^ cells (Hung et al, 1998; Toes et al, 1999; Wang,
2001). It has been shown in a mouse model that protective immunity against MHC-II- 
negative, virus-induced tumour cells is induced through vaccination with a specific 
viral CD4^-MHC-II which generates tumour-specific CD4^ T cells. The importance of 
CD4 manipulation and the immune response cross-priming is manifested through 
tumour rejection modulated by CTLs distinguishing a different viral antigen 
(Ossendorp et al, 1998). Tumour antigens such as mutated CDC27 which are 
presented by MHC-II and identified by CD4^ T cells have been described (Wang et al, 
1999). Hence, establishment of other tumour antigens presented by MHC-II is 
essential for the induction of ideal antitumor responses (Mapara and Sykes, 2004).
Tumour antigens are classified into two groups according to their expression 
pattern: true tumour-specific antigens (TSA) and tumour-associated antigens 
(TAA).Tumour antigens are mostly of weak immunogenicity, since the majority are 
tumour-associated differentiation antigens already 'seen' by the patient's immune 
system. Tumour-specific antigens, mostly arise by point mutations and viral antigens, 
could be a potent target for immunotherapy. However, they have the disadvantage of 
being tumour-specific and individual-specific (Mapara and Sykes, 2004) (Table 1.4).
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Category Tum our antigens Type of cancer
Cancer testis MAGE-1 Melanoma
antigens MAGE-2 Breast, head& neck
MAGE-3 Bladder, gastric, lung
MAGE-12 Leukaemia,
BAGE osteosarcoma.
GAGE Melanoma
NY-ESO-1 Breast
Differentiation GplOO, tyrosinase Melanoma
antigens Melan-A/Mart-1
TRP-1.TRP-2
MC1R
Tumour-specific Immunoglogulin B cell NHL,MM
antigens Idiotype Lymphoma
CDK4 Melanoma
Caspase-8 Head & neck
B-Catenin Melanoma
CIA 0205 Bladder
BCR/ABL CML
Mutated p21/ras Pancreatic, colon, lung
Mutated p53 Colorectal, lung, bladder, head & neck
Over-expressed Proteinase 3 CML
self antigens WT1 CML, ALL, AML
MUC-1 Breast adenocarcinoma
CEA Colon, breast, pancreatic
Normal p53 Breast, colon & other cancers
Her2/neu Breast, ovary, lung
PAP Prostate
PSA Prostate
PSMA Prostate
A-FETOPROTEIN Liver
G250 Renal cell carcinoma
Viral antigens HPV E6/E7 Cervical & penile cancer
EBV LMP2a EBV + Hodgkin’s disease
HCV Liver
HHV-8 Kaposi sarcoma
Table 1.4 Table show ing w ell-characterised tum our an tigens
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1.3.1.1 Tumour-associated antigens (TAA)
TAA are predominantly self-antigens and hence induce weak TAA-specific 
immune responses, either humoral or cellular (Whiteside, 2006). Four significant 
principles to classify TAA as potential targets for immunotherapy have been 
described by Kessler and Melief: (i) TAA are mainly expressed and available in 
cancer types or patients, (ii) they are specific to tumours and hardly expressed in 
normal tissues, (iii) they have key role in cancer survival or the oncogenic process and 
(iv) there are potential changes in kinetics production of the TAA (Geissler and Weth,
2002) (Table 1.4).
Several TAA have been discovered which could be promising targets for 
immunotherapeutic strategies in different types of cancer. In the case of melanoma, 
targets of anti-melanoma responses have been investigated by many groups applying 
various genetic and biochemical methods and have described four main categories for 
TAA (Mapara and Sykes, 2004). The first group are the cancer-testis antigens, 
including the melanoma antigen gene (MAGE) family and NY-ESO-1. These are 
prototypical onco-fetal antigens that are highly expressed in developing tissues (germ 
cells and placenta) and tumours, however are silenced in the adult. The second group 
consists of differentiation antigens including breast mucin, alpha-fetoprotein and 
prostate-specific antigen. Melanocyte differentiation antigens are Melan A/MART, 
tyrosinase, gp75 and gplOO. The third group compromises of mutated antigens such 
as p-catenin, fibronectin and the cyclin-dependent protein kinase inhibitor-4. Finally 
the fourth group are the amplification antigens which are aberrant or over-expressed 
in tumours and include Wilm's tumour gene, oncoprotein and murine-double-minute-2 
(mdm-2) (Dranoff, 2009).
1.3.1.2 Tumour-specific antigens (TSA)
Tumour-specific antigens (TSA) induce tumour immunogenicity by presenting 
differentially over-expressed and genetically modified epitopes recognised from 
normal cells (Adam et al, 2003; Finn, 2003; Pardoll, 2003). TSA have been proven to
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be potential promising sources of vaccines for cancer immunoprevention and 
immunotherapy (Mittendorf et al, 2007; Purcell et al, 2007; Schlom et al, 2007). 
Furthermore, TSA have been identified on some virally induced tumours and on 
tumours generated with chemical or physical carcinogens. Identifying the presence of 
TSA on spontaneously occurring tumours is challenging since the immune response to 
such tumours eradicates the entire tumour cells bearing sufficient numbers of these 
TSA and therefore selects for cells bearing low levels of these antigens (Jia et al, 
2009). Some examples of potential TSA are tumor-specific chimeric fusion proteins 
(bcr-abl), mutation-carrying tumor suppressor genes ip53), mutated cell cycle 
regulators (CDC27, CDK4), tumor-specific rearrangements of the immunoglobulin 
heavy-chain locus (idiotype [Id] of B-cell neoplasias) and mutated oncogene-encoded 
proteins (ras) (Mapara and Sykes, 2004).
1.3.2 Immunogenic versus non-immunogenic cancers
Although the precise role of the immune system in cancer occurrence and 
regression has not yet been elucidated, it is known that some tumours are 
immunogenic. Defective genes are not recognized by the elements of the immune 
system, but the abnormal proteins that are encoded by the cancer-causing genes are 
recognized (Berkow and Beers, 1997). Spontaneous tumours that often generate a 
specific immune response are also considered as immunogenic. However, it is not 
clear whether they can be controlled by a CTL response (Stutman, 1974; Prehn, 1994; 
Klein et al, 1960). In the immunosurveillance hypothesis which is a process of 
recognition and elimination of tumours by T cells, it is postulated that tumours escape 
T-cell recognition through losing immunogenicity (Shankaran et al, 2001; Street et al, 
2002; Dunn et al, 2002). Willimsky and Blankenstein showed in their mouse model of 
sporadic cancer based on rare spontaneous activation of a dormant oncogene, that 
immunogenic tumours do not escape their recognition but induce tolerance 
(Blankenstein and Qin, 2003; Qin and Blankenstein, 2004). They also indicated that in 
spite of specific recognition by T cells, tumours’ intrinsic immunogenicity is not lost 
and they are rejected after transplantation in immunocompetent recipients (Willimsky 
and Blankenstein, 2005).
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1.3.3 Evasion mechanisms
Most human cancers are poorly immunogenic and are therefore capable of 
evading the host immune system. Avoiding recognition or eliminating immune cells 
are the two general strategies that are employed by tumors to avoid recognition. It has 
previously been proved that tumours are often poor antigen presenting cells (APCs), 
they cause loss or down regulation of HLA class I or antigen processing machinery 
(APM) components, they fail to produce stimulatory cytokines and also lack co­
stimulatory molecules on their surface which all make them poorly immunogenic and 
even tolerogenic. These and other immune evasion mechanisms are further described 
below (Whiteside, 2006).
1.3.3.1 Loss or down regulation of HLA class I molecules
Down regulating the expression of key molecules necessary for interactions 
with immune cells (Lybarger et al, 2005) is a mechanism employed by tumours to 
evade the host’s immune response. This includes loss or down regulation of the 
expression of HLA class I molecules, antigen processing machinery components 
(APM) and TAA (Meissner et al, 2005). Tumours often mis-process and mis­
represent processed TAA since they are not effective APCs. As a result of this, 
defective immunogenic peptides that do not fit into the HLA class I groove are made. 
Consequently, the HLA class I-chain-Pim-peptide complex is either absent from the 
tumour cell surface or it is formed and presented in a way that CTLs can not identify 
it (Whiteside, 2006). Mutations in the genes encoding HLA class I antigen subunits 
(HLA class I heavy chains and/or p2m), down regulation of APM components (TAP 
subunits, proteasome subunits and tapasin) which induce and load peptides onto HLA 
class I molecules are the main molecular mechanisms causing these abnormalities 
(Chang et al, 2005a; Chang and Ferrone, 2007).
Prevention of normal processing of TAA in melanoma or head and neck 
cancer (HNC) (Meissner et al, 2005) has been reported to be caused by mutation or
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down regulation in Transporter associated with antigen processing 1 (TAPI) or TAP2 
(Seliger et al, 2001). Immunohistochemical analysis demonstrates that the percentage 
loss or down regulation of HLA class I antigen in tumours varies greatly (Marincola 
et al, 2000). For example 80% loss or down regulation of HLA class I is observed in 
melanoma and renal cell carcinoma (RCC), whilst only 16% is seen in prostate and 
breast carcinomas (Marincola et al, 2000). Also, a correlation between these 
abnormalities and shorter survival in patients with HNC has been recently reported 
(Meissner et al, 2005; Campoli et al, 2002; Whiteside, 2006). In addition, an 
association between HLA class I antigen defects and malignant transformation of cells 
in most types of solid tumours has been documented analysing surgically removed 
malignant lesions using immunohistochemistry (Chang et al, 2005a; Chang and 
Ferrone, 2007).
Inadequate presentation of endogenous antigen can cause poor 
immunogenicity (Restifo et al, 1991). IFN-y enables the up-regulation of MHC class-I 
expression and therefore results in weak immunogenic tumours to expressing 
endogenous antigen (Restifo et al, 1992). In a study conducted by Tanaka et al., 
reduced tumorigenicity of tumour cells that were modified to secrete IFN-y was 
demonstrated through the up-regulation of MHC class-I antigen expression on tumour 
cells (Gansbacher et al, 1990; Watanabe et al, 1989; Porgador et al, 1993). They 
concluded that enhanced priming of tumour-specific T cells in the tumour-draining 
lymph nodes can be caused by co-transfection of poorly immunogenic murine 
tumours with B7-1 and IFN-7. This group also showed that up-regulation of MHC 
class-I on tumour cells by IFN-T alone was not enough to raise antitumor immunity, 
suggesting that this combination of transfection can assist an appropriate 
microenvironment to prime tumour-reactive T cells (Tanaka et al, 1999).
Immune selection also operates with NK cells and is not limited only to T 
cells. NK cell activity inhibited the expression of MHC class-I molecules (Karre,
2002). Down regulation of MHC calss I may increase heat shock type proteins (HSP) 
to help cover their loss of function. HSP and NK elimination of cancer may take over 
if MHC class-I is lost. Therefore, HLA class I antigen expression may play a role in
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favour of tumour survival where the major source of selective pressure is provided by 
NK cells. For example, this possibility is supported in situations where NK cells 
control the tumour progression such as in lung carcinoma, breast carcinoma and uveal 
melanoma with high level expression of HLA class I antigen (Ericsson et al, 2001; 
Madjd et al, 2005; Ramnath et al, 2005).
1.3.3.2 Down regulation of co-stimulatory molecules
Inability to deliver a co-stimulatory signal (signal 2) crucial for interactions 
with T cells may be why tumours can not serve as efficient APC. Down-regulation of 
the B7 family as members of the co-stimulatory molecules (Wang and Chen, 2004), 
on the tumour cell surface causes MHC-1-restricted antigen presentation that lacks 
transmission of the necessary co-stimulatory signal to lymphocytes. This ultimately 
results in initiation of anergy in tumour-specific T cells (Singh et al, 2003; Whiteside,
2006). Therefore, tumours evade effective T cell eradication due to increased 
expression of inhibitory B7 molecules and become invisible to the immune system in 
the absence of the expression of co-stimulatory B7 molecules. Notably, in a colon 
carcinoma mouse model it has been proven that low expression of B7-1 on the surface 
of tumour cells is an immunoescape mechanism (Tirapu et al, 2006). Hence, the 
exploitation of these pathways is vital for improving efficient tumour immunotherapy.
1.3.3.3 Immunosuppressive cytokines
Tumour evasion may occur through a number of soluble factors that have a 
suppressive effect on immune cells. These cytokines and chemokines include 
interleukin-10 (IL-10), transforming growth factor-p (TGF-p), vascular endothelial 
growth factor (VEGF) and tumour necrosis factor (TNF) which inhibit the function of 
effector cells and also by acting in the early stages of immunopoiesis prevent the 
development of the immune cells (Ohm and Carbone, 2001). Significantly higher 
expression of TGF-a, TGF-P, IL-4 and IL-10 compared to IFN-y, IL-2, IL-12 and IL- 
18 at mRNA level has been reported in patients with non-small cell lung cancer 
(NSCLC) (Li et al, 2003). The prominent expression of type II cytokines in
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comparison to type I is reflective of the tumour immunosuppressive 
microenvironment. The suppressive IL-10 cytokine is capable of inhibiting the in vivo 
production of Thl responses, generation of IL-12 and antigen presentation (De Smedt 
et al, 1997; Sharma et al, 1999). Pancreatic and melanoma (Fortis et al, 1996) cancer 
patients have been found to have high levels of IL-10 (Bellone et al, 1999; Mukherjee 
et al, 2001). Furthermore, elevated levels of transforming growth factor (TGF-p) 
correlated with tumour progression and poor prognosis have been reported in cancer 
patients (Tsushima et al, 1996). Moreover, overproduction of IL-10 in tumours has 
been shown to be induced by TGF-p which results in suppression of anti-tumour 
responses. Vascular endothelial growth factor (VEGF) is essential for tumour 
vascularization. It prevents immune recognition (Ohm and Carbone, 2001) , and also 
inhibits maturation and differentiation of DCs through suppression of the transcription 
factor NF-KB in haematopoietic stem cells (Oyama et al, 1998). Poor prognosis in 
human neoplasms has been associated with high VEGF levels in blood (Lissoni et al, 
2001) due to its angiogenic characteristics or its ability for suppression of DC 
maturation (Lissoni et al, 2001; Inoshima et al, 2002; Talmadge, 2007) (Table 1.5).
Effect TGF-p IL-10 VEGF
Inhibition of T-cell growth + - +
Inhibition of CTL differentiation + + +
Inhibition of cytokine production + + -
Induction of T-cell anergy + - -
Downregulation of cytotoxic potential + + -
Inhibition of antigen presentation + + -
Shift in the Th1-Th2 balance towards Th2 + + -
Downregulation of adhesion/costimulatory 
molecules
+ + -
Resistance to CTL-mediated lysis - + -
Table 1.5 Table showing the effects of immunosuppressive cytokines on immune 
responses
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1.3.3.4 Regulatory cells
There are two types of cells, CD4^CD25'^ regulatory T cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs), which cause the tumour to escape 
immune recognition by having a suppressive effect on the host’s immune system. 
Inhibited functional activity of a number of T cells in tumour-bearing hosts has been 
investigated comprehensively (Levey and Srivastava, 1996; Plescia et al, 1976), and 
revealed the key role of suppressor cells in cancer progression (Dye and North, 1981).
Tregs, responsible for peripheral tolerance, have been reported to be elevated 
in the blood and tumours of various cancer patients (Janeway et al, 2001). There are 
two main types of Tregs; natural Tregs which are generated in thymus and inducible 
Tregs which can be generated in periphery from naïve T cells. Inducible Tregs include 
Trl and Th3 which secrete high levels of IL-10 and TGF-p respectively. There is an 
association between the production of Tregs and several factors within the tumour 
microenvironment including IL-10, VEGF, indoleamine 2,3-ddeoxygenase (IDO), 
TGF-p, and inhibitory APCs. Secretion of TGF-p and IL-10 in vivo, direct inhibition 
of activation of T cells, suppression of APC function through preventing IL-12 
production and expression of CD80, CD86 and MHC molecules has been shown by 
Tregs. Hence, Tregs are capable of direct and indirect inhibition of TAA-specific 
immunity through APCs (Leen et al, 2007). More details on Tregs will be discussed 
in section 1.6.1 as this cell type is the focus of one of my main projects.
MDSCs with an immature myeloid phenotype are another type of regulatory 
cell that are able to prevent induction of antibodies and CTLs, function of T cells and 
proliferation of lymphocytes (Kusmartsev et al, 2000; Mazzoni et al, 2002, Talmadge,
2007). It has been demonstrated that MDSCs are elevated in various pathologic 
conditions such as traumatic stress, neoplastic diseases, inflammatory diseases, 
infections and graft-versus-host disease (Bronte et al, 2001; Gabrilovich, 2004). 
Different immunosuppressive mechanisms are employed by MDSCs including up- 
regulation of immunosuppressive cytokines, nitric oxide (NO), reactive oxygen 
species (ROS) and L-arginine metabolism. Immature phenotypic markers of human 
MDSCs are described as lineage negative (Lin“), HLA-DR”, CD 14", CDl l b \  CD 13^, 
CD15\ CD33^ and CD34^ cells. MDSCs have been described in the peripheral blood
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of patients with renal cell carcinoma (Apolloni et al, 2000; Zea et al, 2005) 
subsequent to their original discovery in Head and neck cancer patients {Kusmartsev 
and Gabrilovich, 2005). Furthermore, high levels of MDSCs have been observed in 
the murine system with the equivalent phenotype of CD 11b'*', Grl% CD31^, CD115\ 
CD 124'*', IL-4R-a and macrophage-colony stimulating factor receptor (Gallina et al, 
2006; Huang et al, 2006; Leen et al, 2007).
1.3.3.5 Induction of tolerance
Cross-presentation was introduced thirty years ago (Bevan, 1976; Trincheri et 
al, 1976) when considerable evidence showed transfer of tumour antigens for 
presentation to host professional APCs through the MHC class I pathway. The 
activation of high-affinity T cells through cross-reactive recognition of foreign 
antigens that mimic the structure of tumour proteins generates a strong anti-tumour 
immune response (Sioud, 2009). Inducing allo-restricted high-affinity cytotoxic T 
cells against synthetic self-peptides bound to non-self-MHC molecules was described 
by Stauss et al. in 1990. In addition, lack of or weak antigen presentation by most 
tumour cells that does not prime an immune response has been currently suggested. 
Moreover, it has been recently identified that tumours, similar to self-antigens, can 
generate peripheral tolerance thus, explaining the immunosuppressive nature of the 
tumour microenvironment (Rosenberg et al, 2004; Zou, 2005; Van der Most et al,
2006). Peripheral tolerance is a mechanism to prevent self-reactive T cells that escape 
central tolerance in the thymus and cause autoimmunity. Several data suggest 
induction of tolerance rather than priming by tumour antigen presentation. Therefore, 
approaches that alter the balance toward immunity through limiting the inhibitory 
elements responsible for tolerance and positively enhancing priming would be a major 
focus of therapeutic strategies (Tomasi et al, 2006).
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1.4 Interaction between the immune system and tumours
There is now compelling evidence that a dynamic cross-talk between the 
immune system and tumours can modulate tumour growth and metastasis (Croci et al,
2007). Tumour-infiltrating lymphocytes (TILs), macrophages, dendritic cells (DC) 
and B cells as the components of an inflammatory host response to the tumour (Figure 
1.6) generally infiltrate pre-malignant and early tumour lesions (Von Kleist et al, 
1987; Coronella et al, 2001). Convincing evidence over the years indicates that TILs, 
in spite of their activation phenotype, are functionally compromised and augmented in 
TAA-specific memory T cells (Whiteside, 1993). Hence, in response to the signals 
initiated by the tumour, TILs, as opposed to other inflammatory infiltrates, 
accumulate and embrace immune cells specific for various peptides expressed by 
tumour cells. It has been advocated that TILs produce growth factors and cytokines 
crucial for tumour growth and that tumours elaborate chemotactic factors that recruit 
macrophages and lymphocytes to the tumour environment (Balkwill, 2004). However, 
orchestration of this recruitment in response to the tumour is currently a disputed 
matter as to whether it is generated by the tumour or by surrounding tissue cells.
In addition, it has been shown that these recruited cells might fail to have anti­
tumour functions. Recent data support this hypothesis by implying that cytokines are 
generated by TILs in response to TAA, however, they might have weak anti-tumour 
effector functions. Cells forming pre-malignant lesions like carcinomas in situ (CIS) 
or dysplasias may be antigenically identical to normal tissue cells, even though 
genetic abnormalities exist (Zhang, 1997). Upon recognition, the host immune system 
eradicates these clonally expanding tumour cells which are genetically unstable and 
receive chromosomal aberrations. These genetically altered tumour cells that are 
resistant to being detected by the immune system emerge as a consequence of immune 
selection. Hence, the role of the immune system in manipulation of tumour 
progression or host protection from malignancy stays debatable and may be 
contingent on the individual tumour features (Whiteside, 2006).
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Figure 1.6 A schematic diagram of the interaction between the immune system and 
tumour. Activation or suppression of immune cells in response to tumour is affected by 
various factors including pro/anti-inflammatory cytokines and Th1/Th2 environment.
In order to manifest the interaction between tumour cells and tumour- 
associated lymphocytes, Tanaka et al. employed the Mixed Leukocyte/Tumour Cell 
Cultures (MLTC) technique with primed syngeneic splenocytes and the corresponding 
tumour cells to create an ex vivo tumour immunity model. The tumour 
microenvironment was mimicked in their experiment and it was revealed that 
splenocytes from MLTC of poorly immunogenic tumour cells (D5 melanoma cell 
line) in syngeneic settings secrete type 2 cytokines, such as IL-4 and lL-10 and 
immunoinhibitory factor TGF-pl. On the contrary, predominant type 1 immune 
responses were generated by splenocytes of immunogenic tumours (FBL3 and H22 
tumour cell lines), displaying IFN-y secretion. Intracellular cytokine detection assay
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demonstrated higher CD4+IL-10+ T cells and greater CD4+IFN-y+ T cells in 
syngeneic poorly immunogenic MLTC setting and syngeneic immunogenic and 
allogeneic MLTC settings respectively. Despite an immune response, tumours 
eliciting Th2 type response can proceed to grow while tumours inducing Thl type 
response can be eliminated. Moreover, findings obtained by Tanaka et al. also suggest 
that the ex vivo models manifest the in vivo situation to some extent (Li et al, 2003; 
Liu et al, 2003; Xiao et al, 2005). Importantly, CD4^CD25^ Treg cells were ten-fold 
higher in the syngeneic poorly immunogenic MLTC of D5 than that in the syngeneic 
immunogenic MLTC of H22. Poorly immunogenic tumour associated lymphocytes 
secrete Treg-favouring cytokines such as TGF-pl that generates a special 
microenvironment which is antigen specific upon initiation and non-specific fashion 
afterwards. It has been reported that Treg cells are recruited to tumours by the 
chemokine CCL22 and promote a favourable environment for tumour initiation and 
growth (Somasundaram et al, 2002; Wang et al, 2006).
Consequently, skewing the T cell response from type 2 to a type 1 cytokine 
profile as well as potentiating tumour antigen-specific immune responses would be a 
major challenge. The prospect of achieving this objective is highly reliant on a better 
understanding of the mechanisms and interactions functioning during the different 
stages of the cancer immunoediting process (Croci et al, 2007).
1.4.1 Cancer immunoediting
Recently Schreiber et al proposed the cancer immunoediting hypothesis which 
has incorporated classical immunosurveillance with mechanisms of tumour-immune 
escape (Dunn et al, 2004). The resurgence of tumour immunosurveillance as a 
constituent of the recent immunoediting hypothesis originates from the understanding 
that the host’s immune system protects against tumour development and also 
unintentionally encourages tumour growth by choosing poorly immunogenic variants 
of tumour escape.
It has been proposed that the process of cancer immunoediting encompasses 
three essential phases in host and tumour cell interaction (Figure 1.7). The first phase,
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classified as “elimination,” compromises the traditional concept of cancer 
immunosurveillance, in which innate and adaptive immune cells protect the host 
against cancer through recognition and destruction of developing tumours. The seeond 
phase, referred to as “equilibrium,” a prolonged period in whieh immune surveillance 
and persistent tumour growth both reach a dynamic balance with one another. The 
third phase is “escape”, in which variants of tumour capable of eluding immune- 
mediated eradication originate and progress into clinieally manifest neoplasms (Dunn 
et al, 2004). Therefore, an improved awareness of the interaetions between the 
immune system and tumours will contribute to innovative and more efficient cancer 
immunotherapy strategies (Croci et al, 2007).
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1.4.2 Metastasis in cancer
The role of the immune system in tumour metastasis is another controversial 
matter in cancer immunotherapy. In order to metastasize, the tumour must exhibit 
certain specific features, such as the potential to infiltrate the endothelium and obtain 
motility within tissues in addition to blood vessels or lymphatics (Bogenrieder and 
Herlyn, 2003). Phenotypic features of lymphoid eells are adopted by solid tumour 
eells enabling them to migrate employing exactly the same mechanisms (Nathanson,
2003). However, circulating tumour cells are specifieally sensitive to lysis by 
monocytes or natural killer eells (Whiteside and Herberman, 1995). Additionally, 
anti-tumour Abs as effeetor cells of innate immunity that mediate antibody-dependent 
cellular cytotoxicity (ADCC) also effectively eradicate tumour targets (Mellstedt,
2003).
Upon tumour cell evasion from immune mediation in the lymphatic circulation 
or peripheral blood and its arrival at a new tissue site, the tumour is then reliant on the 
local microenvironment for structural support by the extracellular matrix (ECM) and 
growth factors. It has been postulated that sueh growth factors can be produeed by 
tumour-speeific immune eells responding to TAA, hence contributing to metastasis 
formation. Consequently, the dual role of the host immune system in tumour 
elimination /promotion depends on local signals and circumstances presented by the 
tumour. Moreover, it has been proven that highly aggressive tumours are more 
successful in destroying the microenvironment containing immune cells to promote 
tumour demands (Whiteside, 2006).
1.4.3 Inflammation in cancer
The concept of immunostimulation was originally postulated by Richmond 
Prehn in 1971 suggesting that stimulation of tumour development rather than their 
inhibition often occurs in case of a mild immune response against certain tumour 
types (Prehn and Lappe, 1971). The findings of Stewart et al. on human breast cancer 
showed that a mild inflammatory response at initial stages of tumour progression
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stimulates the development of certain types of human mammary carcinomas, 
confirming Prehn’s postulation (Steinman et al, 2003; Croci et al, 2007).
Infiltration of inflammatory cells into tissue and the generation of various 
growth factors, cytokines or chemokines stimulating or suppressing cellular 
proliferation is normally induced by tissue trauma. Mononuclear cells infiltrate the 
majority of human tumours during different stages of their development. As a result 
of prolonged inflammation within the tumour environment soluble factors and 
reactive oxygen species (ROS) are released which can lead to induction of dysplastic 
alterations in the genetically modified initiated tissue cells. In sustained inflammation 
such as cell death and necrosis, depending on the cellular composition of the 
microenvironment, the local immune responses eould be either promoted or 
suppressed by the cytokine cascade that is mediated. Continuous proliferation of 
transformed cells at sites of ehronic inflammation whieh associate with growth factors 
and inflammatory cells such as tumour necrosis factor- a (TNF-a) leads to the 
eontinuous inflammatory progression that can become an essential stage in 
carcinogenesis. In addition, it has been shown by recent findings that establishment of 
chronie inflammatory states, that support careinogenesis, require B lymphocytes (De 
Visser et al, 2005). Association of many cancers with persistent inflammation has 
been proven and some examples of such include colon cancer with inflammatory 
bowel disease, oral squamous cell carcinoma with gingivitis, lung carcinomas with 
asbestosis or silicosis and pancreatic cancer with panereatitis (Coussens and Werb, 
2002; Whiteside, 2006). The assoeiation of soluble factors with immunostimulation 
has been proposed by several publications. For instance, stimulating the development 
of metastatic B-cell lymphoma by IL-10 and its receptor (IL-IOR) and creating an 
autocrine loop has been shown (Rico et al, 2005). Moreover, it has been proposed that 
elevated production of IL-10, generated by carcinoembryonic antigen (CEA), 
augments liver métastasés in human colorectal carcinomas (Jessup et al, 2004). 
Furthermore, other types of soluble factors such as VEGF involved in angiogenesis 
has been demonstrated to be positively assoeiated with caneer progression (Mor et al, 
2004; Poon et al, 2001).
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Recently performed studies by Karin et al. in cytokine knock out (KO) mice 
have demonstrated that inflammation-induced tumour growth is reliant on production 
of the pro-inflammatory cytokine TNF-a by host hematopoietic cells and which has a 
crucial role in induction of carcinogenesis via the NFkB pathway (Suganuma et al,
1999). In addition, Langowski et al. showed in their studies that CTL infiltration and 
subsequent immunosurveillance is promoted by IL-12, whereas tumour-associated 
inflammatory responses and reduction in infiltration of CTLs is promoted by IL-23 
that shares the p40 subunit with IL-12 (Langowski et al, 2006). Consequently, tumour 
progression may be positively or negatively affeeted by closely associated cytokines 
through the regulation of the intensity and nature of tumour-associated inflammatory 
responses (Croei et al, 2007).
Several cancers are correlated with or introduced by unrestrained pathogenic 
infections and chronic inflammation such as cervical carcinoma with human 
papilloma virus (HPV), Kaposi's sarcoma with Herpes simplex virus (HSV)-8, gastric 
cancer with Helicobacter pylori, and adult T-cell leukaemia with human T-cell 
lymphotropic virus and liver cancer with hepatitis B and C viruses (Whiteside, 2006). 
Most of the adjuvants (i.e. IL-12) in combination with cancer vaccines cause 
inflammation which usually enhances immunity (Rosenberg et al, 2004), whereas 
others such as chemotherapy and radiation generate apoptosis which can promote 
inflammation and also supply tumour antigens (Tomasi et al, 2006). Notably, 
depending on the signals in the local microenvironment and the ability of the host to 
regulate these signals, the tenuous balance between immune promotion and immune 
surveillance is probable to switch. In this situation, cancer develops when the host's 
immune system is unable to diminish chronic inflammation and establish the healing 
proeess (Dworak, 1986; Whiteside, 2006).
Moreover, findings have shown that cytokines such as interferons (IFNs), 
interleukin-2 (IL-2) and messengers (chemokines) can be involved in the activation of 
immune effector mechanisms that restrict the growth of the tumour as well as their 
involvement in tumor growth, invasion, metastasis, careinogenesis and malignant 
transformation. In addition to their direct induction by malignant cells, cytokines are 
induced by immune cells and host stromal cells in response to inflammation caused by
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tumour growth or molecules secreted by tumour cells. The local cytokine network 
fluctuates at various stages of tumour development depending on their receptor 
expression patterns and relative concentrations. Thereby, they provide the means by 
which T cells recognize tumour cells and manipulate them, leading to reliable 
induction of tumour regressions (Nencioni et al, 2008).
1.5 Immunotherapy in cancer
The concept of immunotherapy of cancer is more than a century old, but only 
over the last two decades have molecularly defined therapeutic approaches been 
developed (Matzku and Zoller, 2001). Despite difficulties in prevention and treatment 
of human cancer due to poor immunity and lack of a specific target, recent advances 
in both molecular biology and immunological aspects of tumour expansion, as well as 
increased understanding of the fundamental mechanisms of the regulation of the 
immune response, are leading to the development of a variety of specific and 
unspecific immunostimulatory strategies for anti-tumour vaccines (Hong and Fan,
2008). The clinical goal of tumour immunotherapy is to elicit either active or passive 
immunity directed against tumour antigens by harnessing the immune system to target 
tumours and thereby break tolerance and improve survival and quality of life of 
cancer patients (King et al, 2008).
Immunotherapy is a complementary or alternative approach to current 
treatment strategies. There is no anti-tumour specificity with surgery, radiation and 
chemotherapy at the single cell level, unlike the immune-mediated anti-tumour 
mechanisms. Thus, it is not feasible to eliminate every tumour cell, without common 
occurrences of cancer recurrence. Moreover, these modalities can lead to resistance 
rather than memory of tumour. It may be possible to achieve complete tumour 
elimination and durable remissions with properly designed cancer vaccines alongside 
conventional treatment modalities. Due to specificity of immune responses in 
targeting malignant cells and avoiding normal cells minimal toxicity is predicted. 
Immunotherapy also seems to be a particularly promising systemic approach to the 
curative therapies for advanced or recurrent forms of cancer.
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1.5.1 Immunotherapeutic strategies in cancer
To date, various forms of immunotherapeutic approaches have been 
investigated. Employing natural biological products by most of these techniques cause 
activation of the immune system through genetic engineering and hybridoma 
methods. The different types of immunotherapy divide into three main classes: 
monoclonal antibodies, immune response modifiers, and vaccines. All of these have 
increasingly become successful therapeutic agents for the treatment of solid and 
haematological cancers in preclinical models, clinical trials, and practice (Baxevanis 
et al, 2009). Antibody-based therapies which are a form of passive immunotherapy 
(Kulcsar, 1997b), involve introducing substances into the body that induce an 
extrinsic immune response as opposed to the body generating an intrinsic immune 
response. However, vaccines are a form of active immunotherapy which induce an 
intrinsic immune response. They are also regarded as a specific form of 
immunotherapy since they stimulate immune responses directly towards the tumour 
antigens compared to nonspecific methods that generally induce the immune system 
to produce cytokines (Adam et al, 2003).
1.5.1.1 Monoclonal antibodies
Monoclonal antibody therapy has evolved as a standard cancer therapy in 
recent years (Trauth et al, 1989). There is convincing evidence that shows effector 
cell-mediated responses provide remarkable in vivo antibody potency, therefore, 
several approaches are investigated currently to enhance the interaction between 
tumour antigens and effector cells that express Fc receptor. Implementation of 
antibodies directed against the Fc receptor with specificity for both cytotoxic Fc 
receptor on effector cells and tumour-antigen are among these approaches. 
Consequently, cytotoxic inducer substances on killer cells are selectively involved by 
bispeciflc antibodies and prevent interaction with inhibitory Fc receptors. It has been 
demonstrated in vitro that comparing conventional IgG antibodies with chemically 
linked bispeciflc antibodies directed against the Fc a-receptor FcaRI (CD89) and the 
Fc y-receptors FcyRI (CD64) and FcyRIII (CD 16), the latter are conspicuously more 
efficacious. Nevertheless, Peipp and Valerius showed obvious limitations of these
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molecules in their clinieal trials such as short plasma half-lives in comparison with 
conventional antibodies (Peipp and Valerius, 2002). The inhibition of growth factor 
receptor signalling, the products of oncogenes and protooncogenes and the 
immunologieal employment of antigenic differences between malignant and normal 
cells can be the potential targets for antibody therapy.
Subsequent to its evaluation in the 1970s, applieation of monoelonal antibody 
was established as a potential therapy for caneer; however it has only been introduced 
mainstream elinical practice during the past few years. Antibodies ean be targeted 
towards specific tumour antigens. Some examples of cancer therapy using monoclonal 
antibodies direeted against tumour-speeific antigens are Rituximab for the treatment 
of non-Hodgkin's lymphoma, Trastuzumab for breast cancer and Oncoseint for the 
diagnosis of eertain cancers (Plunkett and Miles, 2002). Furthermore, use of other 
monoclonal antibodies such as Herceptin, Avastin, Bexxar and Erbitux as passive 
immunotherapy is the most important and widely used approach that has the potential 
to establish immunotherapy as a true cancer treatment option (Hurwitz et al, 2003; 
Karnes et al, 2006). In addition, it has been proven that monoclonals are capable of 
providing assistance in diagnosis and treatment of antigens that recognise normal cells 
from eaneerous. An example of a poorly-diagnosed and aggressive neoplasm of 
children and young adults is desmoplastic small round cell tumour whieh is sensitive 
to chemotherapy, but due to disease metastasis patients often relapse after therapy. 
Therefore, approaches targeting minimal residual disease are essential in treatment. It 
has recently been evidenced in advanced-stage neuroblastoma that monoclonal 
antibodies specific for tumour-associated antigens have application in diagnosis and 
therapy of microscopic disease at distant sites (Modak et al, 2002). Moreover, 
monoelonals contribute as strong implements to charaeterize, treat, and observe 
relapses of previously treated cancers (Adam et al, 2003). The utility of antibody in 
terms of improving prognosis is currently only when combined with chemotherapy.
In conclusion, although it has been shown that indueing immunity against self 
antigens is dangerous territory because of the potential for autoimmune damage to 
crucial normal tissues, treatments using passive immunization with monoclonal 
antibodies against self antigens have already been successful in objectively shrinking 
established tumours in patients with cancer, without serious toxicities (e.g., the
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administration of rituximab, which is active against CD20 on the surface of B cells for 
the treatment of patients with lymphoma, Herceptin in breast cancer and anti-EGFR 
Abs in eolorectal cancer) (Houghton et al, 1985; Houghton et al, 2004; Rastetter et 
al, 2004).
1.5.1.1.1 Limitations of monoclonal antibody therapy
As well as their cost, there are also a few limitations with antibody therapy. 
First of all, constant administrations of antibody are involved due to lack of induction 
of a memory response. Furthermore, antibodies themselves are potentially 
immunogenic since they are either humanized or chimeric and preserve only a small 
constituent of murine which can lead to complications with continual infusions. 
Moreover, there are limited varieties of applicable targets as only specific proteins 
expressed on the cell surface are recognized with antibodies. Intraeellular proteins are 
disintegrated into numerous cell surfaee-expressed peptides which connect with a 
MHC molecule. The peptide-MHC complexes are then recognized by the TCR that 
targets numerous intracellular tumour antigens (King et al, 2008).
1.5.1.2 Immune response modifiers
Immune response modifiers are extrinsic or intrinsic molecules which 
influence the host immune response. Immune potentiators are one group of extrinsic 
modifiers whieh include endotoxin, C. parvum and BCG, which are microbes or 
microbial products that influence the immune response and cause tumour regression 
or slow growth. The intrinsic group affect the immune response at different stages and 
are referred to as biological response modifiers. These inelude IFN (a, p, and y), IL-1, 
IL-2, TNF, eolony stimulating factors as haematopoietic growth factors and B-cell 
growth factors. To re-establish bone marrow function haematopoietic growth factors 
are generally incorporated with radiotherapy and chemotherapy. Thalidomide with 
antiangiogenic features suppress the generation of TNF-a and is under assessment in a 
number of different cancers at present.
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More than 20 interleukins (IL-1 to IL-18 and IL-23) exist and 5 more proteins 
have been identified recently with the likelihood of being named interleukin. 
Cytokines with autocrine and paracrine functions are protein or glycoprotein 
messengers that are secreted by immune cells and act locally or at a distance to 
improve or reduce immunity. Cytokines function in cascades, modulate the adaptive 
immune system and are used in cancer therapy to enhance immunity. Individual 
cytokines are hardly ever effeetive in clinical trials as they are likely to function 
cooperatively. IL-lp is one of the individual cytokines that have been shown to be 
inadequate in cancer therapy, however, since it contributes to mediate the severe 
toxicity of IL-2 it can still be helpful. The most comprehensively studied interleukin is 
IL-2 which is employed for immunostimulation in malignant melanoma and 
metastatic renal cell carcinoma. TNF has limited effectiveness due to induction of 
severe hypotension once used systemically. IL-4 is toxic and has minimum anticancer 
efficacy. IL-6 has anti-cancer activity, however has proved to be a growth factor for 
myeloma cells. Discrepancies have been found in the use of GM-CSF which is 
applied mainly in stem cell transplant to restore the myeloid cells in melanoma. IL-2 
funetions against lymphoma, renal cell, leukaemia and melanoma. In addition to these 
cancers, IFN has anti-cancer activity against hairy cell leukaemia (HCL), chronic 
myelogenous leukaemia and Kaposi's sarcoma. The haematological values and 
survival of HCL has been shown to be significantly improved in most patients upon 
the application of IFN-a (Zinzani et al, 1997).
Combination of IFN-a and IL-2 with meroxyprogesterone generates a 
reassuring response rate with low toxieity (Naglieri et al, 2002). Nevertheless, 
paradoxical outcomes have been obtained from clinical trials that are limited to 
combination therapy of IFN-a and IL-2 in the treatment of metastatie renal cell 
carcinoma (Ravaud et al, 2002). Up-regulation of endogenous TNF-a and 
reeonstitution of the effeetiveness of the T eell reeeptor family is the way how the 
immune modulator, IFN-a functions in HCL (Baker et al, 2002). Both of these 
cytokines have been accepted by the Federal Drug Agent for cancer treatment. In 
general, IL-2, IL-12, IFN-a and GM-CSF have been assessed for cancer therapy due 
to their utilization in the treatment of immunogenic tumours or haematological 
malignancies (Adam et al, 2003). A list of different types of immune response 
modulators are shown in Table 1.6.
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In addition, anti- CTLA4 antibody is another immune response modifier which 
is commonly used. CTLA4 is homodimeric T cell receptor which binds B7-1 and B7- 
2 ligands but leads to attenuation of the immune response. Anti-CTLA4 antibody can 
act as an antagonist of the CTLA4/B7-1 or B7-2 interaction. This has revealed 
promising results in vitro, in mouse models and in clinical trials for a range of 
malignancies sueh as melanoma, prostatic, ovarian, renal and colon cancer (Peggs et 
al, 2006). However, due to the very long half life of anti-CTLA4 antibodies, adverse 
immune events involving skin and gastrointestinal tract can occur with serious 
autoimmunity consequences including colitis.
Cytokines Lymphokines Chem okines Growth factors
IL-1 a IL-2 IL-8 EGF
IL-1|3 IL-3 Gro- a TGF-3
IL-6 IL-4 Gro- 3 FGF
IL-10 GM-CSF MIP-1a PDGF
IL-13 IFN-y MIP-ip TGF-3 family
TNF-a MCP-1, -2 and -3
Tabie1.6 Table show ing immune re sp o n se  m odulators
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1.5.1.3 Vaccines
There are different vaccination strategies for caneer treatment and prevention 
which are reliant on the prominence of target antigens and whether there are preserved 
antigens shared in similar tumour types in many individuals. Some of the most widely 
studied approaches are discussed below (Table 1.7).
1.5.1.3.1 Modified tumour cell vaccines
The tumour itself is the strongest source of antigens. Nevertheless, application 
of autologous tumour cell vaceines is inconvenient and not compliant to extensive 
produetion of vaccines in addition to inaccessibility of tumour samples. Application 
of generic or allogeneic cell lines as vaccines is a more appropriate approach. 
Secretion of several cytokines from engineered-tumour cells has been demonstrated to 
be proteetive to mice confronting the same type of tumour (Dranoff et al, 1993). GM- 
CSF is the most efficient cytokine studied so far and its local expression promotes 
DCs and other APCs at the site of vaceine infusion. Several genetically modified 
allogeneic or autologous tumour cell vaccines have been examined in clinical trials 
(Simons et al, 1999; Soiffer et al, 1998; Jaffee et al, 2001; Salgia et al, 2003). Data 
has been obtained from patients with metastatic malignant melanoma and advanced 
prostate cancer (Simons et al, 1999; Soiffer et al, 1998) who received irradiated 
autologous tumour cells transfected with a GM-CSF-expressing retroviral vector. It 
showed that 11 of 16 melanoma biopsies had great inflammatory infiltrate with 
fibrosis and necrosis of tumour and only one partial response in 21 melanoma patients 
(Soiffer et al, 1998). Furthermore, another phase I trial revealed that 3 of 14 
pancreatic cancer patients vaccinated with GM-CSF-transdueed allogeneic pancreatic 
cancer cell lines remained disease free at 23 months after surgery (Jaffee et al, 2001). 
Moreover, currently in clinical trials there are several genetically altered allogeneic 
and autologous tumour cell vaccines that express B7.1, IL-2, IL-4 and a-(l, 3) 
galactosyltransferase (Maio et al, 2002; Antonia et al, 2002; Unfer et al, 2003; 
Berzofsky et al, 2004).
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1.5.1.3.2 Peptide vaccines
The finding that 8-10 amino acid-peptide segments positioned into the MHC 
groove, together with the understanding of the amino acid sequences of tumor 
epitopes, urged the employment of peptides as therapeutic factors in cancer therapy. 
These findings were accompanied by cloning of the first human TAA and detection of 
its nonamer peptide sequence (Traversari et al, 1992). It has been demonstrated that 
immunisation with peptide-based CTL epitope vaccines in murine tumour models is 
eapable of inducing specific CTL immunity resulting in eradication of tumour cells 
(Mayordomo et al, 1996). In humans, evaluation of peptide vaceines has been shown 
in patients with malignant melanoma using MAGE-3 as TAA. Tumour regression in 7 
of 25 patients examined was observed with no toxicity; however, no MAGE-3- 
specific CTLs were detected after therapy (Marchand et al, 1999). To enhance 
immunogenieity and to drive the immune system towards appropriate responses, a 
number of different approaches have been established such as epitope enhancement. 
In addition, autologous DCs have been loaded by peptide for vaccination purposes. 
Nevertheless, individual peptides are only effective in patients with adequate HLA 
molecules to present that peptide (Berzofsky et al, 2004).
1.5.1.3.3 Epitope enhancement
Epitope enhancement involves alteration and adjustment of the epitopes’ 
amino aeid sequence in order to enhance the vaccines efficiency. This is achievable 
through several methods including augmentation of TCR triggering (Zaremba et al, 
1997; Fong et al, 2001; Rivoltini et al, 1999), augmentation of peptide affinity for 
MHC molecules (Berzofsky et al, 2001; Berzofsky, 1993; Rosenberg, 1988) or 
preventing peptide proteolysis by serum peptidases (Berzofsky et al, 2001; Parmiani 
et al, 2002; Brinckerhoff et al, 1999). Upon the modifieation of the peptide sequence, 
it is essential to ensure that the altered peptide sequence is still recognized by induced 
T cells. Epitope-enhanced peptides have shown significant efficiency in clinical trials 
(Rosenberg et al, 1998; Berzofsky et al, 2004). For example, in patients with 
metastatic melanoma a synthetie peptide with increased binding ability for HLA-A2
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molecules from the gplOO melanoma-associated antigen was used as a cancer vaceine 
and showed successful immunization in 91% of the patients (Rosenberg et al, 1998).
1.5.1.3.4 Recombinant viral vectors
There are several clinieal trials that either have reported or are currently in 
progress of application of recombinant viruses that express tumor antigens sueh as 
PSA or CEA (Marshall et al, 2000; Zhu et al, 2000). Adenovirus, avipox and vaccinia 
are among the vectors that have been applied. The high frequency of existing antiviral 
neutralizing antibodies might restrict the applieation of these vectors in particular for 
multiple doses, with the exeeption of fowlpoxes which do not generate neutralizing 
antibodies. Mucosal immunization is capable of suppressing potential resistance to 
poxviruses that is due to pre-existing systemic immunity since induction of mucosal 
immunity by systemic immunization is poor, however both mucosal and systemic 
immunity can be generated by mucosal immunization (Belyakov et al, 1999). 
Immunodominance can also be an obstacle sinee stronger immune responses may be 
generated against viral vector antigens eompared to tumor antigens. The supplement 
of genes for cytokines or immunostimulatory molecules can improve the efficacy of 
these vectors (Hodge et al, 1999; Oh et al, 2003). The introduction of such vectors to 
clinical trials is currently in progress. Moreover, these vectors can also be applied for 
antigen expression in DCs (Berzofsky et al, 2004).
1.5.1.3.5 DNA vaccines
Immune responses have been induced by intramuscular injections of naked 
DNA expression plasmids (Tang et al, 1992; Ulmer et al, 1993). Through DNA 
vaceination tumour antigen genes are presented to DCs to be processed and presented 
endogenously to CTLs in draining lymph nodes or they are introduced to other cells to 
be cross-presented by DCs with no neeessity for a viral vector. Therefore, diffieulties 
such as possible risks related to a live virus, competition from viral vector epitopes 
and low efficiency caused by initial immunity to the viral vector can be prevented. 
Constitutive, tissue or tumour-speeific promoters are applied for particular expression.
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Reports from vaccination of 17 metastatic colorectal carcinoma patients with a 
plasmid encoding CEA and hepatitis B surface antigen (HBs) as a control showed no 
production of antibody to CEA, despite a lymphoproliferative response to CEA in 4 
patients and generation of protective levels of anti-HBs antibody in 6 patients (Conry 
et al, 2002). In another trial, 4 out of 12 follicular lymphoma patients who underwent 
vaccination with plasmids encoding tumour-specific idiotypes demonstrated a specific 
anti-idiotype T cell proliferative or a humoral anti-idiotype response (Timmerman et 
al, 2002). Hence, DNA vaccines as anti-tumour vaccination have not yet proved to be 
very promising (Berzofsky et al, 2004).
1.5.1.3.6 Dendritic cell vaccines
Dendritic cells are the professional APCs of the immune system that are 
capable of being loaded with a variety of TAAs and introduced back to the patients as 
vaccine (Morse et al, 1999). Upon DC maturation, they cause down-regulation of 
antigen uptake and proeessing machinery, expression of CD83, up-regulation of co­
stimulatory molecules CD80/CD86, chemokine receptor CCR7 and MHC molecules. 
Consequently, mature DCs move to lymph nodes in order to activate antigen-reaetive 
T cells. Acquired deficiency demonstrated in maturation and function of DCs in 
cancer patients and tumour-bearing animals proposes a principle for application of ex 
vivo-generated DCs as antitumor vaccines. An association between inefficient 
production of CTLs and functional deficiency of DCs in a murine mutant p53 
fibrosarcoma model have been reported by Gabrilovieh and eolleagues (Gabrilovich 
et al, 1996). Stimulation of allogeneic T cells and generation of mutant p53 peptide- 
specific T cell responses by in vz>o-generated DCs from marrow progenitors have 
been shown (Gabrilovich et al, 1996; Mayordomo et al, 1995; Porgador and Gilboa, 
1995). Moreover, inhibition of the growth of murine established tumours eaused by 
immunization with mutant p53 peptide-pulsed DCs have been reported. Protective 
immunity against tumour challenge can be indueed by DCs pulsed with synthetie 
peptide tumour epitopes (Gabrilovich et al, 1996; Mayordomo et al, 1996), tumour 
lysates (Nair et al, 1997), tumour protein extracts (Paglia et al, 1996; Zitvogel et al, 
1996; Ashley et al, 1997) or by irradiated tumour cells-fused DCs (Siders et al, 2003).
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Furthermore, transfer of tumour antigen-encoding nucleic acids into DCs 
applying electroporation of tumour RNA (Ashley et al, 1997), retroviral vectors 
(Akiyama et al, 2000), lentiviruses (Esslinger et al, 2002), recombinant adenoviruses 
(Wan et al, 1997) or plasmid transfection (Chen et al, 2003) has been shown to be 
efficient. Antitumor vaccine efficacy can also be enhanced by targeting antigens to 
DCs through pairing with DC-specific antibodies (Bonifaz et al, 2002) or by 
transferring genes that encode cytokine IL-12 and co-stimulatory molecule B7 into 
DCs (Zitvogel et al, 1996). Two main strategies are currently applied in order to 
develop large numbers of clinical grade human DCs (Caux et al, 1992; Sallusto and 
Lanzaveeehia, 1994). These approaches include proeesses where (i) immature DC 
precursors are purified from peripheral blood (Fong and Engleman, 2000) and (ii) 
DCs are differentiated from peripheral blood monocytes (Sallusto and Lanzaveeehia,
1994) or CD34^ hematopoietic progenitor cells (Banchereau et al, 2001; Mackensen 
et al, 2000). Immature DCs can turn into mature DCs by applying CD40 ligand, TNF- 
a, cytokine cocktails or monocyte-conditioned media (Rosenzwajg et al, 2002) in DC 
vaccine preparation ((Berzofsky et al, 2004).
Consequently, the administration of cancer vaccines in combination with other 
interventions is necessary for achieving a good therapeutie response manifested after 
intensive investigations on various strategies. According to results aehieved from 
some ongoing clinieal trials, it is expected to see a considerable advance on the 
elinical perspectives of combining cancer vaceines with conventional treatments sueh 
as chemotherapy or radiation, also identification and optimal use of new adjuvants 
(i.e. to break immune tolerance towards self-antigens) in the management of 
overcoming at least some human malignancies (Hurwitz et al, 2003; Karnes et al,
2006).
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Vaccine Advantage Disadvantage
Whole tumour 
cell
1. Studied intensively
2. Can be processed to enhance tumour antigen 
presentation (e.g. irradiated tumour cells or tumour 
lysates)
3. Can be administered with adjuvents (e.g. BCG, 
KLH, viruses, etc.)
4. Likely to express the relevant tumour antigens
5. Antigens need not be defined
1. Required availability of 
autologous tumour or an 
allogenic cell line sharing the 
relevant tumour antigen
2. Poor ability to atimulate 
immune responses
3. Few responses and little 
benefit reported when used 
adjuvently in randomized clinical 
trials
Gene-modified 
tumour cell
1. Likely to express the relevant tumour antigens
2. Antigens need not be defined
3. Often engineered to doexpress the relevant 
immunostimulatory molecules and cytokines (e.g. 
GM-CSF, IL-2)
4. Use of allogenic tumour cell lines and fibroblasts 
to accelerate vaccine production
5. Some immunological and clinical responses 
reported
1. Required availability of 
autologous tumour or an 
allogenic cell line expressing the 
relevant tumour antigens
2. Weak antigen presentation by 
many tumours
3. Long manufacturing time
4. Need for ex vivo cell culture
5. Cost, time, and intensive
Plasmid (naked) 
DNA
1. Constructed to express the relevant tumour 
antigen
2. Easy to produce and stable
3. Can be administered as a direct injection or 
biolistacally
1. Required detailed knowledge 
of the antigen DNA sequence
2. Low immunological potency foi 
self (tumour) antigens
4. High doses of plasmid DNA 
are required to generate immune 
responses
Peptides 1. Can limit immune response to epitopes 
distinct from the wild type (e.g. point mutations or 
breakpoint-fusion genes)
2. Epitopes can be enhanced
3. Easy to produce and stable
4. Can be combined as cocktails of peptides
5. Some immunological and clinical responses 
reported
1. Required knowledge of the 
specific epitope
2. Immunogenieity restricted to a 
limited number of MHC 
molecules
3. Usually requires the addition o1 
an adjuvant for immunogenieity
Viral gene transfer 
vector
1. Engineered to express the relevant tumour 
antigen
2. Can be engineered to coexpress 
immunostimulatory molecules and cytokines
3. Wilde variety of available vectors (e.g. 
adenovirus, pox viruses, lentiviruses, etc.)
4. Some cellular immune responses reported
1. Immunodominance of viral 
antigens over tumour antihens
2. Weak anti-tumour responses 
seen with most viral vectors may 
attenuate the antiOtumour 
response
4. Risk of toxicity with live viruses
Antigen modified 
DCs
1. Use of powerful APCs
2. Techniques available to generate large number 
of clinical grade DCs
3. Target antigens may be defined or 
uncharacterized
4. Multiple antigen loading techniques (e.g. 
peptides, lysates, whole protein, RNA transfection, 
viral vectors, etc.) are available
5. Some immunological and clinical responses 
reported
1. Need for ex vivo cell culture
2. Cost, time, and labor intensive
3. Optimal technique for antigen 
loading remains undefined
4. Possibility of tolerization of 
final product
Table 1.7 Table show ing different cancer vaccine s tra teg ies
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1.6 Immunosuppression in cancer
Immunotherapeutic vaccination against tumour-associated antigens represents 
a promising option as viable alternative therapies in certain cancer treatment (Ho et al, 
2008) in regard to the possibility of long-lasting immunity against the cancer, its 
efficacy and safety profile (Kruger et al, 2007). However, despite these advances in 
vaccine technology, vaccines designed to evoke specific T cell based anti-tumour 
immunity have obtained only partial successes in the clinic (Henderson et al, 2005). 
Often, there is relapse of the disease even where complete responses or tumour 
regression was gained (Jay et al, 2004). The key reason possibly stems in part from 
the ability of tumours to suppress related T cell responses (Paul et al, 2007).
Effective immunosurveillance in human tumours is a matter of long-term 
controversy (Lucas & Coulie, 2008). T cell death caused by tumours has a crucial role 
in establishing tumour immuno-tolerance (Lu and Finn, 2008; Viola and Bronte, 
2007). Tolerance to tumour antigens can be mediated through the same pathways that 
induce T cell tolerance to normal self-antigens in order to prevent autoimmunity and 
can develop towards differentiation antigens that are expressed on tumours and 
normal tissues from which they derive (Alder, 2007). In immunocompetent 
individuals, lack of sufficient co-stimulatory and excess of co-inhibitory ligands in the 
tumour microenvironment contributes significantly to tumour cell survival (Gaumann 
et al, 2008). In addition, cancer patients have an abundant number of tumour-released 
microvesicles or exosomes in their body fluids which are likely to be involved in 
tumour progression (Huber et al, 2007).
Tumours employ a variety of potential immunosuppressive mechanisms that 
act both in tumours and systemically in cancer patients resulting in inhibition of 
primed effector T cells from functioning (Elkord, 2007; Rosenberg, 1988; Hong and 
Fan, 2008; Geissler and Weth, 2002). Known immunosuppressive mechanisms 
involved in cancer and the evasive strategies developed by tumours (Rabinovich et al,
2007) are depicted in Figure 1.8 and are described briefly below.
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Fig 1.8 A schem atic  diagram  of barriers faced by tum our-specific T cells. Three phases 
of the T cell response are depicted where immunosuppressive influences can act. Naïve T- 
cell priming leading to the productive proliferation, activation, and survival of tumour-specific T 
cells can be abrogated by several factors (Adapted from Lizee et al, 2007).
Myeloid-derived suppressor cells (MDSCs) are a highly heterogeneous 
cellular population of myeloid cells which includes immature macrophages, early- 
stage myeloid progenitors, granulocytic and dendritic cells (Cruijsen et al, 2007; 
Filipazzi et al, 2007; Movahedi et al, 2008). Recent data from a number of groups 
have established a progressive accumulation of immature myeloid cells (IMCs) 
(suggesting altered haematopoiesis) in the primary tumour site, blood, spleen and 
lymph nodes (Luczyhski et al, 2008; Diaz-Montero et al, 2008; Bond et al, 2001) that 
mediates tumour progression in numerous solid tumours through their inhibition, 
subversion and down regulation of tumour specific immune responses (Serafmi et al, 
2008; Bronte et al, 2001). These cells substantially limit therapeutic effect of immune 
therapy and cancer vaccination in cancer patients and tumour-bearing mice
Î
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(Kusmartsev and Gabrilovich, 2002; Serafmi et al, 2004; Kusmartsev and 
Gabrilovich, 2006). IMG can be actively recruited to the tumour site where these cells 
may differentiate toward tumour-associated macrophages (TAM) and/or endothelial 
cells (Mantovani et al, 2002; Mantovani et al, 2003), therefore promoting 
angiogenesis and tumour growth (Talmadge, 2007; Frey, 2006). At late stages, TAMs 
produce molecules directly promoting tumour invasion, growth, and metastasis 
(Mantovani et al, 2004). However, they may control initial tumour development if 
properly activated (Mantovani et al, 2002). Indeed, a limited tumour mass will 
possibly be inadequate to instruct macrophages into a suppressive phenotype (Nardin 
and Abastado, 2008; Martinez et al, 2008; Gratchev et al, 2006).
It has been shown recently that the differentiation of monocytes to myeloid- 
derived suppressor cells can be promoted by microvesicles released in patients with 
melanoma and colorectal carcinoma (Huber et al, 2007) supporting tumoral growth 
and immune escape [39]. These extracellular organelles have an important role in 
remodelling of tumour-stromal interactions for promotion of malignancy (Huber et al,
2007).
Another mechanism involves the expression of the immunosuppressive 
cytokines IL-10, TGF-B and vascular endothelial growth factor (VEGF) which 
significantly inhibit the activation of professional APC, therefore constituting barriers 
to effective T cell priming (Johnson et al, 2007; Mark et al, 2004). Multiple links 
between the role of immunosuppression and angiogenesis have been revealed in 
tumour biology (Vieweg et al, 2007). VEGF involved in vascular growth and 
permeability is a significant agent of immune tolerance in the tumour 
microenvironment (Johnson et al, 2007).
Poor chemokine trafficking of effector cells due to the lack of T-cell migration 
to tumour sites also plays a major role in the failure of activated T cells to cause 
tumour regression (Gross and Walden, 2008; King et al, 2008). Although T cells 
normally migrate in response to chemokine gradients (Hage et al, 2008), studies have 
shown that the corresponding chemokine receptors that can facilitate T cell migration 
to tumours are not naturally expressed by them, but instead alternate chemokine 
receptors that do not identify tumour-derived chemokines are expressed (Matzku and
52
Zoller, 2001). Even in the case of successful migration of a tumour-specific T-cell 
into the tumour microenvironment, there are several factors present within tumours 
that have been shown to diminish or abrogate T cell effector function (Rabinovich et 
al, 2007). These include absence of Toll-like receptor signalling in tumours causing 
lack of innate immune activation which affect optimal T cell priming and activation 
(Gregory Lizee et al, 2007). Other important negative regulatory pathways include 
metabolic dysregulation through the activity of indoleamine 2,3-dioxygenase (IDO) 
and direct inhibition through inhibitory ligands such as PD-Ll (Gajewski, 2007; 
Augusto et al, 2007).
Regulatory cell (Tregs) populations that may contribute to the 
immunosuppressive network including regulatory T cells, Trl cells and Th3 cells 
have all been described as major strategies employed by tumours to thwart immune 
responses (Hage et al, 2008; King et al, 2008; Belardelli et al, 2004). Tregs and their 
immunosuppressive role in cancer are one of the main focuses of my thesis and are 
therefore reviewed in more detail below.
1.6.1 Regulatory T cells
Immune reactions like every physiologic process need to be controlled and 
down-regulated after completion of its mission otherwise it becomes pathologic 
(Belardelli et al, 2004). Among several hypotheses, one generated by Gershon and 
Kondo in the early 1970s defined a subset of T cells with suppressive activity, and the 
term "suppressor cells" was used to describe these (Gershon et al, 1972). At that time 
there was extensive skepticism towards the entire concept of suppressor T cells and 
even their existence (Janeway, 1988). However, several experiments were performed 
in mice that clearly demonstrated antigen-specific suppression of autologous cytotoxic 
anti-tumour responses by such cells (Beissert et al, 2006; Gallimore and Godkin,
2008).
In 1995, Sakaguchi and co-workers were the first to identify in a murine 
model a population of naturally occurring CD4^CD25^ T cells that are now termed 
regulatory T cells (Tregs) which constituted approximately 5-10% of all peripheral T
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cells and exhibit potent regulatory functions both in vitro and in vivo (Sakaguchi et al, 
1995; Sakaguchi et al, 2001). Therefore, the terms suppressor T cells and regulatory T 
cells are sometimes used interchangeably.
Regulatory T cells are a highly specialised subset of immune cells and are 
functionally defined as T cells that diminish the activity of other cell types directly or 
indirectly leading to inhibition or weakening of immune responses (Wang HY and 
Wang RF, 2007; Beyer and Schultze, 2006). Their physiologic role is to protect the 
host from auto-reactive T cells thereby preventing the pathologic consequences of 
autoimmunity. Increased susceptibility to autoimmune disease results from a 
significant reduction in suppressive function of Tregs in patients with active 
rheumatoid arthritis, multiple sclerosis, type I diabetes, polyglandular syndrome of 
type II, myasthenia graves and psoriasis in comparison with healthy donors (Cools et 
al, 2007). Defective Treg function, rather than its frequency is suggested to contribute 
to disease development, as both these patients and healthy controls show the same 
percentage of Treg cells in their peripheral blood. Also individuals with asthmatic or 
allergic disease show dysfunction and/or a decrease of Tregs in suppressing Th2 
responses compared to healthy individuals (Beissert et al, 2006; Beyer and Schultze,
2008).
1.6.1.1 Regulatory T cell subsets
To date extensive studies of Treg cells have been done in mice and humans 
which has led to the identification and characterisation of several Treg subsets . These 
subsets have been defined by distinct phenotypic markers and suppressive 
mechanisms and show Treg heterogeneity (Beissert et al, 2006). These different 
subsets of Tregs are described in Table 1.8.
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Treg
su b se t
Regulatory
m echanism s
Transcription
factor
expressed
Target cells Function
CD4+CD25+
Tregs
Cell contact- 
dependent, 
cytokines (IL- 
10?:)
Foxp3 T cells, APCs Suppression of autoimmunity; 
inhibition of allograft rejection 
and of immune responses 
induced by microbial infection; 
mediation of UV-induced 
immunosuppression
CD4+CD25'
Tregs
Mostly 
mediated by 
cytokines
Foxp3 (?2) T/B cells, 
APCs
Suppression of autoimmunity
Tr1 cells Mediated by IL- 
10
Foxp3 (?2) T cells Suppression of autoimmunity
Th3 cells Mediated by 
TGF-P
T cells Suppression of autoimmunity
NKTregs IL-4, IL-10,
TGF-&,
cytotoxicity
T cells, APCs, 
tumour cells
Elimination of tumours and 
pathogens; suppression of 
autoimmunity; mediation of 
UV-induced suppression of 
protective tumour immunity
CDS'" Tregs Cell contact- 
dependent, 
cytotoxicity, 
cytokines (?^)
Foxp3 (?2) T cells Suppression of autoimmunity; 
regulation of peripheral TCR 
repertoire
Th17 IL-17,IL-22 ? ? Key role in autoimmunity, 
inflammation, tissue injury
CD8+CD28"
Tregs
Induction of 
ILT3/ILT4 in 
DCs
Foxp3 (?") DCs/APCs Regulation of autoimmunity 
(?')
Activatory
Tregs ? ? ?
Suppression of autoimmunity
Table 1.8 Table show ing different su b se ts  of regulatory T cells. (Adapted from Beissert et 
al, 2006).
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1.6.1.2 Phenotypic markers of regulatory T cells
Cytokines and co-stimulatory molecules are crucial factors in the homeostasis 
of Tregs. Although the expression of CD25 (IL-2 receptor a-chain) on T cells has 
been a good marker of Treg murine cells as these animals are held under pathogen- 
free conditions, its expression is not necessarily associated with Treg cell function in 
humans due to the constant exposure to foreign antigens resulting in a significant 
fraction of recently activated non-regulatory effector lymphocytes (Sakaguchi et al,
1995). In mice, all CD4VCD25^ T cells possess immunosuppressive action, whereas, 
in humans, only CD4^ T cells with the highest level of CD25 expression are 
characterised by T cell suppressive activity. Human CD4^ T-cells with low or 
intermediate CD25 levels have been shown to represent either naive/resting or 
memory/effector T cells (Wing et al, 2002; Dannull et al, 2005).
Among the cell-surface markers associated with Treg phenotype and function, 
other molecules including the glucocorticoid-induced tumour necrosis factor receptor- 
related protein (GITR), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), 
Lymphocyte activation gene-3 (LAG-3), CD39 (Fletcher et al, 2009), programmed 
death-1 (PD-1) (Wang et al, 2009) and fork head box P3 transcription factor (F0XP3) 
are the most prominent markers for Treg cells. However, since both CTLA-4 and 
GITR are activation markers, they are also expressed on activated effector T cells 
(Beyer and Schultze, 2006).
The transcription factor F0XP3 is the best marker of CD4^ Tregs identified to 
date as it is uniquely expressed in Treg cells in mice (Hori et al, 2003; Fontenot et al, 
2003; Khattri et al, 2003) and its expression has been proposed as a lineage marker in 
developing Treg cells. Congenital absence or mutations of F0XP3 causes a rare 
inflammatory disease, IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, and X-linked syndrome), which destroys the immunoregulatory 
environment of affected male infants and optimal therapy for this syndrome is limited 
(Yong et al, 2008). F0XP3-expressing Tregs are produced by the thymus and travel 
through the peripheral blood to tumours, bone marrow, and lymphatics (Vieweg et al, 
2007). Recent studies in humans demonstrated induction of F0XP3 in activated
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conventional T cells at a relatively low level without suppressive activity (Beyer and 
Schultze, 2006). Indeed, several differences between F0XP3 in humans and mice 
have been reported in recent studies. Human F0XP3 contains two isoforms: one 
encodes the full length of F0XP3, whilst the other encodes a short version of the 
protein that lacks exon 2 (amino acids 71-105) (Ziegler, 2006; Allan et al, 2005). In 
murine CD4+ Treg cells there is no short form of Foxp3. In humans, over-expression 
of F0XP3 alone or together with the short isoform is not effective in generating Treg 
cells (Allan et al, 2005). The major difference between humans and mice is that 
F0XP3 expression in human CD4+ T cells is tightly linked to T-cell receptor (TCR)- 
mediated activation (Ziegler, 2006).
Additionally, family members of nuclear factor of activated T cells (NFAT) 
are also involved in Treg-effector T cell interaction. NFAT, four calcium-regulated 
transcription factors (NFATl-4), modulate gene expression in various organs such as 
the immune system, bone, muscle and brain. NFAT is vital for the differentiation of 
different cell types including slow twitch muscle fibers, osteoclasts and effector T 
cells (Hogan et al, 2003). It has been shown that many of the genes regulated by 
NFAT are also target genes for F0XP3. For instance, they both up-regulate the 
expression of CD25 and CTLA4 genes. The mechanism of effect of F0XP3 on the 
expression of NFAT-dependent genes is not clear. However, it has been proposed that 
expression of IL-2 is down-regulated by F0XP3 through competition with NFAT for 
binding to DNA (Coffer and Burgering, 2004; Fontenot and Rudensky, 2005). 
Another suggestion based on physical interaction of NFAT and F0XP3 with each 
other in cell lysates (Bettelli et al, 2005), is that NFAT-driven cytokine transcription 
is down-regulated through isolation of NFAT from DNA. Nevertheless, the most 
compelling alternative mechanism is that the activating effect of F0XP3 on CD25 and 
CTLA4 genes and its repressive effect on the expression of cytokine genes manifest 
joint complex formation between F0XP3 and NFAT (Wu et al, 2006).
More recently, it has been found that CD 127 expression (a-chain of the 
interleukin-7 receptor) inversely correlates with F0XP3 expression and the 
suppressive function of CD4+ Treg cells (Liu et al, 2006; Seddiki et al, 2006). CD 127 
expression on effector T cells is down regulated after T cell activation. Thus, the
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combination of markers including CD25+, F0XP3+ and CD 127- better define the 
Treg cell population with suppressive function (Wang HY and Wang RF, 2007).
1.6.2 Regulatory T cells in cancer
As was discussed in previous sections Tregs are important mediators of active 
immune evasion in cancer and play an essential role in the mechanisms which are 
actively involved in suppression of pro-inflammatory immune responses, therefore 
providing a beneficial action in the detrimental effects in cancer.
1.6.2.1 Increased frequency of regulatory T cells in cancer
Numerous studies have now clearly demonstrated that Tregs exist in markedly 
higher proportions within tumour-infiltrating lymphocytes, peripheral blood 
lymphocytes and/or regional lymph node lymphocytes of patients with several types 
of cancer (Baecher-Allan and Anderson, 2006; Koenecke et al, 2008). Increased 
percentages of TGF-p secreting CD4^CD25^ Treg cells in tumour-infiltrating 
lymphocytes was reported for the first time by Woo et al. in ovarian cancer and non­
small-cell lung cancer (Koenecke et al, 2008). Furthermore, the finding of an 
increased prevalence of CD4^CD25^ Treg cells in the tumour microenvironment as 
well as in the peripheral blood was confirmed by a larger study of invasive pancreatic 
and breast cancer patients. This study went on to show that Tregs present in tumour- 
infiltrating lymphocytes and regional lymph nodes infiltrated by tumour secreted IL- 
10 and TGF-p prevented activated CD4^CD25" and CD8^ cells from proliferating 
(Liyanage et al, 2002). Interestingly, in a very recent study Ahmadzadeh et al. showed 
that the frequencies of CD4^FOXP3 Tregs were three to five-fold higher in tumours 
compared to peripheral blood of matched patients and thus they suggested that Treg 
frequencies in peripheral blood do not properly reflect the tumour microenvironment 
(Ahmadzadeh et al, 2008).
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In addition to solid tumours, data from previous work has established reports 
of an increase in Treg cell frequencies in haematological malignancies. Marshall et al. 
showed that in patients with Hodgkin’s lymphoma (HL), CD4^CD25^ and IL-10 
secreting Trl Treg cells infiltrate with peripheral blood mononuclear cells (PBMCs) 
and lymphocytes, in which they mediate suppression by CTLA4 expression, cell-to- 
cell contact and IL-10 secretion (Marshall et al, 2004). Also, increased frequencies of 
CD4‘"CD25^FOXP3'"CTLA4^GITR^ Treg cells and F0XP3^CTLA4^ Treg cells have 
been established in patients with B cell chronic lymphocytic leukaemia (CLL) and B 
cell non-Hodgkin lymphomas (B-NHLs) respectively (Beyer et al, 2005). Peripheral 
expression of CD4^CD25^F0XP3^ Treg cells has been reported in multiple myeloma 
(MM) patients in whom these cells co-express CCR7 and CD45RA markers (Prabhala 
et al, 2006). Moreover, a higher number of Treg cells have been identified in patients 
with acute myeloid leukaemia (AML) and monoclonal gamopathy of undetermined 
significance (MGUS). Similar to findings in solid tumours, Treg cells in AML 
patients were shown to have a higher proliferation rate and be more prone to apoptosis 
in comparison with healthy individuals (Wang et al, 2005). Figure 1.9 shows a 
representative image of the infiltration of T cells and Tregs in a prostate cancer biopsy 
sections.
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Figure 1.9 Triple im m unofluorescent staining of prostate  cancer biopsy sec tio n s for 
Tregs. CDS'" T cells were detected using an Alexa fluor 546 (red), CD4^ cells were detected 
using an Alexa fluor 647 (blue) and F0XP3^ T cells were detected using an Alexa fluor 488 
(green) isotype specific secondary Ab. The merged image shows CD3''CD4'^FOXP3'’ T cells 
in which CD3‘*’CD4'' T cells (purple) contain the typical nuclear localisation of F0XP3 (green; 
as depicted by the arrows) (Ismail and Bokaee et al; 2009).
To date little is known about the origin and true specificity of human Tregs 
that infiltrate the tumour environment. In a study by Wolf et al. they addressed the 
question of whether the increased levels of peripheral blood Tregs found in cancer 
patients is due to redistribution from bone marrow or secondary lymphoid organs or 
active proliferation. Their finding of preserved telomere length of Tregs despite in 
vivo proliferation together with the fact that telomerase activity of Tregs was readibly 
inducible in vitro led the authors to conclude that indeed active proliferation was 
responsible for the increased frequencies of Tregs in the peripheral blood of cancer 
patients (Wolf et al, 2003). In addition there is now considerable evidence that tumour 
cells and surrounding macrophages produce the chemokine, CCL22, which mediates
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Treg recruitment and expansion to the tumour microenvironment through CCR4. Thus 
tumours augment immunosuppression by selective chemokine-mediated recruitment 
of Tregs into the tumour microenvironment (Figure 1.10) (Wolf et al, 2005).
Tumour-infiltrating
macrophages
Tumour cells
H-ferritin
Effector T cell
Tumour antigen
Tolerogenic DC
A Aa
CCR4+
7+ \CCR7
CD45RA+
NaiVe Treg cell
Treg cell
CCR4+ — s.
CCR7*/- J^4)
CD45RA-
Memory T cell
Figure 1.10 A schem atic diagram  of the accum ulation of Treg cells in hum an tum ours.
One of the possible scenarios for how Treg cell attraction to the tumour site and expansion of 
Treg cells occurs may be the release of CCL22 as well as H-ferritin by tumour cells and 
tumour-infiltrating macrophages leading to the accumulation of CCR4^ naive Treg cells in the 
tumour microenvironment. Interaction with PGEg-induced tolerogenic DCs then gives rise to 
the differentiation and peripheral expansion of naive Tregs into memory Tregs. Together with 
tolerogenic DCs, these Treg cells then inhibit the generation of effector T cells, resulting in the 
induction of tolerance against the tumour. (Adapted from Beyer and Schultze, 2006).
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1.6.2.2 Tumour-specific regulatory T cells
Several studies have now demonstrated that antigen-specific CD4^ Tregs are 
present at tumour sites and mediate antigen-specific and local immune suppression of 
anti-tumour immunity (Sytse et al, 2008). Tregs specific for the self antigens LAGE-1 
(a homolog of NY-ESO-1) and ARTCl (antigen-recognized by Treg cells) presented 
among melanoma- infiltrating lymphocytes, share the common characteristics of 
naturally occurring Treg cells in terms of cytokine production and CD25, F0XP3, 
CTLA4 and GITR expression. LAGEl and ARTCl are expressed in normal testis and 
cancer but not in other normal tissues, thus these Tregs only induce immune tolerance 
upon encounter with tumour cells (Wang et al, 2004). NY-ESO-1 has been known as 
one of the most immunogenic tumour antigens identified. The reason that some 
antigens stimulate CD4^ Tregs preferentially (i.e. LAGE-1 and ARTCl), while others 
activate CD4^ Th cells in cancer patients (such as LDFP) is still not clear. In 
melanoma patients, Treg specific antigens NY-ESO, gplOO, survivin and TRPl were 
identified in the peripheral blood (Nishikawa et al, 2005).
There are some data demonstrating the co-existence of Treg cells specific for 
tumour-specific antigens as well as non-mutated self-antigens in the tumour 
microenvironment. Some therapeutic vaccines designed to enhance immune responses 
have tumour-associated antigens (TAA) and tumour-specific antigens (TSA) as their 
prime components, therefore they may cause activation of pre-existing TSA/TAA- 
specific Tregs present in tumours and lymph nodes of cancer patients. Thus, the 
hypothesis that tumour-specific Treg cells exist in cancer patients and suppress 
antigen-specific anti-tumour immunity is strongly supported (Yokokawa et al, 2008; 
Weiping, 2006).
1.6.2.3 Increased Tregs are associated with tumour progression
The increased frequencies of Tregs observed in cancer patients have also been 
suggested to be strongly related to tumour progression and inversely correlated with 
the efficacy of treatment (Wolf et al, 2003). A study by Kono et al in gastric and
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oesophageal cancer was the first to report a link between Treg numbers and patient 
survival that showed an increase in specific CD4"^CD25 '^^  ^Treg cells correlates with 
tumour stage, recurrence and poorer survival rates (Kono et al, 2006). Another study 
looking at 149 patients with gastrointestinal malignancies and ascites in 7 patients 
with peritoneal dissemination reported a correlation between higher number of Treg 
cells with decreased survival rates and poor prognosis. They also showed in their 
experiment that the isolated Tregs secreted anti-inflammatory cytokines IL-4 and IL- 
10 but not IL-2 which inhibit production of cytokines by CD4+CD25- T cells upon in 
vitro stimulation (Sasada et al, 2003). Further studies have suggested that the 
increased Tregs are related to compromised immune responses in patients with 
hepatocellular carcinoma (HCC). This study showed that elevated number of 
CD4^CD25^FoxP3^ Treg can boost disease progression, impair the effector function 
of CD8  ^T cells and therefore serve as a therapeutic target and a potential prognostic 
marker for hepatitis virus (HBV) related HCC individuals (Fu et al, 2007).
A further investigation in 49 patients with renal cell carcinoma (RCC) with 
elevated numbers of Tregs also showed a decreased survival. These Tregs contained 
higher proportions of GITR and CD45RO compared to normal donors (Griffiths et al,
2007). In contrast, in a study conducted by Siddiqui and colleagues in 170 RCC 
patients who underwent radical or partial nephrectomy it was reported that there was 
not a significant association between the presence of CD4+CD25+FOXP3+ T cells 
and RCC death. In addition, CD4+CD25+FOXP3- T cells which are representative of 
activated helper T cells or a unique set of Tregs showed a significant association with 
the outcome (Siddiqui et al, 2007).
In a large human cancer study involving a cohort of 104 ovarian cancer 
patients, the observations by Curiel et al (2004) and Whiteside and her group (2005) 
on head and neck squamous cell carcinoma (HNSCC) showed CD4"^CD25^ T cells 
similarly express F0XP3, CTLA-4 and GITR which inhibit TAA-specific immunity 
in vitro and in vivo, therefore allowing tumour growth. In recent studies enrichment of 
lymph nodes by Treg cells has been reported. It has been documented by Liyanage 
and his group (2002) that tumour-draining lymph nodes (TDLNs) contain Treg cells. 
However in noneancerous patients, lymph nodes showed similar levels of Treg cell 
enrichment as obtained from TDLNs of ovarian cancer patients contrasting with the
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previous results. Although, in later stages of the disease, a reduced frequency of Treg 
accumulation in TDLN was suggested to demonstrate preferential recruitment of Treg 
cells to the tumour sites and related ascites (Alhamameh et al, 2008).
1.6.3 Targeting regulatory T cells to overcome immunosuppression in cancer
Below the suppressive effects of regulatory T cells on the immune system is 
depicted (Figure 1.11).
NK cell
Tumour cell
Suppression of innate response
TGF-p, IDO Proliferation
Conversion
TAM ,Suppression of adaptive response
Tumour associated 
TregsMDSC Priming phase
DC
CD4 T cell CD8 T cell
Effector phase
Figure 1.11 A schem atic  diagram  of regulatory T cells In the  network of 
Im m unosuppression. Tumour cells produce suppressive factors that directly act on Tregs or 
license MDSCs, tumour-associated macrophages DCs to expand Tregs. Such expansion 
occurs through the proliferation of pre-existing Tregs and the conversion of naive precursors 
into de novo induced Tregs. Tumour-associated Tregs suppress both the innate and the 
adaptive immune response, including the priming and effector phase of both CD4 and CD8 T 
cells.
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1.6.3.1 Advantages and disadvantages of current anti-Treg strategies
To date various strategies in humans have been used to target regulatory T 
cells. These include CD25+ T cell depletion with anti-CD25 antibodies/Ontak, anti- 
CTLA4 antibodies, Cyclophosphamide, blockade of TGF-B, reversal of Treg function 
through triggering TLR8 or 0X40 (Colombo & Piconese, 2007; Juang et al, 2007; 
Peggs et al, 2006) (Table 1.9).
Therapy A dvantages D isadvantages
Anti-CD25
antibodies/Ontak
depletion or functional inactivation 
of Treg cells
Depletion of activated 
effector T cells
Anti-CTLA-4 antibodies Depletion of Treg cells Increased susceptibility to 
autoimmunity.
Cyclophosphamide Depletion of Treg cells Autoimmunity
TGF-R) blockade Inhibition of conversion Autoimmunity
IDO blockade Inhibition of conversion Autoimmunity
TLR8/OX40 triggering Functional inactivation of Treg 
cells
Autoimmunity
Table 1.9 Table show ing advan tages and d isadvan tages of curren t anti-Treg s tra teg ie s
The ultimate aim of immunotherapy is to expand cytotoxic T-cells that target 
and destroy tumour cells; a concomitant reduction of immune suppression can 
augment anti-tumour efficacy. However, each of the above strategies has their own 
disadvantages. As CD25 is expressed by both Tregs and activated effector T cells, 
depletion of CD25 by PC61 in well-established tumours can be ineffective since both 
effector lymphocytes and regulatory T cells may be eliminated (Colombo and 
Piconese, 2007).
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CTLA-4 is a molecule which acts as a negative regulator of T-cell activation 
which is expressed by CD4+CD25+ Tregs and inhibits the function of antigen 
presenting cells and bystander T cells. Its blockade has been an obvious strategy to 
enhance immune responses against weak antigens, e.g. tumour antigens, during 
vaccination and is currently being tested in clinical cancer trials. However, 
CD4+CD25+ Treg depletion using CTLA-4 blockade has failed to consistently 
enhance immune-based therapies, and caused considerable toxicities (Peggs et al, 
2006). In addition, depletion of Tregs using other strategies mentioned in Table 1.10, 
may result in development of autoimmunity as these methods inhibit the proliferation 
or conversion of Tregs, therefore interfering with cellular immune homeostasis.
1.6.3.2 Preference of Treg inactivation over depletion
Currently there are different anti-Treg strategies available, as was discussed 
previously; however, functional inactivation of Tregs is thought to be the most 
effective approach. The potential benefit obtained through the interleukin-2 receptor 
depletion of Tregs is lost since activated effector lymphocytes are eliminated 
concurrently and there is also the possibility of induction of a new wave of Treg 
replenishment. In contrast, when Tregs are inactivated functionally, their high level 
will be maintained in tumours and their replenishment from the peripheral lymphocyte 
pool will be avoided, thus they will not be capable of further suppression of the 
effector lymphocyte anti-tumour response (Colombo and Piconese, 2007) (Figure 
1.12).
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Figure 1.12 A schematic diagram of different strategies to neutralize regulatory T cells 
and their possible outcomes. Depletion of CD25+ cells results in the elimination of Tregs 
(dark green), as well as CD4 (light green) and CD8 (orange) cells. Conversion could be 
avoided by targeting mechanisms that are involved in conversion, such as IDO and TCP. TOP 
blockade could also inhibit Treg proliferation, without affecting pre-existing Tregs. Treg 
functional inhibition inactivates their suppression (yellow) without inducing a new wave of 
conversion, thus leading to effective tumour rejection. (Adapted from Colombo and Piconese, 
2007).
A recent study using a transplantable murine melanoma model B16/BL6, 
failed to promote tumour rejection with therapeutic Treg depletion. This was not 
related to lack of systemic Treg cell depletion, or to elimination of CD25^ effector T 
cells, or to a failure to enhance systemic antitumor T cell responses. However, the 
failure correlated with a lack of effector cells infiltrating the tumour thus not 
increasing the intratumoural ratio of effector T-eell/Treg cell (Quezada et al, 2006). 
Therefore, it may be more effective in the therapeutic setting to abrogate intratumoral
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Treg function than strive to deplete systemic Treg numbers (the latter causes 
significant immune related adverse effects (IRAE) as observed in murine studies and 
human trials) (Reuben et al, 2006).
Induction of Treg expansion is beneficial to the tumour as it affects all the 
immune components by the inhibitory function of these cells. It is potentially useful to 
avoid physical depletion of Tregs since in this way de novo induction of peripherally 
converted Tregs that can also redirect potential effector cells skewed towards Tregs is 
prevented (Colombo and Piconese, 2007). Consequently, it is postulated that 
inactivation of Treg cells to impair their suppressive function is a desirable strategy to 
overcome immunosuppression in cancer.
In addition to overcoming immunosuppression in cancer by targeting 
regulatory Tcells, identifying and targeting potential tumour antigens could also lead 
to enhancement of immune response in cancer. Therefore, immunotherapeutic 
potential of EN2, HOXAl and H0XB13 (members of the homeodomain-eontaining 
(HOX) genes) as vaccine targets will be studied in this project.
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1.7 Aims of this research
We hypothesise that targeting HOX genes could be a potential 
immunotherapeutic strategy in enhancing immune responses in cancer. We propose 
this as there is evidence that HOX genes are reactivated in most of cancers. Therefore, 
the aim of this research is to identify new immunotherapeutic targets for cancer 
vaccines. In order to do this, the candidate targets will be assessed to determine 
whether they meet the recognised characteristics of an ideal cancer antigen. Therefore, 
we will determine the:
>  Expression level of the antigen of interest at the molecular level by screening 
normal and cancer cell lines using quantitative RT-PCR analysis.
>  Expression level of the antigen at the protein level by screening normal and 
cancer tissues using immunohistochemical analysis.
>  Immunogenieity of the antigens:
o Detection of serum auto-antibodies to antigen of interest, 
o Generation of T cell responses to antigen of interest.
Additionally, we hypothesise that targeting and eliminating Tregs that mediate 
blocking of effective anti-tumour immune responses through immunosuppression is 
another immunotherapeutic strategy. Hence, to address and overcome the common 
cause of immunosuppression in cancer, we will develop a Treg-targeting agent 
(HWFT peptide) which targets Tregs by blocking the F0XP3 : NFAT interaction. 
Thus, we will also evaluate in both murine and human system:
> Apoptotic effects of HWFT on Tregs versus other cell populations.
> Effects of HWFT on suppressive function of Tregs.
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Chapter 2
Materials and methods
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2. MATERIALS AND METHODS
2.1 Cell Culture Media
All the cell culture media used are shown below (Table 2.1) with their source 
and required supplements.
Medium Supplem ents Source
RPM11640 10% PCS, 50U/ml penicillin, SOgg 
streptomycin, 2mM glutamax-l
Invitrogen, UK
MEM 10% PCS, 50U/ml penicillin, SOpg 
streptomycin and 2mM glutamax-l
Invitrogen, UK
McCoy’s 10% PCS, 50U/ml penicillin, SOpg 
streptomycin, 2mM glutamax-l
GIBCO, UK
DMEM 10% PCS, 50U/ml penicillin, 50pg 
streptomycin, 2mM glutamax-l
Sigma, UK
LEIBOVITZ 20% PCS, 50U/ml penicillin, 50pg 
streptomycin, 2mM glutamax-l
Sigma, UK
IMDM 10% human serum, 50U/ml penicillin,
50pg streptomycin, 2pM glutamine, 116 
ug/ml L-arginine, 36ug/ml L-asparagine
Invitrogen, UK
C.T.L media 50U/ml penicillin, 50pg streptomycin, 
2mM glutamax-l
Cellulat Technology 
Ltd., UK
X-VIVO 15 media 50U/ml penicillin, 50pg streptomycin, 
2mM glutamax-l
Lonza, uk
Table 2.1 Table show ing different cell culture m edia used.
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2.2 Human cell lines
All cell lines used were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) with the exception of the melanoma cell lines marked 
with * which were obtained from Dr Wolchok, Memorial Sloan-Kettenng Cancer 
Centre, New York and the ones marked with ** obtained from Prof Dorothy Bennett, 
St George’s, University of London, All of the human cell lines listed below are 
adherent lines with the exception of the T2 cell line which grows in suspension (Table 
2.2).
Cell line Medium & supplements Tissue type HLA-A2
T2 RPM11640 + 10% PCS B-lymphoblastoid cell line, 
TAP deficient
+
K562 RPM11640 + 10% PCS CML N/A
l\/IDA-MB231 RPM11640 + 10% PCS Breast adenocarcinoma +
SKBr3 McCoy's 5A + 10% PCS Breast adenocarcinoma -
T47D RPMI 1640 + 10% PCS Breast ductal carcinoma -
MCF-7 MEM + 10% PCS Breast cancer +
UACC812 Leibovitz 20%PCS Breast cancer +
0VCAR3 RPM11640 + 10% PCS Ovarian adenocarcinoma +
ES-2 McCoy's 5A + 10% PCS Ovarian cancer -
Caov3 DMEM + 10% PCS Ovarian cancer +
Caov4 Leibovitz + 20%PCS Ovarian cancer +
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Mel 888 DMEM + 10% PCS Primary melanoma
A375M DMEM + 10% PCS Melanoma
MEWO MEM +10%  PCS Melanoma
SK-MEL-5 MEM + 10% PCS Melanoma
SK-MEL-21’ RPM11640 + 10% PCS Melanoma
SK-MEL-28' RPM11640 + 10% PCS Melanoma
SK-MEL-29' RPM11640 + 10% PCS Melanoma
SK-MEL-37*
SK-MEL-52*
ML**
MK**
RPM11640 + 10% PCS Melanoma
RPM11640 + 10% PCS Melanoma
DMEM + 10% PCS Primary melanoma
DMEM + 10% PCS Primary melanoma
Table 2.2 Table showing different human cell lines used.
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2.3 Peptides
All peptides were purchased from Alta Bioscience, Birmingham. Peptides 
were dissolved in 100% DMSO (Sigma, UK) and stored at -80 until required 
(Table 2.3).
Peptide Amino acid position Protein Code
ALATYNNSL 167-175 HOXAl HOXAl. 1
QLNETQVKI 262-270 HOXAl .2
FLVGRGVQI 48-56 HOXAl.3
SLQLNETQV 260-268 HOXAl .4
GLLPISPAT 286-294 HOXAl.5
YALNQEADV 106-114 HOXAl .6
FTTKQLTEL 231-239 HOXAl .7
LLLADKSPL 177-185 H0XA4 H0XA4.1
GLKGKEPV 186-193 HOXA4.2
CLSERQVKI 253-261 HOXA4.3
YTRQQVLEL 222-230 HOXA4.4
HLPLQQPQL 52-60 HOXA4.5
ALYPAHGAA 88-96 HOXA4.6
TLCLSERQV 251-259 HOXA4.7
QIYPWMRKL 175-183 H0XA5 H0XA5.1
CLSERQIKI 233-241 HOXA5.2
YTRYQTLEL 202-210 HOXA5.3
ALCLSERQI 231-239 HOXA5.4
CLTERQIKI 193-201 H0XA6 H0XA6.1
RMNSCAGAV 142-150 HOXA6.2
ALCLTERQI 191-199 HOXA6.3
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SLQPGASTL 55-63 H0XB2 H0XB2.1
YTNTQLLEL 150-158 HOXB2.2
DLTERQVKV 181-190 HOXB2.3
SLAECLTSF 17-25 HOXB2.4
CLTSFPAVL 21-29 HOXB2.5
LLDLTERQV 179-187 HOXB2.6
ALSADPRPL 255-263 HOXB2.7
ELDFFTSTL 330-338 HOXB2.8
ADPRPLAV 258-265 HOXB2.9
SLQGSLDSP 325-333 HOXB2.10
SLSERQITI 254-262 H0XB13 H0XB13.1
TLMPAVNYA 41-49 HOXB13.2
YLDVSWQT 143-151 HOXB13.3
TLAAYPAET 105-113 HOXB13.4
ALAGGWNSQ 173-181 HOXB13.5
GAGGGRNLV 20-28 HOXB13.6
VLAKVKNSA 274-282 HOXB13.7
GLAAYTAPL 311-319 H0XD3 H0XD3.1
YTSAQLVEL 201-209 HOXD3.2
NLQGSPVYV 350-358 HOXD3.3
SMAPASGPV 365-375 HOXD3.4
GQLPPVPGL 284-292 HOXD3.5
LLNLTERQI 230-238 HOXD3.6
NLTERQIKI 232-240 HOXD3.7
YTAPLSSCL 315-325 HOXD3.8
GTALKQPAV 124-132 H0XD4 H0XD4.1
RIRELTANL 329-337 HOXD10 HOXD10.1
QTCGLLPSL 49-57 HOXD10.2
GLLPSLAKR 52-60 HOXD10.3
GLPEERSCL 224-232 HOXD10.4
FLVDSLISA 13-21 HOXD10.5
NVHPYIPQV 70-78 HOXD10.6
RLVPESCPV 133-141 HOXD10.7
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NLTDRQVKI 304-312 HOXD10.8
YTKHQTLEL 273-280 HOXD10.9
ALNQPDMCV 256-264 H0XD13 H0XD13.1
NLSERQVTI 306-314 HOXD13.2
HVPGYIDMV 194-202 HOXD13.3
AAPPSAPAL 109-117 HOXD13.4
SSFPGDVAL 249-257 HOXD13.5
YTKLQLKEL 275-283 HOXD13.6
GLGGGDLSV 185-193 EN2 EN2.1
SLNESQIKI 282-290 EN2.2
LMLPAVLQA 48-56 EN2.3
FTAEQLQRL 251-259 EN2.4
Control peptides
GLCTLVAML 280-288 EBV(BMLFI) EBV
GILGFVFTL 55-63 FLU (Matrix) FLU
KIFGSLAFL 369-378 HER2/neu HER2
SLYNTVATL 77-85 HIV (P I7) HIV
Table 2.3 Table showing different peptides used.
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2.4 Isolation of plasma and PBMC from healthy donors and cancer patients
3Omis of blood from healthy control donors or cancer patients was venesected 
into 3x10ml sodium heparin blood tubes (BD Vacutainer System, UK) and spun at 
690g for 10 minutes. Following centrifugation, a total of 10ml plasma was removed, 
re-centrifuged as above and then frozen in five 2ml aliquots and stored at -80°C.
PBMCs were isolated in a sterile environment. The blood was diluted 1:1 in 
RPMI-1640 supplemented with Glutamax-l (Invitrogen, UK) and 
penicillin/streptomycin (Sigma, UK) and layered onto Histopaque™ 1077 (Sigma, 
UK) for density gradient centrifugation in 50ml Falcon™ tubes. The tubes were then 
centrifuged at 690g at 20°C for 25 minutes, with the deceleration brake set on 
medium. The PBMC layer was then removed using a plastic Pasteur pipette and 
placed into a fresh 50ml Falcon tube containing lOmls of RPMI medium and spun at 
690g for 10 minutes. The pellet formed was resuspended in lOmls of Red Blood Cell 
(RBC) lysis solution (Qiagen, UK) and spun as above. Following the spin, the pellet 
was resuspended in RPMI medium and counted.
2.4.1 Cell viability count and storage
Cell viability was assessed by trypan blue (Sigma, UK) exclusion. The dye is 
taken up by dead cells which then appear blue by light microscopy, in contrast to 
living cells which remain colourless. Cell suspension was diluted 1:10 with trypan 
blue and counted using a haemocytometer counting chamber.
Cells were then centrifuged at 690g for 5 minutes and subsequently 
resuspended in freezing media consisting of RPMI-1640 supplemented with 20% PCS 
and 10% dimethyl sulfoxide (DMSO) (Sigma, UK). Following this, cells were frozen 
overnight at -80°C in cryo-tube vials (nunc™) (in Mr Frosties) at a concentration of 
5xl0Vml in 1ml aliquots. The following day, the samples were transferred to liquid 
nitrogen storage tanks. All subjects provided written informed consent approved by 
the Surrey Research Ethics committee and the Royal Surrey County Hospital 
Research and Development committee (ethics number: 09/Hl 103/50).
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2.4.2 HLA-A2 typing of PBMCs
0.5 X 10  ^ PMBCs were incubated with 0.5mg/ml of FITC-conjugated mouse 
anti-human HLA-A2 antibody (BD Pharmingen™, USA) or Img/ml of mouse- 
IgG2b-FITC antibody (Southern Biotech, USA) as isotype control for 30 minutes in 
the dark at 4°C. Cells were then washed in 1ml of binding buffer (BD Pharmingen™, 
USA) and resuspended in 300pl of binding buffer and run on a MACS Quant flow 
cytometer (Miltenyi Biotec, Germany). Data were analyzed using the MACS Quantify 
software (Miltenyi Biotec, Germany).
2.5 In  vitro expansion of peptide-specific CTLs
The method used to generate peptide specific T cells, was one described by 
Hida et al, 2002. Briefly, PBMCs (1 x lO^cells/well) were cultured with 4pg/ml of 
peptide (listed in Table 2.3) and 150U/ml of recombinant human IL-2 (Peprotech, 
UK) in 96-round bottomed plates (TPP, Switzerland) in 200pl of media per well. The 
media used was IMDM containing 10% Human Serum, L-asparagine, L-arginine 
(Sigma, UK), 50U/ml penicillin and 50pg streptomycin and 2mM glutamax-I 
(Invitrogen, UK). Cells were then incubated at 37®C. After three days lOOpl of the 
media was removed and replaced with fresh media containing IL-2 and the relevant 
peptide. This was repeated every three days until the cells had been stimulated 5 
times. After the last restimulation the cells were washed with fresh media and left for 
three days without peptide and IL-2 before testing their specificity.
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2.5.1 Enzyme linked immunosorbent assay (ELISA)-IFN-y
Human IFN-y ELISA Development Kit (Peprotech, UK) was used to test the 
specificity of peptide-stimulated PBMCs. ELISA Plates (Nunc MaxiSorp, UK) were 
prepared by diluting the capture antibody (lOOpg/ml) with PBS to a concentration of
1 pg/ml and adding 100pi to each well. Plates were sealed and incubated overnight at 
room temperature. The following day, the wells were aspirated to remove the liquid 
and washed 4 times using 300pl of wash buffer (0.05% Tween-20 (Sigma, UK) in 
PBS per well. After the last wash plates were inverted to remove residual buffer and 
were blotted on paper towel. Then, 300pl of block buffer (1% BSA in PBS) was 
added to each well and incubated for 1 hour at room temperature. Plates were 
aspirated and washed 4 times. Next, human IFN-y standard (1 pg/ml) was diluted 
from 3ng/ml to zero in diluent (0.05% Tween-20, 0.1% BSA in PBS). Immediately 
lOOpl of standard or test sample was added to each well in triplicate and incubated for
2 hours. Following 4 washes, the detection antibody (lOOpg/ml) was diluted in diluent 
to a concentration of Ipg/ml, and lOOpl added to each well before incubating for 2 
hours. After 4 washes, avidin-HRP conjugate (Peprotech, UK) was diluted 1 : 2000 in 
diluent and added to each well at lOOpl followed by a further incubation for 30 
minutes at room temperature. Subsequently, plates were aspirated and washed 4 times 
prior to adding lOOpl of ABTS (2,2’-azino-bis 3-ethylbenzothiazoline-6-sulfonic 
acid) liquid substrate solution (Sigma, UK) to each well. Plates were then incubated at 
room temperature for colour development. The plates were monitored at 5-minute 
intervals for approximately 20 minutes. The reaction was stopped using 1% Sodium 
Dodecyl solution (SDS). Colour development was measured with a DTX 880 
Multimode Detector ELISA plate reader (Beckman Coulter, UK) at 405nm with 
wavelength correction set at 650nm.
2.5.2 Preparation of effector and target cells for ELISPOT assay
Following the complete period of in vitro generation of peptide-stimulated 
PBMC, effector cells were harvested, counted and plated-out at lOOpl/well at a 
concentration of 1 x 10  ^ cells/well in serum-free C.T.L-media (CTL Europe). T2 
target cells were labelled with 4pg/ml of relevant peptides and irrelevant peptide (HIV
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peptide) by incubating for 2 hours at 37^C, 5% CO2 . Cancer cell lines were 
trypsinized (1 x sterile-filtered, Bioreagent, 0.5 g porcine trypsin and 0.2 g EDTA) 
(Sigma, UK), washed and counted. Both target cancer cell lines and the T2 cell line 
were plated-out at lOOpl/well at a concentration of 1 x 10"^  cells/well in serum-free 
CTL-media. 1.25pg/ml of Streptococcus enterotoxin B (SEB) (Sigma, UK) was used 
as a positive control for the assay.
2.5.3 IFN-7 -ELISPOT for the recognition of target cells by peptide-specific T 
cells
Recognition of T2 cells loaded with relevant peptides (listed in Table 2.3) and 
cancer cell lines (listed in Table 2.2) by peptide-stimulated PBMC was carried out 
using an ELISPOT-IFN-y assay (Mabtech, Sweden). Briefly, multi-screen plates 
(Millipore, MA) were coated overnight at 4^C with 2pg/ml of human IFN-y capture 
antibody (Mabtech, Sweden) in sterile PBS at 50pl/well. The following day the 
capture antibody was removed and the plates were blocked for 2  hours at 37®C with 
CTL media supplemented with glutamine just before use. Peptide-stimulated PBMCs 
were plated out at a concentration of 0.5x10^ cells/ml at a 10:1 ratio with peptide 
pulsed T2 cells or cancer cell lines. Control wells were set up which contained 
effector cells alone, target cells alone and unlabelled T2 cells with effector cells. After 
incubation overnight at 37°C the cells were removed and the plates washed first with 
dHiO for 10 minutes and then 5 times with sterile PBS. Following this the plates were 
incubated with 0.2pg/ml of human IFN-y detection antibody (Mabtech, Sweden) in 
PBS containing 0.5% PCS for 2 hours at room temperature. Subsequently, plates were 
washed as in the previous step and incubated with strepavidin-HRP in PBS containing 
0.5% PCS for 20 minutes at room temperature in the dark. Following a further 
washing step, spots were developed using an alkaline phosphatase substrate solution 
kit (Bio-Rad, Hertfordshire UK) until distinct spots emerged. Plates were then washed 
immediately with tap water 3 times; residual water and the back of the plates were 
removed and left to dry. Plates were then scanned using an ELISPOT reader (CTL 
immunoSpot analyser, Germany).
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2.6 Cr-release cytotoxicity assay
2.6.1 Preparation of target cells
The target cells used were the peptide transport-deficient lymphoblastoid cell 
line, T2 (ATCC), used alone as a negative control or loaded with peptides. In 
addition, cancer cell lines (listed in Table 2.2) were used as target cells, as well as the 
NK-sensitive target cell line K562 (chronic myeloid leukaemia cell line) (ATCC, 
USA).
T2 cells were washed with RPMI-1640 medium and the pellets were loaded 
with 4pg/ml of the relevant and irrelevant peptides resuspended in RPMI and 
incubated at 37°C and 5% CO2 for 2 hours. The cancer cell lines were trypsinized and 
similarly to the K562 cells (suspension cells) were washed, counted and plated out at 
a concentration of 2.5 xlO^ cells/ml.
Following pulsing with the peptides, target cells were centrifuged and the 
supernatant discarded. 15pl (1.85 MBq) of chromium-51 (^^Cr) (Amersham 
Biosciences, UK) was then added to the dry pellet and the cells were incubated at 
37°C for 2 hours with intermittent agitation.
2.6.2 Preparation of effector cells
Effector cells were harvested and washed in RPMI 10% PCS. Serial dilutions 
were performed in a 96-well round bottomed plate, which gave a range of effector: 
target (E:T) ratios from a maximum of 100:1 to a minimum of 12.5:1. Each E:T ratio 
was set up in triplicate. Effector cells were plated-out at lOOpl/well.
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2.6.3 Plate set-up and harvest
Following 2 hours incubation, the radiolabelled targets were washed twice 
with RPMI-1640 medium and centrifuged at 690xg for 5 minutes. The cells were 
counted in Trypan blue and resuspended in RPMI 10 % PCS to adjust the 
concentration. lOOpl of target cells were added to the effector cells to give a final 
volume of 200pl/well. The maximum release consisted of lOOpl of target cells plus 
lOOpl of 1% SDS and the spontaneous release consisted of lOOpl of target cells plus 
lOOpl of RPMI 10% PCS medium. The plate was then centrifuged at 690xg for 2 
minutes and then incubated at 37°C and 5% CO2 for 4 hours.
After 4 hours incubation, plates were spun and 50pl of supernatant were 
harvested. lOOpl of OPTIPHASE SUPERMIX (Perkin Elmer, Boston, US) was added 
to the supernatant. Plates were then read against ^-emission (3H-tritium-14C) by 
FilterMate Harvester machine (Perkin Elmer, Boston, US). Cytotoxicity was 
calculated according to the following formula:
% of Cytotoxicity = (Experimental release -  spontaneous release) xlOO
(Maximum release -  spontaneous release)
2.7 ELISA to detect auto-antibodies to HOX and EN2 proteins
ELISA MaxiSorp 96-well plates (Nunc, UK) were coated with relevant 
antigen (whole-length recombinant HOXAl, H0XB13 and EN2 protein) at a 
concentration of 4pg/well in O.IM carbonate buffer (33.5 mM Na2C0 3 , 0.1 M 
NaHCOs, pH 9.6) and incubated overnight at 4°C. Plates were blocked with 3% 
bovine serum albumin (BSA) in PBS for 2 hours at room temperature on a rapid 
shaker. All washes were performed with PBS containing 0.1% Tween-20. Following 
4 washes, plates were incubated with patients and control serum/plasma diluted 1 : 
100 in 3% BSA in PBS for 1 hour at room temperature on a rapid shaker. All 
sera/plasma were assayed in triplicate. Anti-human HOXAl-RabIgG (Sigma, UK), 
HOXB13-RabIgG (Invitrogen, UK) or EN2-RabIgG (Abeam, UK) antibodies were
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used as positive controls. Plates were washed and incubated with goat anti-human IgG 
conjugated to horseradish peroxidase (Jackson ImmunoResearch, UK) for the 
sera/plasma. For the positive controls, goat anti-rabbit IgG conjugated to horseradish 
peroxidase (Jackson ImmunoResearch, UK) was used at 1 : 10,000 in 3% BSA/PBS 
for 1 hour on a shaker at room temperature. Plates were developed with 
tetramethylbenzidine (TMB) (Sigma, UK) for 5 minutes at room temperature and the 
reaction was stopped by addition of 2M H2SO4. The optical density of each well was 
analysed at 450nm on a DTX 880 Multimode Detector ELISA plate reader (Beckman 
Coulter, UK).
2.8 Extraction of RNA from cancer cell lines
Total RNA was extracted from the cancer cell lines listed in Table 2.2 using 
the RNAeasy Plus Mini kit (Qiagen, UK). The cells were trypsinized and washed in 
PBS. Cells were then treated according to the manufacturer’s instruction. Extracted 
RNA was eluted in RNase-free water and quantified using a Nanodrop ND-1000 
Spectrophotometer.
2.9 Generation of cDNA from cancer cell lines
Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen, UK) was used in 
order to generate cDNA from the total RNA extracted. A master reaction mix of the 
following components was prepared as shown in Table 2.4:
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C om ponents Per reaction
RNA 1 P9
DEPC-treated water Adjust the volume to 10 pi
5x cDNA Synthesis Buffer 4 pi
0.1 M DTT 1 pi
10 mM dNTP Mix 2 pi
Oligo (dT)2o 1 pi
RNase OUT (40 U / pi) 1 pi
Cloned AMV RT (15 units / pi) 1 pi
Table 2.4 Table show ing the required com ponen ts for cDNA sy n th esis  per reaction.
Next, the reaction tube was transferred to a heating block preheated to 50°C 
for 30 minutes. Then, the reaction was terminated by incubating at 85°C for 5 
minutes. Following this, the cDNA reactions were used immediately for PCR or 
stored at -20°C.
2.10 qRT-PCR analysis for the expression of EN2 and HOX genes from cancer 
cell lines
SYBRGreen JumpStart Taq ReadyMix Kit (Sigma, UK) was used in order to 
perform PCR on cancer cell lines listed in Table 2.2 for the expression of HOX and 
EN2 genes (listed in Table 2.6). The qPCR Master Mix was prepared as below (Table 
2.5):
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C om ponents Per reaction
cDNA 1 pi
RNase Free Water 6.25 pi
2x SYBRGreen JumpStart Taq ReadyMix 12.5 pi
Reference Dye (ROX) 0.25 pi
Total 20 pi
Table 2.5 Table show ing required com ponents for qPCR per reaction.
5 pi of primers listed in Table 2.6 were added to the relevant wells of the PCR
plate and 20 pi of the prepared Master Mix was added. Quantification reverse
transcription PCR was done using the Stratagene MX 3000P real-time PCR machine.
Human HOX g en es RT-PCR prim ers
HOXAl U10421; 511 to 663 ; 153bp
F: 5’ CTGGCCCTGGCTACGTATAA 3’
R: 5' TCCAACTTTCCCTG1 1 1 1GG 3'
H0XA2 NM_006735; 1027 to 1202; 176bp
F: 5’ TTCAGCAAAATGCCCTCTCT 3’
R: 5' TAGGGCAGCTCCACAGTTCT 3’
H0XA3 NM_030661; 1525 to 1751; 227bp
F: 5’ AGCTGTGATAGTGGGCTTGG 3’
R: 5’ ATAGAGGGATTGGAGGAAGG 3’
H0XA4 NM_002141; 633 to 903; 271 bp
F; 5’ GGGTGGATGAAGAAGATGGA 3’
R: 5’ AATTGGAGGATGGGATGTTG 3’
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H0XA5 NM_019102; 796 to 988; 193bp 
F: 5’ CCGGAGAATGAAGTGGAAAA 3’ 
R: 5’ ACGAGAACAGGGCTTCTTCA 3’
H0XA6 NM_024014; 361 to 518; 158bp 
F: 5’ AAAGCACTCCATGACGAAGG 3’ 
R: 5’ TCCTTCTCCAGCTCCAGTGT 3’
H0XA7 NM_006896; 38 to 322; 285bp
F: 5' TGGTGTAAATCTGGGGGTGT 3'
R: 5' TCTGATAAAGGGGGCTGTTG 3'
H0XA9 NM_152739; 653 to 855; 203bp 
F: 5’ AATAACCCAGCAGCCAACTG 3’ 
R: 5’ ATTTTCATCCTGCGGTTCTG 3’
HOXAl 0 NM_018951; 1040 to 1198; 159bp 
F: 5’ ACACTGGAGCTGGAGAAGGA 3’ 
R: 5’ GATCCGGTTTTCTCGATTCA 3’
HOXAl 1 NM_005523; 800 to 1078; 279bp 
F: 5' CGCTGCCCCTATACCAAGTA 3' 
R: 5’ GTCAAGGGCAAAATCTGCAT 3’
HOXAl 3 NM_000522; 1061 to 1236; 176bp
F: 5' GGATATCAGCCACGACGAAT 3’ 
R: 5’ ATTATCTGGGCAAAGCAACG 3’
H0XB1 NM_002144; 176 to 332; 157bp 
F: 5' TTGAGGAGAACTOGGGCTAT 3' 
R: 5' GGTGGGTGTGGTTGTGATTG 3’
H0XB2 NM_002145; 9 to 267; 259bp
F; 5’ GTGGGAAAATGGGTGGATTA 3’
R: 5’ GAAAGGAGGAGGAGGAGGAA 3’
H0XB3 NM_002146; 1970 to 2268; 299bp 
F: 5’ TATGGGGTGAAGGAGGTTTG 3' 
R: 5' AAGGGTGGGTAGGAGGTTGT 3’
H0XB4 NM_024015; 593 to 747; 155bp 
F: 5’ TGTTGGAGGTGGAGAAGGAA 3’ 
R: 5' GTTGGGGAAGTTGTGGTGTT 3’
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H0XB5 NM_002147; 1543 to 1731; 189bp 
F: 5' AAGGCCTGGTCTGGGAGTAT 3’ 
R: 5' GCATCCACTGGCTCACTACA 3’
H0XB6 NM_156037; 151 to 334; 184bp 
F: 5’ ATTTGGTTGTGGGGGTGAGT 3’ 
R: 5' GGAAGGTGGAGTTGAGGAAA 3’
H0XB7 NM_004502; 143 to 391; 249bp 
F: 5’ GAGGGTGAAGTTGGGTTTTG 3’ 
R; 5' GGGAGAGGTTGTGGTGAAAG 3’
H0XB8 NM_024016; 964 to 1228; 265bp 
F: 5’ GTAGGGTTGAGGTGGGAGTG 3’ 
R: 5’ GGGAGGGTTTGGTTAAATGG 3’
H0XB9 NM_024017; 533 to 730; 198bp 
F: 5’ TAATGAAAGAGGGGGGTAGG 3’ 
R: 5’ GTAGGGTGGGTGGTGAGGTA 3’
H0XB13 NM_006361; 154 to 387; 234bp 
F: 5' GTTGGATGGAGGGAAGGATA 3’ 
R: 5’ GGGGGTGGAAAGTAAGGATA 3’
H0XC4 NM_014620; 1121 to 1396; 276bp 
F; 5' GGGTGGAGGAGAGGGTATAG 3’ 
R: 5' GGTGTGGGAGTGGTGTTGAG 3’
H0XG5 NM_019953; 555 to 822; 268bp
F: 5' GAGTTAGAGGGGGTAGGAGA 3’
R: 5’ AGAGAGGAAAGGGGAAAAGG 3’
H0XG6 NM_004503; 774 to 963; 190bp
F: 5' AAGAGGAAAAGGGGGAAGAG 3’
R: 5’ GGTGGAGGTTTGAGTGGGTA 3’
H0XG8 NM_022658; 390 to 539; 150bp 
F: 5' GTGAGGGTAGGAGGAGAAGG 3’ 
R: 5’ TTGGGGGAGGATTTAGAGTG 3’
H0XG9 NM_006897; 704 to 893; 190bp
F: 5’ AGAGGGTGGAAGTGGAGAAG 3’
R: 5’ AGGGTGGGTAGGGTTTAGGA 3'
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HOXC10 NM_017409; 982 to 1270; 289bp 
F: 5’ CGCCTGGAGATTAGCAAGAC 3’ 
R: 5’ GGTCCCTTGGAAGGAGAGTC 3’
H0XC11 NM_014212; 353 to 538; 186bp 
F; 5’ CGGAACAGCTACTCCTCCTG 3’ 
R: 5' CAGGACGCTGTTCTTGTTGA 3’
H0XC12 NM_173860; 654 to 833; 180bp 
F: 5’ CAAGCCCTATTCGAAGTTGC 3’ 
R: 5’ GCTTGCTCCCTCAACAGAAG 3’
H0XC13 NM_017416; 1840 to 2009; 170bp 
F; 5’ GTGGAAATGCAAGGAGGACA 3' 
R: 5' TTGTTGAGGGAGGGAGTGTG 3’
H0XD1 NM_024501; 929 to 1160; 232bp 
F: 5’ TTGAGGAGGAAGGAAGTGAG 3’ 
R: 5’ TAGTGGGGGTTGTTGGAGAG 3’
H0XD3 NM_006898; 492 to 667; 176bp 
F: 5' GAGGGTGGTGGTGTGAAGTG 3’ 
R: 5' ATGGAGGGGAAGATGTGGTT 3’
H0XD4 NM_014621; 23 to 195; 173bp
F: 5’ TGAAATGTGGGATAGGAAGG 3’
R: 5’ TGGATAGGGGGGTGGTAGTT 3'
H0XD8 NM_019558; 1167 to 1456; 290bp 
F: 5’ TGAAATGTTTGGGTGGATGA 3’ 
R: 5' GGTGTTGGGGTTGGTTTTTG 3'
H0XD9 NM_014213; 1803 to 2038; 236bp 
F: 5’ TGGGGGATGTTTGTGAAAAG 3’ 
R: 5’ GGGGTGGTGTAAGGGTGAGT 3’
HOXD10 NM_002148; 364 to 517; 154bp 
F: 5’ GGTGGTTGAGGAGGAAGATT 3' 
R: 5' AAATATGGAGGGAGGGGAAG 3’
H0XD11 NM_021192; 302 to 554; 253bp 
F: 5’ GGGGGTAGGGTGGGTAGTAG 3’ 
R: 5' GGTGGGTGGTAGAAGTGGTG 3’
H0XD12 NIVI_021193; 113 to 313; 201 bp
F: 5’ CGCTTCCCCCTATCTCCTAC 3’ 
R: 5’ CTTCGGGCGCATAGAACTTA 3’
H0XD13 NM_000523; 868 to 1132; 265bp
F; 5’ GGGGATGTGGCTCTAAATCA 3’ 
R: 5’ AACCTGGACCACATCAGGAG 3’
EN2 F: 5’ GAACCCGAACAAAGAGGACA 3’
R: 5’ CGCTTGTTCTGGAACCAAAT 3’
Table 2.6 Table showing the HOX primer sequences
2 .1 1  Immunohistochemical analysis of cancer tissue arrays for the expression 
of HOX and EN2 proteins
Paraffin embedded normal and cancer tissue arrays (Biomax, US) were 
deparaffinised in a series of xylene and then rehydrated in a series of 100%, 70% and 
50% ethanol. The sections were then subjected to heat mediated antigen retrieval in a 
microwave using Citrate buffer (lOmM, pH 6.0) or Tris/EDTA (lOmM, pH 9.0). 
Slides were then blocked for 15 minutes with 4% horse serum followed by an 
avidin/biotin blocking step (Vectorlabs, USA). Following this, primary antibodies 
were diluted in 1% BSA in PBS and incubated on the sections overnight at room 
temperature (see Table 2.7). Following washing, sections were then incubated with 
pre-diluted biotinylated universal secondary antibody from R.T.U. VECTASTAIN 
ABC Kit (Vectorlabs, USA) for 30 minutes. Peroxidase activity was detected using a 
DAB kit (Vectorlabs, USA). Sections were then counterstained with Haematoxylin 
(Vectorlabs, USA) for 45 seconds and dehydrated in a series of alcohol and mounted 
with VectaMount mounting medium (Vectorlabs, USA). Slides were scored by two 
independent investigators for the intensity of staining (0, +1, +2 and +3 in ascending 
order) and where there was discrepancy in scoring, an agreement was made.
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Tissue array Primary antibody
Breast cancer (BR1502) H0XA1-RabIgG (Sigma, UK) 
EN2-RablgG (Abeam, UK)
Ovarian cancer (OV802 & OV2082) H0XB13-RablgG (Invitrogen, UK) 
EN2-RablgG (Abeam, UK)
Melanoma cancer (ME2082) EN2-RablgG (Abeam, UK)
Normal tissue (MN0961& BN484) H0XA1-RabIgG (Sigma, UK) 
H0XB13-RablgG (Invitrogen, UK) 
EN2-RablgG (Abeam, UK)
Table 2.7 Table show ing the primary antibodies used  for im m unohistochem ical 
analysis of different tissu e  arrays.
2.12 Immunofluorescent staining of cancer cell lines for the expression of EN2 
and HOX protein
Cell lines of interest were incubated for monolayer growth for 2 days at 37°C, 
5% CO2 in 8 -chambered polystyrene culture treated glass slides (BD Biosciences, 
UK) with relevant media for each cell line. Cells were then washed 3 times with 
HBSS and covered with 100 pi of labelling solution for 10 minutes at 37 °C. Next, 
cells were washed twice with HBSS to remove the labelling solution and were then 
fixed with 4% formaldehyde for 15 minutes. Following 3 washes of HBSS, cells were 
permeabilized with 0.2% Triton X-100 in sterilised H2O for 15 minutes, washed and 
blocked with 4% horse serum (Vectorlabs, Burlingame, CA, USA) for 15 minutes. 
Then, the slides were incubated with primary antibody; rabbit anti-human-EN2
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(Abeam, UK) or rabbit anti-human-HOXAl (Sigma, UK) diluted 1: 200 and 1:100 in 
1%BSA/PBS respectively, at 4°C under moist conditions over night. Next, slides were 
washed and incubated with the secondary antibody, Alexa Fluor 488-goat anti rabbit- 
IgG (Invitrogen, UK), under moist conditions at room temperature for 30 minutes. 
Subsequently, slides were washed 3 times and mounted with Vectashield with DAPI 
mounting medium (Vector, USA). Images from slides were taken using Leica DM 
IRE2 confocal microscopy and were then analysed by Leica confocal software.
2.13 FACS analysis of melanoma cancer cell lines for the expression of EN2 
protein
In order to assess melanoma cancer cell lines for the surface expression pattern 
of EN2, FACS analysis was performed. Briefly, melanoma cancer cell lines were 
washed with PBS and then were detached from the flasks using 2pM EDTA (Sigma, 
UK). Then, cells were washed in FACS buffer followed by centrifugation at 1500 rpm 
for 3 minutes. Next, cells were incubated with humanised-EN2 primary antibody 
(AbD serotec, Germany) generated using serotec’s Human Combinatorial Antibody 
Library (HuCAL®) for 30 minutes at 4°C in the dark. Subsequently, cells were 
washed twice with FACS buffer and incubated with PE-conjugated mouse anti-human 
IgG secondary antibody (BD Pharmingen) for 30 minutes at 4°C. Cell surface staining 
was then analyzed using a MACCSQuant Analyser flowcytometer (Miltenyi Biotec, 
UK).
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2.14 BALBC mice/Animals
Female BALBC mice were purchased from B& K Universal (Hull, England). 
All mice were kept under specific pathogen-free conditions and were used between 
28-34 days. Animal experiments were carried out in accordance with the schedule 1 
guideline of animal use. Homogenized splenocytes were mashed using a 5 ml syringe, 
debris were removed and the cells were resuspended in lysis buffer (RBC lysis 
solution) (Qiagen, UK) for 3-5 min at 37 °C to lyse the red blood cells. Cells were 
cultured in warm RPMI 10% PCS medium and counted after two washing steps.
2.15 Isolation of murine regulatory T cells
Murine Tregs were isolated using a Mouse CD4+CD25+ regulatory T cell 
isolation kit and a MACS separator (Miltenyi Biotec) to > 90% purity. Isolated 
fractions included CD4+CD25+ natural Tregs, CD4+CD25- cells and CD4+ cell- 
depleted accessory cells as outlined in Figures 2.1 and 2.2.
Cell suspejision
Depletion of non CD4+ T cells
1. Indiroct magnetic labeling ofnon-CD4^ T  
cells with Biotin-Antibody CocktaQ and. 
Anti-Biotin MicroBcads
2. Labeling o f CD25'*’ cells with CD25-PE 
antibody
3. Magnetic separation rising LD Column or 
autolvlACS
Flow-tlirougli fraction: CD4  ^T cells
Positive selection of CD4^CD2 5^  cells
1. Indirect magnetic labeling o f  CD 25"^  cells 
with Anti-PE MicroBeads
2. Magnetic separation using trTO M S Columns 
or autolvlACS
Elution frojii column: 
CD4+CD25+ regulatory T cells
Figure 2,1 Isolation of murine Treg cells.
92
2.16 Isolation of human regulatory T cells
Heparinised whole blood (50ml) was diluted 1:1 in RPMI 1640 medium and separated 
by centrifugation on Histopaque. Peripheral blood mononuclear cells (PBMCs) were 
harvested from the interface, washed and counted. To isolate human Treg cells, 
human CD4+ T helper cells were first positively selected using human CD4 
Microbeads and a MACS separator (Miltenyi Biotec). Isolated CD4+ cells were 
stained against CD4-FITC, CD25-APC and CD127-PE (BD Biosciences, UK) for 30 
minutes at room temperature. Following washing cells were then FACS sorted into 
CD4+CD25+CD127- and CD4+CD25-CD 127+ fractions using an automated FACS 
Aria sterile cell sorter machine (BD Biosciences, UK) (Figure 2.2). Cell sorting was 
done by the kind help of Dr Alexandra Bermudez-Fajardo.
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Figure 2.2 Identification and isolation of human Tregs
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2.17 Annexin V apoptosis detection assay (mice and human)
In order to investigate the effects of the HWFT peptide and WHINE (mutant 
control peptide) (see Table 2.8 for the peptide sequences) on murine and human cells, 
sorted populations of CD4^ CD25^ Tregs, CD4^CD25" T cells and non-CD4'^ cells 
were treated at various concentrations (0.625pM -  20pM). Following a two hour 
culture period, staining for Annexin-V/7AAD (BD Biosciences) was performed to 
determine the percentage of apoptosis in each cell population.
Peptide Sequence
HWFT TLNEIYHWFTESEKRRRRRRRRR
WHINE SEFEYKTWHINETLRRRRRRRRR
Table 2.8 Table show ing HWFT and WHINE peptide seq u en ces.
2.18 Suppression assays (mice and human)
FACS sorted human CD4^CD25^CD127" Tregs and CD4+CD25-CD127+ 
fractions and MACS sorted murine CD4+CD25+ Treg and CD4+CD25- responder T 
cells (Tresp) were used for testing the functional activity of Tregs in suppression 
assays. Tregs were co-cultured with CD4+CD25- or CD4+ Tresp cells at different 
ratios in the presence of a polyclonal stimulus, either the Treg Suppression Inspector 
(anti-CD3/CD28) as suggested by the manufacturer (Miltenyi Biotec) (for the human 
assay) or anti-CD3 (BD Bioscience) (for the mouse assay). The suppression assay was 
performed with a dilution series ranging from a ratio of 1 : 1 to 8 : 1 of Tresp cells : 
Treg cells in the presence or absence of HWFT and the control peptide (WHINE) at 
various concentrations (5pM-0.6125pM). The dilution series was carried out in 
triplicate. Cells were incubated for four days and on day 5 cell proliferation was 
determined by 3H-thymidine (Perkin Elmer, Boston, US) incorporation.
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2.19 Murine IL-10 ELISA
Murine IL-10 ELISA Development Kit (Peprotech, UK) was used to measure 
the production of IL-10 by Trges and CD4 T cells treated with the HWFT peptide. 
ELISA Plates (Nunc MaxiSorp, UK) were prepared by diluting the capture antibody 
(200pg/ml) with PBS to a concentration of 2 pg/ml and adding lOOpl to each well. 
Plates were sealed and incubated overnight at room temperature. The following day, 
the wells were aspirated to remove the liquid and washed 4 times using SOOpl of wash 
buffer (0.05% Tween-20 (Sigma, UK) in PBS) per well. After the last wash plates 
were inverted to remove residual buffer and were blotted on paper towel. Then, 300pl 
of block buffer (1% BSA in PBS) was added to each well and incubated for 1 hour at 
room temperature. Plates were aspirated and washed 4 times. Next, murine IL-10 
standard (1 pg/ml) was diluted from 3ng/ml to zero in diluent (0.05% Tween-20, 
0.1% BSA in PBS). Immediately lOOpl of standard or test sample was added to each 
well in triplicate and incubated for 2 hours. Following 4 washes, the detection 
antibody (lOOpg/ml) was diluted in diluent to a concentration of 0.5pg/ml, and lOOpl 
added to each well before incubating for 2 hours. After 4 washes, avidin-HRP 
conjugate (Peprotech, UK) was diluted 1 : 2000 in diluent and added to each well at 
lOOpl followed by a further incubation for 30 minutes at room temperature. 
Subsequently, plates were aspirated and washed 4 times prior to adding lOOpl of 
ABTS (2,2’-azino-bis 3-ethylbenzothiazoline-6-sulfonic acid) liquid substrate solution 
(Sigma, UK) to each well. Plates were then incubated at room temperature for colour 
development. The plates were monitored at 5-minute intervals for approximately 25 
minutes. The reaction was stopped using 1% Sodium Dodecyl solution (SDS). Colour 
development was measured with an ELISA plate reader at 405nm with wavelength 
correction set at 650nm.
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2.20 Modified IFN-y-ELISPOT assay (human)
In order to test the ability of HWFT to enhance human recall-antigen 
responses in vitro, IFN-y-ELISPOT assay was performed. Whole PBMCs, CD25- 
depleted PBMCs, HWFT peptide-treated PBMCs and WHINE peptide-treated 
PBMCs of healthy donors and several different cancer patients were cultured with a 
common recall antigen of interest. PBMCs were plated in 96-well polyvinylidene 
difluoride plates (Millipore, Bedford, Mass.) which had been pre-coated overnight 
with 2 pg/ml of the anti-gamma interferon (IFN-y) capture monoclonal antibody 1- 
DIK (Mabtech, Stockholm, Sweden). Each peptide including Epstein - Barr virus 
(EBV), varicella zoster virus (VZV), Mumps, Tetanus, purified protein derivative 
(PPD) and surviving was added at a final concentration of 20pg/ml. A total of
200,000 cells per well were added in CTL medium (RPMI 1640 + 7.5% Human AB 
serum, 2mM glutamine). Cells were treated with HWFT or WHINE peptide at a 
concentration of 2pM and 0.5pM. For negative controls, cells were incubated in 
medium alone. Phytohemagglutinin (PHA, Sigma) was added at a concentration of 
2pg/ml (Sigma, UK) to serve as a positive control. The cells were incubated overnight 
at 37°C with 5% C02. The plates were developed by washing them six times with 
phosphate-buffered saline (PBS) + 0.05% Tween20 (no Ca or Mg; Mediatech), and 
0.5 pg of biotinylated anti-IFN-y detection monoclonal antibody 7-B6-1 (Mabtech)/ml 
was added for 3 hours at room temperature. The plates were again washed and 
incubated with a 1 :2 , 0 0 0  dilution of streptavidin-coupled alkaline phosphatase 
(Mabtech) for 2 hours at room temperature in the dark. The plates were washed again, 
and IFN-y production was detected as blue spots after a short incubation with alkaline 
phosphatase substrate kit (Biorad, UK). The colour reaction was stopped by washing 
the plates with cold tap water. The spots were counted using the AID ELISpot Reader 
unit (Autoimmun Diagnostika GmbH, Germany), and the results were expressed as 
spot-forming cells (SFC) per million input cells.
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2.21 Immunohistochemistry
In order to characterise the immune cell infiltrate in prostate and pancreatic 
cancer biopsies various immunohistochemical techniques were used. 4pM paraffin 
sections were dewaxed and rehydrated. Endogenous peroxidase was blocked using 
Methanol / 0.3% H2O2 for 20 min. The sections were then subjected to heat mediated 
antigen retrieval in a microwave using Citrate buffer (lOmM, pH 6.0). For single 
enzymatic staining primary Abs were diluted in 1% BSA in PBS and incubated 
overnight at room temperature. The bound primary Abs were detected enzymatically 
using VECTASTAIN R.T.U. Universal kit (Vectorlabs, Burlingame, CA, USA) for 
30 minutes. Peroxidase activity was detected using a DAB kit (Vectorlabs, USA). 
Sections were then counterstained with Haematoxylin (Vectorlabs, USA) for 45 
seconds and dehydrated in a series of alcohol and mounted with VectaMount 
mounting medium (Vectorlabs, USA).
For triple fluorescent and silver staining of tumour infiltrating lymphocytes, 
cancer biopsy sections were first treated as above before being stained by a silver 
staining kit (Aurion, The Netherlands) with the anti-AMACR-mIgG 1 /rab-IgG. Next a 
combination of cell specific primary antibodies was added to each slide. Tumour 
infiltrating lymphocytes were visualized by a combination of Alexa Fluor isotype 
specific fluorescent antibody conjugates. CD3^ T cells were detected using an Alexa 
fluor 546 (red), CD4^ cells were detected using an Alexa fluor 647 (blue) and 
F0XP3^ T cells were detected using an Alexa fluor 488 (green) isotype specific 
secondary Ab. VectaMount mounting medium (Vectorlabs, USA) was used to mount 
the slides. Images were captured with a confocal laser scanning microscope (LSM510, 
Zeiss, Germany) in a multitrack setting.
Tonsil sections were used as positive controls for the phenotypic antibodies in 
the multiple fluorescent staining.
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2.22 Statistical analysis
2.22.1 Spearman’s rank correlation test
Associations between EN2, HOXAl and HOXB 13 with other established 
markers (all of which are recorded on ordinal scales) are examined using a 
Spearman’s rank correlation test. The coefficient p (rho) is reported for each pair, 
along with level of statistical significance.
2.22.2 Student’s t-test
Unpaired student’s t-test was performed to evaluate the statistical significance 
of the number of spots generated from T cells stimulated with T2 cells pulsed with 
relevant peptide compared to unlabelled T2 cells.
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3. EN2 AS A POTENTIAL VACCINE TARGET IN MELANOMA
3.1 INTRODUCTION
There are two main types of skin cancer, malignant melanoma of the skin and 
non-melanoma skin cancer (NMSC). In the latest decades, cutaneous melanoma has 
been reported to be the most aggressive skin malignancy with an increasing rate of 
incidence (Petrescu et al, 2010). The lifetime risk of developing malignant melanoma 
has been estimated to be 1 in 77 for women and 1 in 91 for men in the UK 
(http ://infb .cancerresearchuk.org/cancerstats/types/skin/?script=true). Treatment
strategies include surgical tumour excision with safety margins of 1 - 2  cm and radical 
lymphadenectomy after positive sentinel lymph node biopsy. In advanced stages of 
melanoma the adjuvant therapy (i.e. chemotherapy, unspecific immunotherapy and 
interferon) is not considered successful (Petrescu et al, 2010). New imaging 
techniques such as dermoscopy and computer dermoscopy, ultrasound, MRI, CT, PET 
and PET/CT also play a key role in management of melanoma (Petrescu et al, 2010).
In addition to non-specific immunotherapeutic approaches (including cytokine 
therapy, whole tumour cell vaccine and toll-like receptor agonists), identification of 
tumour-associated antigens has made targeted immunotherapy possible (Schultz and 
Schuler, 2008; Lens, 2008). Hence, for decades immunotherapy has been considered 
as a crucial part of the therapeutic strategies (Schultz and Schuler, 2008). A range of 
clinical trials have shown that immune responses play an important role in total or 
partial regression of primary melanomas associated with lymphoid infiltrates (Hersey, 
2010).
Melanoma has become an excellent target for the active specific 
immunotherapy since it has been considered to be a highly immunogenic tumour 
(Lens, 2008). Significant achievement has been made in the identification of 
melanoma-associated antigens (MAA) that are recognized by cytotoxic T 
lymphocytes (CTL). These antigens are classified into three main categories: tumour- 
associated testis-specific antigens (MAGE, BAGE, GAGE and PRAME), melanocyte 
differentiation antigens (tyrosinase, Melan-A/MART-1, gplOO, TRP-1 and TRP-2)
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and mutated or aberrantly expressed antigens (MUM-1, CDK4, beta-catenin, gplOO- 
in4, p i5 and N-acetylglucosaminyltransferase V) (Zeuthen et al, 1998). There is still 
an essential need to fully exploit the therapeutic potential of MAA as well as attaining 
new strategies in order to accomplish an efficient and durable in vivo immune control 
of melanoma growth and progression (Castelli et al, 2000).
Engrailed (EN) is a homeodomain-containing transcription factor with a 
multifunctional nature. It has multiple regulatory roles at different stages of 
development such as transcriptional and translational regulation as well as secretion 
and internalization. It is the murine homolog of the Drosophila segment polarity gene 
engrailed and has key roles in embryonic and neural development and specific role in 
disease states (Morgan, 2006). In vertebrates there are two engrailed genes; ENl and 
EN2, with specific developmental functions (Martin et al, 2005) in which different 
mutations result in different developmental defects that frequently are lethal (Zhong 
and Yao, 2008). The sequence conservation of murine En homologues at the protein 
levels are relatively limited comparing to the high degree of functional conservation. 
There are four EN homology regions (EHs) within the EN gene sequence, designated 
numbers 1-5. Transcriptional repression is mediated by EHl and EH5, engrailed DNA 
binding affinity and specificity is modified by EH2 and EH3, and the homeodomain 
region is the EH4 (Morgan, 2006).
EN2 is known to be expressed in a number of solid cancers such as brain 
glioblastoma, ovarian and colon carcinomas (Sudeep et al, 2008) as well as acute 
myeloid leukaemia (AML) (Kozmik et al, 1995). Furthermore, EN2 has been 
identified as a candidate oncogene in breast cancer since its ectopic expression has 
been shown in a subset of human breast cancer, suggesting that it might have a role in 
mammary tumourogenesis (Martin et al, 2005). In a previous study it was shown that 
when non-tumourogenic mammary cell lines were forced to express EN2, a number of 
malignant characteristics including a reduction in cell cycling time, a loss of cell to 
cell contact and a failure to differentiate in response to lactogenic hormones were 
subsequently exhibited. In addition, it has also been shown that EN2 expression is 
required for the maintenance of the transformed phenotype in a human breast cancer 
cell line (Martin et al, 2005; Zhong and Yao, 2008). More recently Sudeep et al. 
provided evidence of over-expression of EN2 in human prostate cancer cells
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compared to normal prostate epithelial cells suggesting EN2 contributes to prostate 
tumourogenesis (Sudeep et al, 2008).
Due to the fact that EN2 has been shown to be highly expressed in a variety of 
cancers including melanoma, breast, ovarian and prostate but has little or no 
expression in normal tissues, as well as its potential role in oncogenesis, we aimed to 
investigate the usefulness of EN2 as a target antigen for anti-cancer T cell therapy in 
this study.
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Hypothesis and objectives
The goal of this chapter was to determine the immunogenicity of EN2 in 
melanoma (versus healthy controls) and its potential as a target for immunotherapy. 
We confirmed the expression pattern of EN2 in primary and metastatic malignant 
melanoma (including tumours of differing grade) using a melanoma cancer tissue 
array and compared this to normal tissues. We assessed the immunogenicity of EN2 
by determining the level of autoantibody responses to EN2 in the serum of melanoma 
patients, the presence of EN2 specific T cells in healthy donors’ blood and whether 
these specific T cells could be expanded and were able to recognize melanoma cell 
line targets. Several of our identified EN2 epitopes were used to show that one or 
more of these epitopes is a potent stimulator of specific anti-EN2 immune responses 
from the peripheral blood of healthy donors and cancer patients.
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3.2 RESULTS
3.2.1 Expression of EN2 in a range of normal tissues
3.2.1.1 PCR analysis of a range of different normal tissues for the expression of 
EN2
In order to determine the expression pattern of EN2 genes at the molecular 
level in normal tissues, RNA was extracted from a range of different normal tissues 
and cDNA was synthesised to perform qRT-PCR analysis as described in 2.10. The 
results of qRT-PCR analysis on a range of different normal tissues showed that EN2 
had undetectable or very low level of expression at the molecular level in all of the 
normal tissues tested with the exception of testis (Figure 3.1). For comparison 
purposes the melanoma cancer cell line, MeWo was included which showed a high 
level of EN2 expression compared to all the other normal tissues. Therefore, we 
aimed to investigate further the expression of EN2 at the protein level in different 
normal tissues by comprehensive immunohistochemical analysis and then compare 
the results with EN2 expression in malignant melanoma biopsies.
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Figure 3.1 Expression of EN2 in a range of different normal tissues and MeWo 
melanoma cell line. RNA was extracted from a range of different normal tissues and cDNA 
synthesised. QRT-PCR analysis was performed to determine the expression of EN2 genes in 
various types of normal tissues. Values were normalized to the co-amplification reaction of 
the house-keeping gene, |3-actin.
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3.2.1.2 Immunohistochemical analysis of a range of different normal tissues for 
the expression of EN2
In order to assess the expression pattern of EN2 at the protein level in normal 
tissues, immunohistochemical analysis was performed. A multiple organ normal 
tissue microarray, containing 3 cases of each of breast, colon, lung, liver, ovary, 
pancreas, prostate and skin, duplicate cores per case, was used for the analysis of EN2 
expression. Figure 3.2 shows the tissue array panel display and Figure 3.3 
demonstrates representative examples of immunohistochemical negative staining of 
normal tissues for the expression of EN2. (The specific information regarding each 
individual core within the tissue array is summarised in Appendix 3.1 and the total 
results of EN2 immunohistochemical staining is shown in Appendix 3.2). Prostate 
cancer biopsies were used as a positive control for EN2 staining (data not shown).
Microarray Panel Display
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Figure 3.2 Tissue array panel display used for immunohistochemical analysis of EN2 
expression (Biomax, US).
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Figure 3.3 Representative examples of enzymatic staining of a range of different 
normal tissues for the expression of EN2. Paraffin-ambedded normal tissue array was 
deparaffinised and rehydrated followed by a microwave heat-mediated antigen retrieval 
method. Slides were blocked and then incubated overnight with anti-EN2 primary antibody 
followed by incubation with ABC detection kit. Peroxidase activity was detected using DAB kit 
followed by counterstaining with Hematoxylin.
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As shown in Appendix 3.2, the immunohistochemical analysis of different 
normal tissues demonstrated that EN2 was either not expressed or had only very low 
level of expression in the majority of different normal tissues tested. This confirms the 
qRT-PCR data (Figure 3.1) which similarly demonstrated little or no expression of 
EN2. Therefore, we suggest that EN2 is not expressed at both the molecular and 
protein levels in normal tissues.
Consequently, having obtained these findings, we aimed to further investigate 
the expression pattern of EN2 in malignant melanoma compared to the results gained 
from individual normal tissues. The following sections focus on the expression of 
EN2 in malignant melanoma and whether EN2 can be a potential promising candidate 
for immunotherapy.
107
3.2.2 EN2 in Melanoma
3.2.2.1 EN2 gene expression in melanoma cell lines
In order to determine the expression of EN2 genes in melanoma cell lines, 
qRT-PCR analysis was performed on a range of different melanoma cell lines. Figure 
3.4 shows MEL8 8 8 , ML, MK, MEWO, A375M, SK-MEL-5, SK-MEL-21, SK-MEL- 
28, SK-MEL-29, SK-MEL-37 and SK-MEL-52 melanoma cell lines that were used to 
assess the patterns of EN2 gene expression.
The qRT-PCR analysis of a range of different melanoma cell lines 
demonstrated that 8 out of 11 cell lines tested were positive for EN2 expression. 3 
primary melanoma cell lines, MEL8 8 8 , ML and MK, showed undetectable level of 
EN2 expression. However, A375M cell line was shown to have the highest level of 
expression for EN2. In addition, as well as the MEWO cell line, all of the SK-MEL 
cell lines (SK-MEL-21, 28, 29, 37 and 52) were detected to express EN2, with the 
highest level of expression in SK-MEL-28 cell line.
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Figure 3.4 Expression of EN2 genes in a range of different melanoma cell lines. RNA
was extracted from the melanoma cell lines and cDNA synthesised. QRT-PCR analysis was 
performed to determine the expression of EN2 in various melanoma cell lines. Values were 
normalized to the co-amplification reaction of the house-keeping gene, |3-actin. All cancer cell 
lines used are primary melanoma.
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3.2.2.2 Immunofluorescent staining of melanoma cell lines for the expression of 
EN2 protein
In order to assess the expression of EN2 at the protein level in melanoma cell 
lines, immunofluorescent staining was performed on a range of different cell lines 
(Figure 3.5). Melanoma cell lines MEWO, A375M and SK-MEL-5 as well as 
Hermes-3a (normal melanocyte line) were used.
Figure 3.5 Immunofluorescent staining of melanoma 
cell lines for the expression of EN2 protein.
Melanoma cell lines were grown on chambered slides, 
fixed with 4% formaldehyde, permeabilised and then 
incubated with rabbit anti-human-EN2 primary antibody 
over night. Next, slides were incubated with Alexa Fluor 
488-goat conjugated with rabbit-IgG secondary antibody and then mounted using Vectashield 
mounting medium containing DAP I. Images were taken using Leica DM IRE2 confocal 
microscope and were then analysed by Leica confocal software. EN2 staining is shown in 
green (pointed by arrows) and nuclear staining in blue. Negative control for staining was 
included using the secondary Ab only (dapi: blue staining).
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The immunofluorescent staining and confocal analysis of melanoma cancer 
cell lines demonstrated that EN2 was expressed at the protein level in all 3 melanoma 
cell lines tested (MEWO, A375M and SK-MEL-5) as well as Hermes-3 a line (Figure 
3.5). The nuclear marker, DAPI, was used in order to help determine the localization 
of EN2 expression within these cancer cell lines. EN2 appeared to be predominantly 
expressed within the nucleus of all 4 melanoma cancer cell lines (shown by arrows). 
However, in SK-MEL-5 and Hermes-3 a cell lines, as well as notable nuclear staining, 
EN2 appeared to be expressed on the surface membrane of the cell (shown by arrow). 
EN2 was also found to have cytoplasmic expression as well as nuclear and cell 
surface expression in SK-MEL-5 cell line.
3.2.2.3 FACS analysis of melanoma cell lines for the expression of EN2 protein
In order to confirm melanoma cancer cell lines for the surface expression of 
EN2, FACS analysis was performed. Figure 3.6 shows a range of different melanoma 
cancer cell lines that were stained for cell surface expression of EN2.
The results of FACS analysis for the expression of EN2 on a range of different 
melanoma cell lines showed that all of the SK-MEL cell lines (SK-MEL-29, 37, 5, 28, 
21 and 52) and MEWO cell line had cell surface expression of EN2 which was 
particularly strong in SK-MEL-5 and SK-MEL-52 cell lines. This data is consistent 
with the result obtained from immunofluorescent staining of SK-MEL-5 cell line 
which showed marked surface membrane staining of EN2. However, A375M and ML 
cancer cell lines showed no cell surface staining of EN2. In each individual melanoma 
cell line tested unstained cells and cells stained with the control HuCAL Ab were 
taken along as negative controls which showed no positivity in the PE channel.
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Figure 3.6 Representative cell surface staining of EN2 on a range of melanoma cell 
lines. Melanoma cell lines were incubated with an humanised-EN2 primary antibody for 30 
minutes at 4°C in the dark. Cells were then washed twice with FACS buffer and incubated 
with PE-conjugated mouse anti-human IgG secondary antibody for 30 minutes at 4°C. Cell 
surface staining was then analyzed using a MACSQuant Analyser flowcytometer.
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3.2.2.4 Immunohistochemical analysis of melanoma tissue array for the
expression of EN2
In order to assess the frequency and expression pattern of EN2 at the protein 
level in malignant melanoma, immunohistochemical analysis was performed. A 
malignant melanoma tissue array, containing 128 cases of primary malignant 
melanoma, 64 metastatic malignant melanoma and 8 cases of adjacent normal tissue 
and normal tissue from autopsy was used to analyse the expression of EN2 (Figure 
3.7). Figure 3.8 demonstrates representative examples of EN2 immunohistochemical 
staining performed on this melanoma tissue array. (The specific information regarding 
each individual core within the tissue array is summarised in Appendix 3.3 and the 
total results of EN2 immunohistochemical staining is shown in Appendix 3.4).
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Figure 3.7 Tissue array panel display used for immunohistochemical analysis of EN2 
expression (Biomax, US).
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Figure 3.8 Representative examples of enzymatic staining of melanoma tissue array for 
the expression of EN2. A) Paraffin-embedded melanoma tissue array was deparaffinised 
and rehydrated followed by a microwave heat-mediated antigen retrieval method. Slides were 
blocked and then incubated overnight with anti-EN2 primary antibody followed by incubation 
with an ABC kit. Peroxidase activity was detected using a DAB detection kit followed by 
counterstaining with Hematoxylin. Representative examples of scoring (0, +, ++, +++ based 
on staining intensity) are shown.
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K
E8 (Malignant skin tumour) K8 (Metastatic lymph node)
# /
$
I
H4 (Malignant eye tumour) C2 (Malignant vulva tumour)
Figure 3.8 Representative examples of enzymatic staining of melanoma tissue array for 
the expression of EN2. B) Representative examples of melanoma derived from different 
tissue sites at higher magnification (x20).
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Immunohistochemical studies on the malignant melanoma tissue array showed 
a large proportion of primary malignant melanoma and metastatic malignant 
melanoma cancers expressing EN2 (Appendix 3.4) compared to a range of normal 
tissues including skin and adjacent normal skin tissues (Appendix 3.2) in which EN2 
was expressed at very low levels. The results showed that 62.6% (77 out of 123) of 
primary malignant melanoma tumours and 65.1% (41 out of 63) of metastatic 
malignant melanoma cases were positive for EN2 expression. EN2 expression was not 
only seen in skin tissues, but also ocular, mucosal and metastatic tissue sections 
showed positive staining for EN2 (Figure 3.8). Table 3.1 summarizes the results of 
scoring that was performed for the expression of EN2 on the melanoma cancer tissue 
array.
EN2 sco re Frequency Percent Valid Percent
Cumulative
Percent
Valid -VE 68 35.4 36.6 36.6
+ 28 14.6 15.1 51.6
++ 33 17.2 17.7 69.4
+++ 57 29.7 30.6 100.0
Total 186 96.9 100.0
Missing System 6 3.1
Total 192 100.0
Table 3.1 Summ ary of the  EN2 scoring perform ed on m alignant m eianom a tissu e s .
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In addition, we also performed nonparametric spearman’s rank correlation 
coefficient to determine whether there was an association between the expression of 
EN2 with the age of melanoma patients and the stage of tumour (see Appendix 3.3). 
The results showed that there was no statistically significant correlation between the 
expression of EN2 with any of the variables. Table 3.2 summarizes the results 
obtained from statistical analysis (nonparametric spearman’s rank correlation 
coefficient).
C orrelations EN2score
Spearman's rho Age Correlation Coefficient .029
Sig. (2-tailed) .691
N 186
Stage score Correlation Coefficient .074
Sig. (2-tailed) .318
N 186
Table 3.2 Sum m ary of the statistical analysis perform ed on m alignant m elanom a 
tissu es . Nonparametric spearm an’s rank correlation test was applied to determine the 
correlation between EN2 expression with cancer patients’ age and tumour stage.
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3.2.2.S Immunohistochemical analysis of malignant melanoma patients’ biopsies 
for the expression of EN2
The qRT-PCR analysis and IHC results demonstrated that EN2 was expressed 
highly at both moleeular and protein level (Figure 3.1 and 3.8 respectively) in several 
different melanoma cell lines as well as malignant melanoma tumour sections. 
Therefore, using immunohistochemieal analysis, we further investigated the 
expression of EN2 in biopsies taken from our own patient eohort at St Luke’s Cancer 
Centre with malignant melanoma (Figure 3.9 and Appendix 3.5). Seetions of prostate 
cancer and normal skin were used as positive and negative controls respectively. In 
addition, we analysed testis sections for EN2 expression in order to assess whether 
EN2 is a testis-associated antigen (Figure 3.9).
Negative
m
Figure 3.9 Enzymatic staining of melanoma biopsy sections for the expression of 
EN2. A) Representative examples of IHC staining on prostate cancer, normal skin and
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The results of immunohistochemical analysis on biopsy sections showed that 
all of the melanoma cancer patients strongly expressed EN2 protein (Appendix 3.5). 
Furthermore, for control purposes, we analysed prostate cancer and normal skin 
sections as positive and negative controls. As it has been shown in Figure 3.9, the 
prostate cancer section was stained strongly for EN2, whereas the normal skin stained 
negative for EN2. In addition, analysis of testis sections demonstrated expression of 
EN2 protein, therefore, it can be suggested that EN2 is a testis-associated antigen. 
Moreover, we also stained the melanoma sections for a Pan-melanoma Ab (HMB-45 
and MART-1) for comparison purposes against EN2. HMB-45 and MART-1 are co­
expressed in the majority of melanomas, as well as uniquely expressed in certain 
cases. Thus, the HMB-45 and MART-1 cocktail is potentially more sensitive than 
HMB-45 and MART-1 alone. As Figure 3.9 shows, the melanoma sections had same 
expression pattern of staining with EN2 and Pan-melanoma Ab, while no expression 
was seen in negative control sections.
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3.2.3 EN2 humoral response in melanoma cancer patients
In order to assess the potential auto-antibody response in melanoma cancer 
patients to EN2, an ELISA was performed on a small cohort of patient’s plasma. This 
was compared to age-matched controls with no known history of cancer. Figure 3.10 
shows the humoral response to EN2 in each individual group tested.
EcoID
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6/16=37.5%
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n=33
0/33=0%0.4
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Figure 3.10 IgG hum oral re sp o n se  to  EN2 In m alignant m elanom a patien ts bu t not In 
healthy controls. ELISA plates were coated overnight with whole-length EN2 protein diluted 
in 0.1 M carbonate buffer. Plates were then incubated with patient or control serum for 1 hour 
followed by incubation with anti-human IgG conjugated to horseradish peroxidase. Then, 
plates were washed and developed with TMB. The optical density was analysed at 450nm on 
a DTX 880 Multimode Detector ELISA plate reader. Student t-test showed humoral response 
in melanoma cancer was significant (***P ^ 0.0001) as compared to age-matched controls. 
The cut-off point for controls (0.3978) was calculated by the average point (0.23378) plus two 
standard deviations (0.0820). The smallest observation (minimum), lower quartile, median, 
upper quartile, and largest observation (maximum) are respresentative of the whisker plots.
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We tested the plasma of 16 melanoma cancer patients and 33 age-matched 
control donors with no known personal history of cancer. The ELISA results showed 
that 37.5% of melanoma cancer patients (6  out of 16 patients) had an antibody 
response to EN2 above the cut off compared to 0% of aged-matched controls (0 out of 
33 controls). This observation confirms that melanoma cancer patients had significant 
EN2 auto-antibody response using student t-test (P ^ 0.0001).
3.2.4 EN2 cell mediated immune responses
In order to investigate whether a cell-mediated immune response can be 
generated to EN2, potentially immunogenic HLA-A2 restricted epitopes from the 
EN2 protein sequence were selected using the computer algorithm SYFPEITHI. This 
predicts HLA class 1 specific epitopes according to specific factors including anchor 
residues and proteasomal cleavage sites (Schirle et al, 2001) (Table 3.3). Following 
this, high binding epitopes from the EN2 sequence (EN2.1, 2.2, 2.3 and 2.4) were 
synthetically generated and tested against healthy donor PBMCs using an IFN-y 
ELlSpot assay. (The cut off point used was 23 according to SYEPEITHI score).
Protein
code Peptide Amino acid position
SYFPEITHI
sco re
EN2.1 GLGGGDLSV 185-193 28
EN2.2 SLNESQIKI 282-290 25
EN2.3 LMLPAVLQA 48-56 23
EN2.4 FTAEQLQRL 251-259 23
Table 3.3 EN2 peptides with SYFPEITHI sco res .
The target cells used were the T2 cell line which is B lymphoblastoid, TAP 
deficient cell line expressing HLA class-1 A2. T2 cells without peptide and effector
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cells alone were used as negative controls for the assay. All four selected EN2 
epitopes tested (EN2.1, EN2.2, EN2.3 and EN2.4) generated specific responses 
against T2 target cells loaded with the relevant peptide and thus were shown to be 
immunogenic (Figure 3.11).
Donor 1EN2.1 Donor 2 EN2.2
E 40
12  plus peptide T2 without peptide Effector celis alone T2 plus peptide T2 without peptide Effector cells alone
Donor 3EN2.3 Donor 4EN2.4
200
72 plus peptide 12  without Effector cells alone 72 plus peptide 72  without peptide Effector cells alone
Figure 3.11 EN2-reactive T cell lines can be generated from the blood of healthy 
donors. T cells were stimulated with peptide five times before testing their specificity in an 
IFN-gamma ELlSpot assay. Targets were T2 cells pulsed with EN2 peptides. Representative 
examples are shown here from four different healthy donors. * p < 0.05, ** p < 0.01, *** p < 
0.001. Number of spots is per 2x10^ cells/well (representative data of triplicates).
As the results of IFN-gamma ELlSpot assay show in Figure 3.11, peptide- 
specific immune responses were generated from the peripheral blood of healthy 
controls. Specific immune responses were generated against EN2.1 in donor 1, 
specific responses against EN2.2 in donor 2, specific responses against EN2.3 in 
donor 3, also donor 4 showed specific immune responses against peptide EN2.4. In all
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donors, specific immune responses generated against each individual peptide (T2 & 
peptide) were significant compared to negative controls (T2 alone and effectors 
alone). This was confirmed by the student T test to calculate the significance between 
the numbers of spots generated from T cells stimulated with T2 cells pulsed with 
relevant peptide compared to unlabelled T2 cells.
3.2.5 In  vitro expansion of EN2-specific CTLs
Having generated specific cell-mediated immune response to EN2 from 
peripheral blood of healthy donors (Figure 3.11), next we sought to investigate 
whether these specific responses can be induced from PBMCs of cancer patients. In 
order to do this, our previously identified immunogenic HLA-A2.1 restricted EN2- 
specific T-cell epitopes were used to expand EN2-specific CTLs from the peripheral 
blood of melanoma cancer patients applying the same method described previously 
(Hida et al, 2002). The EN2stimulated CTL lines were then tested against T2 cells 
loaded with or without the peptide of interest in a standard chromium release assay 
to see whether any specific CTLs had been generated.
As shown in Figure 3.12, EN2-specific CTL responses were generated from 
the peripheral blood of two melanoma cancer patients. CTL responses were generated 
from the PBMC of both of the melanoma patients against one or more of the EN2 
epitopes. In patient MEL04, responses generated against EN2.1 and EN2.4 were 
more prominent than EN2.2 and EN2.3 at the two effector to target ratios tested. In 
patient MEL02, specific cytotoxic responses were observed against all four EN2 
epitopes with the response to peptide EN2.4 being most dominant.
123
45
40 -
35 -
■S 30 - 
u
5  25 -u
g.
W 2 0  - 
15 - 
10 
5 H 
0
MEL02
E:T ratio
■ 50:1
25:1
T2 without pep T2+EN2.1 T2+EN2.2 T2+EN2.3 T2+EN2.4
45 -1
40 -
35
« 30 - 
>•
g  25 -
g
W 20 - 
15 - 
10 -  
5 - 
0
MEL 04
E:T ratio
h L
50:1
25:1
T2 without pep T2+EN2.1 T2+EN2.2 T2+EN2.3 T2+EN2.4
Targets
Figure 3.12 EN2-speciftc CTLs can be generated from the blood of melanoma patients.
T cells were stimulated with the four EN2 peptides five times before testing their specificity in 
a standard ^'chromium release assay. Targets were T2 cells pulsed with or without EN2 
peptides. Representative examples are shown here from two different cancer patients. 
Number of spots is per 2x10^ cells/well. (E:T ratio = Effector ; Target ratio).
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3.2 DISCUSSION
Engrailed (EN) gene is a homeodomain-containing transcription factor with 
multifunctional nature. It has been shown that EN2 is involved in multiple regulatory 
roles at different stages of development. These regulatory roles include transcriptional 
and translational regulation, as well as secretion and internalization. In an early study 
by Davis and Joyner in 1988, it was demonstrated that EN2 expression is restricted to 
the central nervous system and branchiolar arches in mice during embryogenesis and 
EN2 null mutants are viable but harbor reductions in cerebellar size (Joyner et al, 
1991). In a similar study conducted by Martin et al in 2005, the prominent position of 
EN and other homeobox-containing genes in the developmental regulatory hierarchy 
was suggested. This group showed that EN2 is ectopically expressed in a subset of 
human breast cancer and in a large proportion of breast cancer cell lines. They also 
demonstrated that the ectopic expression of EN2 readily transforms mammary 
epithelial cells in vitro and promotes adenocarcinoma formation in vivo as well as its 
critical function in a breast cancer cell line.
In addition to the discovery that EN2 has been known to be candidate 
oncogene in breast cancer, its expression has also been detected in SAGE libraries 
derived from human brain glioblastoma, colon and ovarian carcinomas (Library 
numbers NCI CGAP Bm23, NCI CGAP Co 16 and CL ES2-1, respectively, 
http://www.ncbi.nlm.nih.gov/UniGene). Moreover, the expression of EN2 has been 
detected in acute myeloid leukaemia (AML) (Kozmik et al, 1995) as well as a number 
of solid cancers (Sudeep et al, 2008). Therefore, considering the findings from 
previous studies on EN2 and its critical role as an oncogene in various cancers, we 
aimed to investigate the usefulness of EN2 as a target for anti-cancer T cell therapy.
The expression pattern of EN2 at the molecular level on a range of different 
normal tissues was determined using quantitative RT-PCR analysis. The results 
showed that EN2 expression was limited to testis tissue. In addition a very low level 
of EN2 expression was detected in brain tissue which is consistent with the data 
reported in the literature. These observations were confirmed at the protein level by 
immunohistochemical analysis which revealed that all the different normal tissues 
were negative for the expression of EN2 with the exception of the liver tissue.
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However, the expression of EN2 was not detected in the liver when analysed at the 
molecular level. This controversy in expression of EN2 at molecular and protein level 
could be due to non-specific binding of the EN2 antibody to the liver tissue when 
tested using IHC. This could be explored by control for negative staining.
Having tested a range of different normal tissues for EN2 expression, we next 
investigated its expression in melanoma cancer. Using quantitative RT-PCR analysis, 
we found that EN2 was expressed in a large proportion of established melanoma cell 
lines (8 out of 11 or 72%). These findings were also confirmed at the protein level 
applying both immunofluorescent staining and FACS analysis for the expression of 
EN2 protein in melanoma cell lines. However, the expression pattern of EN2 varied 
among each individual melanoma cell line. The results demonstrated predominant 
nuclear expression of EN2 protein in some cell lines (i.e. A375M), whereas other cell 
lines appeared to have cytoplasmic expression and/or cell surface expression (SK- 
MEL-5). So, different patterns of EN2 expression were observed by PCR, FACS and 
IHC staining which could be due to the use of different Abs applied for each method.
To determine whether EN2 was also expressed in primary human melanoma 
tumours as well as melanoma cell lines, immunohistochemical analysis was 
performed on primary and metastatic malignant melanoma. The results showed over 
expression of EN2 protein in a large proportion of malignant melanoma sections 
(62.6% of primary and 65.1% of metastatic malignant melanoma) when compared to 
normal skin or adjacent normal skin tissues. Alongside this, we correlated the 
expression of EN2 with patients’ age and tumour stage. Statistical analysis 
demonstrated that there was no significant correlation between the over expression of 
EN2 with patients’ age and stage of the tumour. Hence, in order to determine whether 
EN2 has oncogenic role in melanoma, we suggest investigating the effects of knock­
down EN2 on a range of different cancer cell lines using RNA silencing methods. 
This will allow assessing possible adverse effects of EN2 on expression of certain 
other genes. Furthermore, we also assessed the expression of EN2 in biopsies taken 
from our own cohort of melanoma patients. Consistent with our previous data, EN2 
was strongly expressed in patients’ biopsies.
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Additionally, we investigated the potential of EN2 as a target for 
immunotherapy. This was tested by determining the presence and level of IgG auto­
antibodies to EN2 in the plasma of melanoma cancer patients using an ELISA assay. 
In order to assess the significance of these responses, we compared the results 
obtained from melanoma cancer patient plasma to control plasma from healthy age- 
matched donors with no known history of cancer. The ELISA results showed that 
37.5% (6 out of 16) of melanoma cancer patients had strong significant EN2-humoral 
response (P < 0.0001), while none (0 out of 33) of the age-matched controls had an 
auto-antibody response to EN2. This observation confirms that melanoma patients had 
significant EN2 auto-antibody response.
In a systemic review by Reuschenbach et al. in 2009, humoral responses 
against tumour associated antigens have been summarized with a focus on frequencies 
of antibody and the potential diagnostic, prognostic and etiologic relevance of 
antibodies against TAAs. They detected antibodies against NY-ESO-1, Her-2/neu, 
p53, p62, survivin, MUCl and cyclin B1 in median 14% of analyzed tumour patients 
with generally very low frequencies in healthy individuals. In comparison, we showed 
that humoral response against EN2 was detected in 37.5% of our melanoma patients 
which is higher compared to these well-established tumour antigens.
In another study, Goodell et al. demonstrated that Her-2/neu antibody 
frequency was higher in patients with Her-2/neu expressing tumours (82%) as 
compared to patients with Her-2/neu negative tumours (no antibody response) 
(Goodell et al, 2008). Moreover, a strong correlation between NY-ESO-1 over­
expression and humoral responses has been reported (up to 83% antibodies in cases 
with strong expression versus no antibodies in cases with weak expression) (Maio et 
al, 2003; Jâger et al, 1999). However, in spite of a strong over-expression of the 
antigen (Melan A, pl6^"^^), undetectable or very low antibody frequencies were 
found (Stockert et al, 1998; Reuschenbach et al, 2008). Despite the fact that all our 
cohort of melanoma patients were found to have strong EN2 expression in their tissue 
biopsies, only 37.5% showed humoral response against EN2.
Expression of antigen in tissues that are not analyzed for expression (i.e. 
distant métastasés) or loss of antigen-expression after immune priming and selection
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of antigen negative tumour cells may explain cases where humoral responses exist in 
patients with antigen-negative tumours (Maio et al, 2003; Akcakanat et al, 2004). 
Humoral responses to several TAAs such as NY-ESO-1, tyrosinase, p53 and survivin 
were found to be induced more frequently in advanced tumour stages which confirm 
the importance of antigen load and duration of antigen exposure for the generation of 
antibody responses (Akcakanat et al, 2004; Fossa et al, 2004; Wadle et al, 2006). 
Despite increase of Her-2/neu antigen expression in advanced metastatic disease, 
higher titers and incidence of MUCl and Her-2/neu antibodies have been detected 
largely at early stages. Therefore, in spite of persistent or enhanced expression of the 
antigen the loss of antibodies may lead to disease progression (von Mensdorff-Pouilly 
et al, 2000; Traina et al, 2006; Ferretti et al, 2007). Considering data obtained from 
these studies, it is interesting to investigate whether there is a correlation between 
EN2 expression and humoral responses in both primary and metastatic malignant 
melanoma. Additionally, a further study is required to find any association between 
(over)-expression of EN2 and titre/incidence/frequency of auto-antibody responses 
against EN2 at different stages of malignant melanoma tumours.
Having observed a significant humoral response generated against EN2, next 
we investigated generation of cell-mediated immune responses against EN2. Our 
initial studies to identify specific immunogenic epitopes from EN2 showed that four 
immunogenic EN2 epitopes were identified (EN2.1, EN2.2, EN2.3 and EN2.4) which 
generated peptide-specific immune responses in all of donors tested. These specific 
immune responses generated against each individual peptide (T2 & peptide) were 
significant compared to controls (T2 target alone and effectors alone). In addition, 
when we tested the peripheral blood of two melanoma cancer patients stimulated with 
these HLA-A2 restricted EN2 epitopes, EN2-specific CTL responses were induced. In 
both of the melanoma patients, these CTL lines were generated against all four EN2 
epitopes. Since in these experiments the induction of specific responses were 
measured based on the production of IFN-y, hence the involvement of Thl and Th2 
responses can be concluded. However, further study is required to test these EN2- 
specific CTL lines against melanoma cancer cell lines to assess whether EN2-specific 
CTL are able to recognise and kill specifically HLA-A2-restricted cancer cell lines. 
This needs to be investigated since recognition of melanoma cancer cell lines by these
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CTL lines also would suggest whether these epitopes are naturally processed and 
presented.
Furthermore, we are currently undertaking in vivo experiments using a murine 
model of cancer to assess the effects of EN2 peptide as a vaccine modality. In 
conclusion, taking into consideration the results obtained from this project, we suggest 
that the specific expression of EN2 in melanoma tumours and its immunogenicity 
makes EN2 a promising novel target for vaccine therapy to treat melanoma patients.
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Chapter 4
HOXAl as potential 
vaccine target in breast
cancer
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4. HOXAl AS A POTENTIAL VACCINE TARGET IN BREAST 
CANCER
4.1 INTRODUCTION
Breast cancer still remains the most common cancer in women worldwide with 
an estimated one million newly diagnosed cases each year (O'Driscoll and Clynes, 
2006). In the UK Breast cancer is the most common type of cancer in women with 
over 44,600 new cases occurring each year and has a significant health problem in 
terms of both morbidity and mortality (O'Driscoll and Clynes, 2006). Whilst increased 
awareness, screening and development of treatments has increased the five year 
survival rate to around 80%, nearly 12,000 women still die from the disease each year 
fhttp://info.cancerresearchuk.org/cancerandresearch/cancers/breast/). Nevertheless, 
the burden is not evenly distributed and a number of complex factors underlie these 
variations, including lifestyle, population structure (age, race, and ethnicity), disease 
stage at diagnosis, environment, risk factor prevalence, mammographie screening, 
socioeconomic status, and access to high-quality care.
To improve survival of this disease further, the current repertoire of treatment 
modalities available i.e. surgery, radiotherapy and chemotherapy could be expanded 
to include more targeted therapy and immunotherapeutic strategies. For example, 
although chemotherapy forms part of a successful treatment regime in many cases, 
only as few as 40% patients may benefit from the therapy which is due to intrinsic or 
acquired multiple drug resistance (MDR) (Hortobagyi et al, 2005). A way to improve 
the survival rate further could be to use alternative therapies such as immunotherapy, 
which target only cancer cells thereby avoiding the side effects of traditional 
treatments and allowing for elimination of metastatic disease. For example, chemo 
resistant cancer cells may still be highly susceptible to cytotoxic immune cells.
The basis of immunotherapeutic treatments involves targeting the immune 
system against specific tumour antigens expressed on cancer cells. In the case of 
breast cancer a number of over-expressed tumour associated antigens (TAA) have
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been identified including CEA, MUC-1 and Her2/neu. Specific immune responses 
against these antigens have been detected in breast cancer patients showing these 
patients are not immunosuppressed and have pre-existing specific responses 
(Rentzsch et al, 2003). In particular Her2/neu is over-expressed in 20-30% of breast 
cancers (Beano et al, 2008) and is associated with poor prognosis. Therapies targeting 
this antigen include a monoclonal antibody (mAb) Trastuzumab (Herceptin) which is 
routinely used to treat patients with Her2/neu positive breast cancers (Renard and 
Leach, 2007). Unfortunately only around 25-30% of these patients actually respond to 
this therapy (Beano et al, 2008). Therefore there is still a need to identify other breast 
TAA which could be explored to therapeutically target a high proportion of breast 
cancer patients. Peptide based vaccines are one of the most common strategies to 
target breast cancer. In a peptide-based vaccine trial by Disis et al, it was shown that 
peptide-specific CTL responses capable of lysing tumour expressing Her2/neu were 
generated. This resulted in long-lasting immunity involving putative T helper epitopes 
of Her2/neu with HLA-A2 binding motifs of the peptide (Disis et al, 2004).
Microarray gene expression analysis has revealed four major breast cancer 
intrinsic subtypes. These include the estrogen receptor/progesterone receptor 
(ER/PgR)-positive or hormone receptor (HR)-positive luminal A and B (sensitive to 
hormonal treatment), human epidermal growth receptor 2 (Her-2)-positive (sensitive 
to trastuzumab, lapatinib), the basal-like breast cancer (BLBC), and the triple negative 
breast cancer (TNBC) subtype. TNBC accounts for approximately 15% of all breast 
cancer diagnosis and is defined by lack of the expression of all the three receptor (ER, 
PgR and Her-2). Therefore, patients with triple negative tumours have a relatively 
poor outcome and are not sensitive to standard therapies (De Laurentiis et al, 2010; 
Foulkes et al, 2010).
Homeobox (HOX) genes are a large group of regulatory genes which encode 
transcription factors involved in developmental processes (Abe et al, 2006). These 
include the control of cell growth, differentiation, programmed cell death (apoptosis) 
and cellular interactions (e.g. cell-cell and cell-extracellular matrix) (Abdel-Fattah et 
al, 2006). In humans there are 39 HOX genes which are divided into four genomic 
clusters A, B, C and D. During embryonic development these genes are expressed to 
varying degrees however the majority of them are then subsequently down-regulated
132
throughout ‘adult life’ (Lappin et al, 2006). Re-expression of some of these HOX 
genes in adults has been shown to be linked to the development of tumours. For 
example expression of HOX genes has been found in a variety of different cancers 
including breast (Cantile et al, 2003a), lung (Abdel-Fattah et al, 2006), kidney (Cillo 
et al, 1992), bladder (Cantile et al, 2003b), colon (De Vita et al, 1993), prostate 
(Miller et al, 2003), cervical cancer (Alami et al, 1999), leukaemia and melanoma 
(Morgan et al, 2007). This re-expression of HOX genes in tumours leads to further 
progression of the growth due to their role in key regulatory processes. In our 
laboratory the importance of HOX in tumour development has been shown 
extensively by the use of a small cell-permeable peptide (HXR9), which disrupts 
HOX interactions with other transcription factors such as PBX thereby triggering 
apoptosis in cancer cells (i.e. melanoma) (Morgan et al, 2007). Whilst this has been 
shown to be effective, another strategy which has not been investigated as yet is to use 
HOX as an immunotherapeutic target, especially since they are over expressed in a 
number of different cancers.
Similar to MART and MAGE (Castelli et al, 2000) over-expression of HOX 
gene products in cancer provides a distinction between tumour and ‘normal’ cells 
therefore classifying it as a tumour associated antigen and making it a potential target 
for immunotherapy (Mitra, 2003). Designing immunotherapeutic treatments can be 
challenging and can target many different aspects of the immune system, although the 
overall outcome is the same i.e. to kill tumour cells and preserve ‘normal’ cells 
(Adam et al, 2003). Most of these approaches use biological agents to target the 
immune system and can be divided into three main categories; monoclonal antibodies, 
immune response modifiers, i.e. cytokines and vaccines (Adam et al, 2003). Whilst all 
these have their advantages and disadvantages, in this project we have focused on the 
vaccine approach, which usually comprise of immunisation with an antigen plus an 
adjuvant (Paczesny et al, 2003). Antigens can be delivered as whole cells, lysates, total 
protein, peptides, DNA or RNA (Henderson et al, 2005) i.e. whole tumour material or 
specific epitopes from tumour antigens (such as the HOX proteins).
One of the Homeobox genes, HOXAl, has previously been shown to be 
oncogenic in breast cancer in both humans and mice (Zhang et al, 2003; Dermime et
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al, 2004). Expression of HOXAl is seen in neoplastic lesions of the mammary gland 
but not in normal developed mammary glands. Inducing expression of HOXAl in 
immortalised human mammary epithelial cells can lead to oncogenic transformation 
(Svingen and Tonissen, 2003; Zhang et al, 2006). Further to this, in vivo implantation 
of these transformed immortalised human mammary epithelial cells lead to the 
formation of tumours in severe combined immunodeficiency (SCID) mice (Dermime 
et al, 2004 ; Ratkaj et al, 2010). HOXAl increases proliferation and survival of cancer 
cells directly by activating transcription of a number of pro-oncogenic factors 
including Bcl-2 and cyclin D1 (Svingen and Tonissen, 2003; Zhang et al, 2006). 
HOXAl over expression in breast cancers makes it a potential immunotherapeutic 
target.
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Hypothesis and objectives
The goal of this chapter was to determine the immunogenicity of HOXAl in 
breast cancer (versus healthy controls) and its potential as a target for immunotherapy. 
We confirmed the expression pattern of HOXAl in breast tumours (including tumours 
of differing grade and histological subtype) using a breast cancer tissue array and 
compared this to normal tissues. We assessed the immunogenicity of HOXAl by 
determining the level of autoantibody responses to HOXAl in the serum/plasma of 
breast cancer patients, the presence of HOXAl specific T cells in healthy donors’ 
blood and whether these specific T cells could be expanded and able to recognize 
breast cancer cell line targets. Several of our identified HOXAl epitopes were used to 
show that one or more of these epitopes is a potent stimulator of specific anti-HOXAl 
immune responses from the peripheral blood of healthy donors.
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4.2 RESULTS
4.2.1 HOX gene expression in breast cancer cell lines
HOX genes have been shown to play a role as oncogenes and their expression 
pattern in breast cancer and breast cancer cell lines have been shown to be up or 
down-regulated (Dermime et al, 2004). Therefore, in order to determine the 
expression of HOX genes in breast cancer cell lines, qRT-PCR analysis was 
performed on a range of different breast cancer cell lines. Figure 4.1 shows the breast 
cancer cell lines (MCF-7, MB-231, MB-468, T47D and SKBr3) that were used to 
assess the patterns of HOX gene expression, for the whole HOX network (39 genes).
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Figure 4.1 Expression of HOX genes in a range of different breast cancer cell lines.
RNA was extracted from the breast cancer cell lines and cDNA synthesized. QRT-PCR 
analysis was performed to determine the expression of HOX genes in various breast cancer 
cell lines. Values were normalized to the co-amplification reaction of the house-keeping gene, 
(3-actin.
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Cell line Organ Disease Derived from metastasised site Cell type
MCF7 mammary gland; 
breast
adenocarcinoma pleural effusion epithelial
MB-231 mammary gland; 
breast
adenocarcinoma pleural effusion epithelial
MB-468 mammary gland; 
breast
adenocarcinoma - epithelial
T47D mammary gland; 
breast
ductal carcinoma pleural effusion -
SKBRS mammary gland; 
breast
adenocarcinoma pleural effusion -
Table 4.1 Summary of the origin and properties of the breast cancer cell lines used.
The qRT-PCR analysis of breast cancer cell lines for the expression of HOX 
genes showed different patterns of expression of individual HOX gene clusters. 
Overall, HOXA genes appeared to have the most prevalent expression compared to all 
the other HOX gene clusters (B, C and D). MB-468 cell line showed the highest level 
of HOXA expression among all 5 breast cancer cell lines. The expression of the 
majority of HOXB genes (except from H0XB4, B5 and B13) was down-regulated 
among all of the cell lines in comparison to healthy cell lines. However, the 
expression of HOXC genes appeared to be up-regulated in most of the cell lines with 
the exception of H0XC5, C6 and C8 genes which showed undetectable or low level 
of expression. In addition, except from HOXDl gene of the HOXD cluster which had 
low level of expression in MB-231 breast cancer cell line, the rest of the HOXD genes 
demonstrated negligible and the least prevalent expression among all HOX gene 
clusters.
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4.2.2 HOX gene expression in normal and neoplastic breast
The expression of certain HOX genes has been shown to be up-regulated in 
primary human breast eancer compared to normal breast (Cantile et al, 2003). Figure
4.2 demonstrates the patterns of HOX gene expression, for the whole HOX network 
(39 genes), in normal breast (large squares) and in fourteen breast cancer biopsies 
(small ovals). Red squares represent the HOX genes that are not expressed in normal 
breast but are expressed in the majority of breast cancer biopsies tested.
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Figure 4.2 Expression of HOX genes in normal and neoplastic breast. Closed or open 
symbols indicate active or silent HOX genes, respectively. Large squares represent normal 
breast, small ovals represent each individual cancer biopsy tested. Small ovals in the sam e 
position in the figure refer to the sam e breast cancer biopsy. Diagram adapted from M. 
Cantile et al. European Journal of Cancer, 2003; 39:257-264.
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The results of this study showed that individual HOX genes were expressed 
differently in normal breast compared to primary breast cancer tissues. 17 of 39 HOX 
genes were detected in normal adult breast with a prevalent expression of loci A and 
C compared with loci B and D (Figure 4.2). The expression patterns in the paralogous 
groups revealed that in the normal breast HOX gene expression mostly appeared in 
thoracic (7/11 active genes) and lumbo-sacral (7/16) parts of the network compared to 
HOX genes expression in cervical (3/12) part. However, specific HOX genes were 
expressed similarly in normal and neoplastic breast tissue suggesting involvement of 
these genes in breast organogenesis. Furthermore, expression pattern of other HOX 
genes were altered in primary breast cancers compared to normal breast indicating 
that these genes may be involved in breast cancer tumourigenesis.
Comparing these findings with the results we obtained on HOX gene 
expression in breast cancer cell lines, we found some interesting observations. A 
single gene, HOXAl in the cervical part of the network, appeared to be silent in 
normal breast whereas it was active in 5 out of 14 breast cancer biopsies tested 
(Figure 4.2) and was also expressed in one of the breast cancer cell lines that we 
tested (Figure 4.1). Similarly, they also showed that both H0XA5 and H0XA6 genes 
were not expressed in normal breast but were expressed in breast cancer biopsies. 
Furthermore, H0XB4 and HOXB 13 genes were shown to be silent in normal breast 
but active in (3/14 and 11/14 respectively) breast cancer tissues as well as being up- 
regulated in all breast cancer cell lines we analysed. In addition, consistent with our 
results which showed high expression of HOXC 13 in all breast cancer cell lines; this 
group also demonstrated that that HOXC 13 was active in both normal and cancerous 
breast tissues. However, contrary to our data which found undetectable expression 
level of H0XD3 in breast cancer lines, they observed that this gene was up-regulated 
in all breast cancer biopsies whereas it was silent in normal breast tissue.
Therefore, considering the evidence in previous studies on HOXAl as 
oncogene in breast cancer (Dermime et al, 2004), as well as our data gained from 
qRT-PCR analysis, we narrowed our focus down to investigate further whether 
HOXAl could be a good candidate gene with potential immunogenic characteristics 
for a vaccine target in breast cancer.
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4.2.3 Immunofluorescent staining of breast cancer cell lines for the expression 
of HOXAl protein
In order to assess the expression of HOXAl at the protein level in breast 
cancer cell lines, immunofluorescent staining was performed on a range of different 
cell lines (Figure 4.3).
SKBrS (neg control)
Figure 4.3 Immunofluorescent staining of breast 
cancer cell lines for the expression of H0XA1 protein.
Breast cancer cell lines were grown on chambered slides, 
fixed with 4% formaldehyde, permeabilised and then 
incubated with rabbit anti-human-H0XA1 primary antibody 
over night. Slides were incubated with goat anti-rabbit IgG 
secondary antibody conjugated with Alexa Fluor 488 and 
then mounted using Vectashield mounting medium containing DAP I. Images were taken 
using Leica DM IRE2 confocal microscope and analysed by Leica confocal software. 
Negative control for staining was included using the secondary Ab only (dapi: blue staining).
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The immunofluorescent staining and confocal analysis of breast cancer cell 
lines demonstrated that HOXAl was expressed at the protein level in all 4 cell lines 
tested (Figure 4.3). The nuclear marker, DAPI, was used in order to determine the 
localization of HOXAl expression within these cancer cell lines. HOXAl appeared to 
be predominantly expressed within the nucleus of all 4 breast cancer cell lines (shown 
by arrows). However, in UACC812 breast cancer cell line, as well as notable nuclear 
staining, HOXAl appeared to be expressed on the surface membrane of the cell 
(shown by arrow).
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4.2.4 Expression of HOXAl in normal tissues
4.2.4.1 PCR analysis of a range of different normal tissues for the expression of 
HOXAl
In order to determine the expression pattern of HOXAl genes at the molecular 
level in normal tissues, RNA was extracted from a range of different normal tissues 
and cDNA was synthesised to perform qRT-PCR analysis (Figure 4.4).
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Figure 4.4 Expression of H0XA1 in a range of different normal tissues and MB-468 
breast cancer cell line. RNA was extracted from a range of different normal tissues and 
cDNA synthesised. QRT-PCR analysis was performed to determine the expression of HOXAl 
genes in various types of normal tissues. Values were normalized to the co-amplification 
reaction of the house-keeping gene, P-actin.
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The results of qRT-PCR analysis on a range of different normal tissues 
showed that HOXAl had undetectable or very low level of expression in all the 
normal tissues stained. These included several vital tissues such as brain, liver, heart, 
lung, etc. For comparison purposes the breast cancer cell line MB-468 was included 
which showed a high level of HOXAl expression compared to all the other normal 
tissues. However, normal breast tissue was not included in this panel of tissues; 
therefore, we further investigated the expression of HOXAl in normal breast tissue by 
a comprehensive immunohistochemical analysis and then compared the results with 
HOXAl expression in breast cancer tissues (following section).
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4.2.4.2 Immunohistochemical analysis of a range of normal tissues for the 
expression of HOXAl
In order to assess the expression pattern of HOXAl at the protein level in 
normal tissues, immunohistochemical analysis was performed. A normal tissue array 
including 35 tissue types, most of which had triplicates from 3 individuals was used. 
The majority of the tissues were from surgical resection. Those highlighted by * were 
from autopsy. Figure 4.5 shows the tissue array panel display and Figure 4.6 
demonstrates the representative examples of HOXAl immunohistochemical staining 
performed on this normal tissue array. (The specific information regarding each 
individual core within the tissue array is summarised in Appendix 4.1 and the total 
results of HOXAl immunohistochemical staining is shown in Appendix 4.2).
M icroarray  Panel D isplay
.Bon,'
.ure.i
Legend: Adr - Adrenal gland", 8la - Bladder, Bon - Bone marrow", Bre - Breast, Cer - Cerebral cortex". Eye - Eye", 
Fa! - Fallopian tube, GI- - GI-Rectum, Hea - Heart", Kid - Kidney, Liv - Liver, Lun - Lung, Ova - Ovary, Pan 
- Pancreas", Par - Parathyroid, Pit - Pituitary gland", Pla - Placenta, Pro - Prostate, Ski - Skin, Spi - Spinal 
cord", Spi - Spleen, Str - Striated muscle". Tes - Testis, Thr - Thyroid, Thy - Thymus", Ton - Tonsil, Ure - 
Ureter, Ute - Uterus-endometrium 
- Normal tissue, ©  - Unknown
Figure 4.5 Tissue array panel display used for Immunohistochemical analysis of 
H0XA1 expression (Biomax, US).
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Figure 4.6 Representative example of enzymatic staining of normal breast tissues for 
the expression of HOXAl. Paraffin-embedded normal tissue array was deparaffinised and 
rehydrated followed by a microwave heat-mediated antigen retrieval method. Slides were 
blocked and incubated overnight with anti-H0XA1 primary antibody followed by incubation 
with ABC detection kit. Peroxidase activity was then detected using DAB kit followed by 
counterstaining with Hematoxylin.
The immunohistochemical analysis of different normal tissues showed that 
HOXAl was either not expressed at all (including bone marrow, cerebral cortex, 
heart, spinal cord, spleen, striated muscle and thyroid) or had only very low level of 
expression in normal breast tissues and a range of other normal tissues (listed in 
Appendix 4.2 and Figure 4.6). These results are consistent with our qRT-PCR data 
shown previously for the expression of HOXAl gene in a range of different normal 
tissues. Moreover, these immunohistochemical results are similar to the results 
obtained by Cantile et al. which also showed that HOXAl was not expressed in 
normal breast tissue (Figure 4.2). Consequently, taking into account all these data, 
HOXAl appears to be only weakly expressed in normal breast tissues both at the 
molecular and protein level as well as in several more vital normal tissues compared 
to breast cancer tissues (Figure 4.2, 4.4 and Appendix 4.2).
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4.2.5 High expression of HOXAl in breast cancer
4.2.5.1 Immunohistochemical analysis of breast cancer tissue array for the 
expression of HOXAl
In order to assess the prevalence and expression pattern of HOXAl at the 
protein level in breast cancer, immunohistochemical analysis was performed. A breast 
cancer tissue array including 75 cases of normal, reactive, premalignant and malignant 
(various grades and stages) tissues of the breast in duplicate was used (Figure 4.7). 
Figure 4.8 demonstrates the representative examples of HOXAl 
immunohistochemical negative staining performed on this breast cancer tissue array. 
(See Appendix 4.3 and 4.4 for the specific information regarding each individual core 
of the tissue array and the images taken from the breast cancer tissue array stained for 
HOXAl, respectively).
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Figure 4.7 Tissue array panel display used for immunohistochemical analysis of 
H0XA1 expression (Biomax, US).
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Figure 4.8 Representative examples of enzymatic staining of breast cancer tissue array 
for the expression of HOXAl. A) Paraffin-embedded breast cancer tissue array was 
deparaffinised and re hydrated followed by a microwave heat-mediated antigen retrieval 
method. Slides were blocked and incubated overnight with anti-H0XA1 primary antibody 
followed by incubation with ABC kit. Peroxidase activity was detected using DAB kit followed 
by counterstaining with Hematoxylin.
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A15 (Malignant breast tumour) 
x20 magnification
C9 (Malignant breast tumour) 
x20 magnification
D9 (Malignant breast tumour) 
x20 magnification
D10 (Malignant breast tumour) 
x20 magnification
Figure 4.8 Representative examples of enzymatic staining of breast cancer tissue array 
for the expression of HOXAl. B) Images showing higher magnifications (x20) of different 
breast cancer cores.
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Immunohistochemical studies on the breast cancer tissue array (Figure 4.8 
AND Appendix 4.4) showed a large proportion of the breast cancer sections analysed 
expressed HOXAl (73.28% positivity). In comparison, normal breast tissue and a 
range of other normal tissues analysed showed only weak or no expression of HOXAl 
protein (including bone marrow, cerebral cortex, heart, spinal cord, spleen, striated 
muscle and thyroid) (Appendix 4.2). The expression pattern of HOXAl staining in 
breast cancer tissues seemed to be more of a cytoplasmic and membrane (Figure 4.8 
B). Furthermore, these results are consistent with data obtained from other studies 
(Cantile et al, 2003) which also showed over-expression of HOXAl in breast cancer 
biopsies compared to normal breast tissue. Table 4.2 summarizes the results of 
scoring that was performed for the expression of HOXAl on the breast cancer tissue 
array.
H0XA1 sco re Frequency Percent Valid Percent
Cumulative
Percent
Valid -VE 35 25.0 26.7 26.7
+ 65 46.4 49.6 76.3
++ 21 15.0 16.0 92.4
+++ 10 7.1 7.6 100.0
Total 131 93.6 100.0
Missing System 9 6.4
Total 140 100.0
Table 4.2 sum m ary of the  H0XA1 scoring perform ed on b reast cancer tissu e s .
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In addition, we also performed nonparametric spearman’s rank correlation 
coefficient to determine whether there was an association between the expression 
pattern of HOXAl in breast cancer patients with various factors such as grade of 
tumours, hormonal receptors status, etc. (see Appendix 4.3). The results showed that 
there was a statistically significant positive correlation between the expression of 
HOXAl with androgen receptor (AR) (P = 0.035). Additionally, there was a strong 
indication of a positive correlation between HOXAl expression and estrogen receptor 
(ER) (P = 0.066), and progesterone receptor (PR) (P = 0.59), as well as Her2-neu (P = 
0.072). Table 4.3 summarizes the results obtained from statistical analysis 
(nonparametric spearman’s rank correlation coefficient). Highlighted values in green 
demonstrate statistically significant correlation between HOXAl and AR, for other 
variables, where 0.10> P >0.05, they are shown in yellow.
Correlations H0XA1
Spearman's rho Age Correlation Coefficient .135
Sig. (2-tailed) .123
N 131
gradescore Correlation Coefficient .128
Sig. (2-tailed) .146
N 130
(\Rscorel Correlation Coefficient [ i s i
Sig. (2-tailed) 039
N 13l|
ARpct Correlation Coefficient 197
Sig. (2-tailed) 024
N 131
ERscore Correlation Coefficient 161
Sig. (2-tailed) .066
N 131
ERpct Correlation Coefficient 102
Sig. (2-tailed) .245
N 131
PRscore Correlation Coefficient 165
Sig. (2-tailed) 059
N 131
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PRpct Correlation Coefficient .116
Sig. (2-tailed) .188
N 131
PSSscore Correlation Coefficient -.024
Sig. (2-tailed) .784
N 131
P53pct Correlation Coefficient -.012
Sig. (2-tailed) .894
N 129
EGFRscore Correlation Coefficient .102
Sig. (2-tailed) .245
N 131
Ki67score Correlation Coefficient -.049
Sig. (2-tailed) .578
N 131
Ki67pct Correlation Coefficient .016
Sig. (2-tailed) .857
N 130
HER2score Correlation Coefficient .158
Sig. (2-tailed) .072
N 131
Table 4.3 summary of the statistical analysis performed on breast cancer tissues.
Nonparametric spearm an’s rank correlation test was applied to determine the correlation 
between H0XA1 expression and other factors.
It has been reported that patients with triple negative tumours have a relatively 
poor outcome and are not sensitive to standard therapies, thus we further investigated 
cases of triple negative breast cancer patients (ER, PR, and Her-2/neu negative) to 
assess whether there was an association between these and the expression of HOXAl. 
The results showed that 71.42% (10 out of 14 cases) of triple negative cases were 
positive for the expression of HOXAl.
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4.2.6 HOXAl humoral response in breast cancer patients
In order to assess the auto-antibody response in breast cancer patients to 
HOXAl, an ELISA was performed on patient’s plasma and serum. This was 
compared to plasma from female age-matched controls with no known history of 
cancer. In addition plasma from ovarian and prostate cancer patients was also used to 
test the specificity of the HOXAl antibody response for breast cancer. Figure 4.9 
shows the humoral response to HOXAl in each individual group tested.
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Figure 4.9 Levels of HOXAl IgG auto-antibodies in the serum and plasma of breast, 
prostate and ovarian cancer patients. ELISA plates were coated overnight with H0XA1 
recombinant protein. Plates were then incubated with patient or control serum followed by 
incubation with anti-human IgG conjugated to horseradish peroxidase. Plates were developed 
with TMB and the optical density was analysed at 450nm on a DTX 880 Multimode Detector 
ELISA plate reader. The humoral response in breast cancer was significant (P=0.001) 
compared to other cancers and age-matched controls. A positive HOXAl IgG antibody result 
was defined as HOXAl IgG antibody levels equal to or greater that the mean value plus 2 
standard deviations obtained in the total healthy control group. (*** P=0.001)
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We tested serum and plasma of 198 breast cancer patients, 86 age-matched 
controls, 31 ovarian cancer patients and 45 prostate cancer patients. The ELISA 
results showed that 32% of breast cancer patients (64 out of 198 patients) had an 
antibody response to HOXAl compared to 3.5% of aged-matched controls (3 out of 
86 controls). In addition, the ELISA results from other cancer patients showed 
no/minimum humoral response to HOXAl in ovarian cancer patients (0 out of 31 
patients) and 6.6% humoral response in prostate cancer patients (3 out of 45 patients). 
This observation confirms that only breast cancer patients had a significant HOXAl 
auto-antibody response (P=0.001). Individual sera were scored as positive which had 
an OD value equal to or greater than two standard deviations from the mean of control 
subjects.
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4.2.7 HOXAl cell-mediated immune responses
In order to investigate a cell-mediated .immune response to HOXAl, 
potentially immunogenic HLA-A2 restricted epitopes from the HOXAl protein 
sequence were selected using the computer algorithm SYFPEITHL This predicts HLA 
class I specific epitopes according to specific factors including anchor residues and 
proteasomal cleavage sites (Schirle et al, 2001) (Table 4.4). Following this, high 
binding epitopes (HOXAl. 1, A 1.2, A1.3, A1.4, A1.5, A1.6 and A1.7) were 
synthetically generated and tested against healthy donor PBMCs. (The cut off point 
used was 20 according to SYEPEITHI score).
Protein
code Peptide Amino acid position
SYFPEITHI
score
H0XA1.1 ALATYNNSL 167-175 28
H0XA1.2 QLNETQVKI 262-270 25
H0XA1.3 FLVGRGVQI 48-56 23
H0XA1.4 SLQLNETQV 260-268 22
H0XA1.5 GLLPISPAT 286-294 21
H0XA1.6 YALNQEADV 106-114 20
H0XA1.7 FTTKQLTEL 231-239 20
Table 4.4 H0XA1 peptides with SYFPEITHI scores.
The target cells used were the T2 cell line which is B lymphoblastoid, TAP 
deficient cell line expressing HLA class-I A2, as well as three breast cancer cell lines. 
T2 cells without and effector cells alone were used as negative controls for the assay, 
in addition to HLA-A2 negative T47D breast cancer cell line. Three out of the 7 
selected HOXAl epitopes tested (HOXA 1.1, HOXA 1.2 and HOXA 1.5) generated 
specific responses against T2 target cells loaded with the relevant peptide and thus
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were shown to be immunogenic (Figure 4.10). Furthermore, these peptide specific 
CD4 IFN-y were also tested against breast cancer cell lines (HLA-A2 positive MCF-7 
and MDA-MB231 cell lines and HLA-A2 negative T47D cell line) in IFNy-ELISpot 
assays (Figure 4.10).
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Figure 4.10 H0XA1 peptide specific responses generated from different healthy 
donors. A) T cells were stimulated with peptide five times before testing their specificity in an 
IFN-gamma ELISpot assay. Targets were either T2 cells pulsed with or without the relevant 
peptide as well as breast cancer cell lines MCF7 and MDA-MB231 (HLA-A2 positive) and 
T47D (HI_A-A2 negative). Representative examples of triplicates are shown here. * p < 0.05,
**p<0.01, ***p< 0.001.
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B.
Donor T2&ptide
72
alone
Effectors
alone MCF-7
MDA-
MB231
T47D
1 56 14.6 4.6 117 45 14
2 243 32 23 100.6 74.3 35.3
3 51.3 17.3 14.6 51.3 56.6 15
Figure 4.10 H0XA1 peptide specific responses generated from different healthy 
donors. B) Table summarising the results obtained from stimulating T cells with different 
H0XA1 peptides. Number of spots was calculated based on 2x10® cells/well.
As the results of IFN-gamma ELISpot assay show in Figure 4.10, peptide- 
specific immune responses were generated from the peripheral blood of healthy 
controls. As it can be seen in Figure 4.10, specific immune responses were generated 
against HOXAl.l in donor 1, specific responses against H0XA1.2 in donor 2, also 
donor 3 showed specific immune responses against peptide H0XA1.5. In all donors, 
specific immune responses generated against each individual peptide (T2 & peptide) 
were significant compared to negative controls (T2 without peptide and effectors 
alone). This was confirmed by the paired student T test to calculate the significance 
between the numbers of spots generated from T cells stimulated with T2 cells pulsed 
with relevant peptide compared to unlabelled T2 cells. Moreover, specific responses 
against HLA-A2.1 positive breast cancer cell lines (MCF-7 and MDA-MB23I) were 
observed suggesting these epitopes are naturally generated and processed. No 
responses were detected against the HLA-A2.1 negative breast cancer cell line, T47D.
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4.3 DISCUSSION
Targeting and eliminating breast cancer using immunotherapy has shown great 
promise in the clinic with anti-Her2/neu antibody (Baxevanis et al, 2010; Beatson et 
al, 2010). However, only a limited number of patients can benefit from these therapies 
due to the infrequent expression of Her2/neu. There is an urgent need to identify and 
target clinically relevant new antigens for immunotherapeutic treatment of a greater 
proportion of breast cancer patients. It is crucial to determine the potential 
immunogenicity of any newly defined antigen. There are several main considerations 
regarding the choice of tumour antigens for an adoptive transfer of T cells or a 
vaccine strategy. These include specificity of tumour antigens and sufficient 
expression at the surface of the tumour cells for T cell recognition (Lucas and Coulie, 
2008). In cases when potential tumour antigens are not expressed on the surface of 
tumour cells and are inaccessible to antibodies, proteosomes then cleave a sampling of 
all proteins synthesized in the cell into short fragments (peptides) that are loaded onto 
newly synthesized MHC-I molecules; i.e. HLA-A, -B, and -C. Thus, the ideal anchor 
residues, endogenous processing, specific TCR, MHC and co-stimulatory genes, are 
all crucial factors in generating CTL responses in immunotherapy.
Homeodomain-containing proteins (HOX) are transcription factors that 
regulate expression of genes involved in development, differentiation and malignant 
transformation. HOXAl has been shown to be over-expressed in human breast cancer 
cell lines and breast cancer lesions and is thought to be associated with the breast 
cancer phenotype (Zhang et al, 2006; Ratkaj et al, 2010). Taking together the results 
reported from previous studies and data shown in the literature, we aimed to 
determine the immunogenicity of HOXAl. The efficacy of HOXAl as a potential 
target for cellular immunotherapy was also investigated.
Our initial approach involved screening of the whole 39 HOX gene network in 
a number of different breast cancer cell lines in order to assess the pattern of 
expression at the molecular level. The results of qRT-PCR analysis demonstrated 
different pattern of expression of individual HOX gene clusters among the breast 
cancer cell lines tested. It was observed that HOXAl was expressed only in the MB- 
468 cell line at the molecular level. However, we further investigated HOXAl
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expression at the protein level in a range of different breast cancer cell lines by 
confocal analysis. The results of immunofluorescent staining and confocal analysis 
demonstrated that all cancer cell lines tested were positive for HOXAl expression. 
Overall, HOXAl appeared to be predominantly expressed within the nucleus of all 4 
breast cancer cell lines. However, in UACC812 cell line, as well as notable nuclear 
staining, HOXAl appeared to be expressed on the surface membrane of the cell.
In addition, we assessed the expression pattern of HOXAl at the protein level 
in breast cancer, by performing immunohistochemical analysis. A high density tissue 
array with 75 cases of normal, reactive, pre-malignant and malignant (with varying 
grades and stages) breast tissues was used. In comparison, we investigated the 
expression profile of HOXAl by immunohistochemistry on a range of normal tissues 
using a normal tissue array consisting of 35 different types of tissue including breast, 
heart, kidney, lung, liver and brain. The staining was scored based on intensity (Score 
1-3; weak to strong staining). Interestingly, the IHC staining results showed positive 
staining of HOXAl in normal kidney tissues. This was similar to the results obtained 
from PCR analysis on normal tissues.
The scoring results showed that 73.28% of breast cancer sections were 
positive for the expression of HOXAl. Alongside this, we correlated the expression of 
HOXAl with histology, stage, grade, Her2/neu status, estrogen and progesterone 
receptor status. This was done in order to determine any link between the over­
expression of HOXAl and disease progression as well as having an indication if a 
higher proportion of patients express HOXAl compared to other antigens e.g. 
Her2/neu. HOXAl was found to have a statistically significant positive correlation 
with AR (P = 0.035). Additionally there was a strong indication of a positive 
correlation with ER (P = 0.66), with PR (P = 0.059) and with Her-2/neu (P = 0.072). 
Moreover, further analysis on cases of triple negative breast cancer patients (TNBC) 
revealed that 71.42% of the patients were positive for the expression of HOXAl. 
Hence, over expression of HOXAl in TNBC patients can potentially be a diagnostic 
marker. The results of immunohistochemical analysis from both normal tissues and 
breast cancer tissues are consistent with PCR data obtained from another study 
(Cantile et al, 2003) which also showed over-expression of HOXAl in breast cancer 
biopsies compared to normal breast tissue. In their study it was shown that HOXAl
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appeared to be silent in normal breast whereas it was active in 5 out of 14 breast 
cancer biopsies tested.
We investigated the potential of HOXAl as a target for immunotherapy. This 
was tested by determining the presence and level of IgG auto-antibodies to HOXAl in 
the serum and plasma of breast cancer patients using an ELISA assay. In order to 
assess the significance of these responses, we compared the results obtained from 
breast cancer patient sera to control sera from female healthy age-matched donors 
with no known history of cancer as well as to the responses from ovarian and prostate 
cancer patients. The ELISA results showed that 32% of breast cancer patients had an 
antibody response to HOXAl compared to 3.5% of aged-matched controls. However, 
73.28% of breast cancer patients revealed positivity for the over expression of 
HOXAl. Moreover, no humoral response to HOXAl was observed in ovarian cancer 
patients and only 6.6% humoral response was shown in prostate cancer patients. This 
observation confirms that only breast cancer patients had significant HOXAl auto­
antibody response. Disis et al. reported that in patients with early stages of cancer 
TAA-specific serum antibodies can be detected at high titer (Disis et al, 1997). In a 
study by Lu et al, a direct correlation between the over expression of the protein by 
the patient’s tumour and endogenous humoral immunity to Her2/neu was shown. 
They also suggested that Her2/neu-specific auto-antibodies can be detected in patients 
with early stage disease, hence, the presence of antibodies are reflective of tumour 
burden (Lu et al, 2008). Moreover, it has been revealed that antibodies are associated 
with the extent of protein over expression in primary tumour (Goodell et al, 2008).
In a review by Reuschenbach et al. in 2009, studies on humoral immune 
responses against tumour associated antigens in cancer patients (TAA) were 
summarized. They demonstrated that in healthy individuals antibody responses were 
generally very low whereas higher antibody frequencies were detected when tumours 
expressed the respective TAA. It has been reported that 26.6% (weighted average) of 
breast cancer patients had humoral responses to Her2/neu (Goodell et al, 2008; Disis 
et al, 1994) compared to 2% healthy individuals (Chapman et al, 2008). Her2/neu 
which is a tyrosine-kinase receptor and a member of the epidermal growth factor 
receptor (EGFR) family (Tajima et al, 2001) has critical role in the pathogenesis of 
several human cancers (i.e. breast, ovarian, lung carcinomas, colon and renal) (Seliger
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et al, 2000; Koeppen et al, 2001). Other TAAs such as MUC-1, NY-ESO-1 and 
survivin have been analysed for their frequency of antibody responses in breast 
cancer. Humoral response to MUC-1 has been detected in 42.9% (weighted average) 
of breast cancer patients (von Mensdorff-Pouilly et al, 2000; Chapman et al, 2007) 
and 23.3% of healthy controls (von Mensdorff-Pouilly et al, 2000). Furthermore, data 
obtained from a study by Stockert et al. in 1998 showed that 7.7% of breast cancer 
patients had antibody responses to NY-ESO-1 compared to 0% of healthy controls. In 
addition, Zhang et al. demonstrated in their study in 2003 that 14.6% (weighted 
average) humoral response to survivin was observed in breast cancer patients while 
0.7% of healthy individuals had antibody responses. Consequently, we showed that 
humoral response against HOXAl was detected in 32% of our breast cancer patients 
which is higher compared to these well-stablished tumour antigens in previous 
studies. However, these results did not correlate exactly with the expression of 
HOXAl in breast cancer patients (73.28%), which means not all of the patients with 
positive HOXAl expression produce Ab response against HOXAl. Also, the presence 
of humoral response could be representative of involvement of T helper cell 
responses. Therefore, manipulation and induction of T cell responses could potentially 
be helpful in generation of more humoral response.
Having observed a significant humoral response generated against HOXAl, 
next we investigated whether cell-mediated immune responses against HOXAl could 
be generated as well. We undertook initial studies to identify specific immunogenic 
epitopes from HOXAl. From these initial studies three immunogenic HOXAl 
epitopes were identified (A l.l, A1.2 and A1.5) which generated peptide-specific 
immune responses in the majority of donors tested. These specific immune responses 
generated against each individual peptide (T2 & peptide) were significant compared 
to negative controls (T2 target alone and effectors alone). In addition, these HOXAl 
specific responses were also able to recognise HLA-A2 positive (MCF-7 and MDA- 
MB231), but no HLA-A2 negative (T47D) breast cancer cell lines. Recognition of 
breast cancer cell lines by these T cells also suggests these epitopes are naturally 
processed and presented. However, further study is required to investigate whether 
these HOXAl-specific immune responses can be generated in breast cancer patients 
as well. Therefore, the key role of HOXAl in breast cancer development, the over-
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expression specifically in breast tumours and its immunogenicity makes HOXAl a 
promising novel target for vaccine therapy to treat breast cancer patients.
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Chapter 5
HOXB13 as potential 
vaccine target in ovarian
cancer
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5. HOXB13 AS A POTENTIAL VACCINE TARGET IN OVARIAN 
CANCER
5.1 INTRODUCTION
Ovarian cancer has the highest mortality rate of all the malignant
gynaecological tumours (Dundr, 2010). Because of lack of specific symptoms
(Poveda, 2003) and also due to the location of the ovary, ovarian cancer is often 
diagnosed after local or distant metastasis at a relatively advanced stage of the disease 
(Morgan et al, 2010). Each year, approximately 200,000 women are diagnosed
worldwide with ovarian cancer, of whom 115,000 will die (Ozols, 2006). In less
developed countries, there is an increasing risk of 0.4% - 0.5% of developing ovarian 
cancer in women age 65 years, whereas the risk is 0.7% in more developed countries 
(Ferlay et al, 2004).
Carcinomas of surface epithelial-stromal origin account for about 90% of all 
cases of ovarian cancer (Thigpen, 2004). Ovarian carcinomas are a heterogeneous 
group of neoplasms which are divided into two major types, type I and II subgroups, 
each with different prognosis and response to therapy. Type I tumours include low- 
grade endometrioid adenocarcinoma, low-grade serous adenocarcinoma, mucinous 
adenocarcinoma, malignant Brenner tumor and some clear cell carcinomas. Type II 
tumours are high-grade neoplasms which contain high-grade serous adenocarcinoma, 
undifferentiated carcinoma, malignant mixed Müllerian tumor, high-grade 
endometrioid adenocarcinoma, and clear cell carcinomas (Poveda, 2003). In up to 
75% of cases, complete clinical remission (CCR) is achieved by debulking surgery 
and six courses of platinum-based chemotherapy (Thigpen, 2004). Nevertheless, 
within the median time of 18 to 28 months, 75% of the responders will relapse (Stuart,
2003) and survival rate beyond five years is only 20% to 40% (Kikuchi et al, 2005). It 
has been shown that toxicity increases when more than six courses of induction 
chemotherapy is applied with no improvement in progression free survival (PFS) or 
overall survival (OS) (Bertelsen et al, 1993; Lambert et al, 1997).
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Application of prolonged courses of chemotherapy may result in little survival 
benefit but more adverse side effects of treatments (Mei et al, 2010). In spite of the 
trial of numerous chemotherapeutic regimes including carboplatin/paclitaxel (Heintz 
et al, 2006; Sugiyama and Konishi, 2008) which is currently “standard of care”, there 
is a critical need for novel targets in ovarian cancer therapy since patients’ long-term 
survival is poor. Malignant tumours have been shown to be immunogenic in ovarian 
cancer (Zhang et al, 2003; Curiel et al, 2004). Immunotherapies have been evaluated 
in numerous clinical trials in ovarian cancer over the last two decades (Morgan et al, 
2010). Based on the following evidence, immunotherapy (Liu et al, 2010) is 
considered as a potential approach for the treatment of ovarian cancer;
(I) Peptide/MHC complexes are expressed by ovarian cancers and can be 
recognized by CD8 T lymphocytes (Liu et al, 2010).
(II) Tumour-associated antigens are expressed by ovarian cancers. These 
include; 0A3 (Kenemans, 1990), HER2/neu (Disis et al, 2002; Disis et al, 
2004), membrane folate receptor (Coliva et al, 2005), MUCl (Vlad et al,
2004), NY-ESO-1 (Odunsi et al, 2003), TAG-72 (Rosenblum et al, 1999), 
sialyl-Tn (Sandmaier et al, 1999) and mesothelin (Chang and Pastan, 
1996) which can serve as targets for cellular and humoral immune 
responses.
(III) The strong correlation between the presence of TILs and survival (Zhang 
et al, 2003).
(IV) The dynamic interaction between cancer and host immunity suggests that 
the balance between the two forces can be skewed towards favouring the 
host immunity. Therefore, it has been hypothesized that immunotherapy 
could be an effective and innovative therapy for ovarian cancer (Liu et al, 
2010).
Ovarian cancers, in a similar manner to other cancers, are known to over 
express a number of genes involved in early development (Morgan et al, 2010). These 
include the HOX family of homeobox genes which is an important group of 
developmental transcriptional factors with various regulatory roles in differentiation 
and morphogenesis (Abate-Shen, 2002). HOX genes are involved in different aspects 
of the oncogenic process (Shah and Sukumar, 2010) since in-vitro cellular
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transformation and in-vivo tumorigenesis are promoted by ectopic expression of HOX 
genes (Aberdam et al, 1991). One of the homeobox genes, HOXB 13, has been shown 
to be over expressed in human ovarian, endometrial and cervical carcinomas and that 
also over expression of HOXB 13 is correlated with the invasiveness of endometrial 
and ovarian cancer cells (Zhao et al, 2005; Lopez et al, 2006). This evidence 
implicates that HOXB 13 may play an important role in tumours arising from 
endocrine-responsive organs. In a study by Miao et al. in 2007 the prevalence of 
HOXB 13 gene expression in ovarian cancer was determined by RT-PCR analysis of 
10 different primary ovarian tumours and 10 human ovarian cell lines. The results 
demonstrated that HOXB 13 was expressed in 5 of 9 ovarian carcinomas and all but 
one ovarian cancer cell line that were examined. These findings are consistent with 
the observations from another study in which HOXB 13 showed undetectable or low 
expression in normal ovarian tissue but high expression in a subset of ovarian cancers 
(Yamashita et al, 2006; Jung et al, 2004b). Thus, the restricted expression of 
HOXB 13 to ovarian cancer and the important role of HOXB 13 gene in the 
development of ovarian cancer provide the rationale to investigate HOXB 13 as an 
immunotherapeutic target (Yamashita et al, 2006).
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Hypothesis and objectives
Having shown previously (chapter 4) that HOXAl is a good target candidate in 
breast cancer, we investigated whether other HOX genes could be a potential target in 
ovarian cancer. Hence, the goal of this chapter was to determine the immunogenicity 
of HOXB 13 in ovarian cancer (versus healthy controls) and its potential as a target for 
immunotherapy. We confirmed the expression pattern of HOXB 13 in ovarian tumours 
(including tumours of differing grade) using an ovarian cancer tissue array and 
compared this to normal tissues. We assessed the immunogenicity of HOXB 13 in 
ovarian cancer by determining the level of autoantibody responses to HOXB 13 in the 
plasma of patients, the ability to generate HOXB 13 specific T cells in healthy donors’ 
blood and whether these specific T cells could be expanded and were able to 
recognize ovarian cancer cell line targets. Several of our identified HOXB 13 epitopes 
were used to show that one or more of these epitopes is a potent stimulator of specific 
anti-H0XB13 immune responses from the peripheral blood of healthy donors.
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5.2 RESULTS
5.2.1 HOX gene expression in ovarian cancer cell lines
It has been shown that HOXB 13 is over expressed in human ovarian 
carcinomas and that also over expression of HOXB 13 is correlated with the 
invasiveness of ovarian cancer cells (Zhao et al, 2005; Lopez et al, 2006). Therefore, 
in order to determine the expression of HOX genes and in particular HOXB 13 in 
ovarian cancer cell lines, qRT-PCR analysis was performed on a range of different 
ovarian cancer cell lines. Figure 5.1 shows ES-2, 0VCAR3, SKOV-3, Caov3 and 
Caov4 ovarian cancer cell lines that were used to assess the patterns of HOX gene 
expression.
A.
0
1
2
1
2
co
I Ü L I j y
A l A2 A3 A4 AS A6 A7 A9 AlO  A l l  AIB
1000 1
9 0 0  -
7 0 0  -
■  ES2
6 0 0  -
■  0VCAR3
5 0 0  -
SK0V3
4 0 0  -
■  Caov3
3 0 0  -■  Caov4
200  -
100  -
B1 B2 B3 B4 65 B6 B7 B8 B9 B13
■  ES2
■  0VCAR3
■  SK0V3
■  Caov3
■  Caov4
I
6 00
5 0 0
4 0 0
30 0
200
100
C4 C5 C6 C8 C9 CIO C l l  C12 C13
IES2
I0V CA R3
ISK 0V 3
IC ao v 3
IC aov4
J .11
■  ES2
■  0VCAR3
■  SKOV3
■  C aov3
■  C aov4
D1 D3 D4 D8 D9 DIO D l l  D 12 D 13
HOX genes
Figure 5.1 Expression of HOX genes in a range of different ovarian cancer cell lines. A)
RNA was extracted from the ovarian cancer cell lines and cDNA synthesised. QRT-PCR 
analysis was performed to determine the expression of HOX genes in various ovarian cancer 
cell lines. Values were normalized to the co-amplification reaction of the house-keeping gene, 
P-actin.
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Figure 5.1 Expression of HOX genes in a range of different ovarian cancer cell lines. B)
RNA was extracted from the ovarian cancer cell lines and cDNA synthesised. QRT-PCR 
analysis was performed to determine the expression of HQX genes in various ovarian cancer 
cell lines. Values were normalized to the co-amplification reaction of the house-keeping gene, 
p-actin.
The qRT-PCR analysis of ovarian cancer cell lines for the expression of HOX 
genes showed different patterns of expression of individual HOX gene clusters. 
Overall, HOXA genes appeared to have the most prevalent expression compared to all 
the other HOX gene clusters (B, C and D) (Figure 5.1 A). In particular, HOXA 10 of 
HOXA genes showed high level of expression in all cancer cell lines. The majority of 
HOXB genes (except from HOXBl, B2, B7 and B8) were expressed to some extent 
among all of the cell lines. A single HOX gene, HOXB 13 which is the focus of this 
chapter, was shown to be expressed in all of ovarian cell lines tested. However, Caov4 
cell line revealed to have the highest level of HOXB 13 expression (Figure 5. IB).
In addition, most of the HOXC genes (with the exception of H0XC5, C6, CIO 
and C l2) appeared to be expressed in the majority of the cell lines compared to 
overall expression pattern of HOXB and HOXD genes. However, H0XD9 gene of the 
HOXD cluster demonstrated high level of expression in ES-2 cell line compared to
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the expression level of all the other HOXD genes in all 5 ovarian cancer cell lines 
(Figure 5.1 A).
Overall, HOXB 13 may not look to be the best target gene among all other 
HOX genes; however, the tissue array expression data on HOXB 13 was more 
promising compared to the cancer cell line experiments. Thus, taking into 
consideration the data obtained from the qRT-PCR analysis of HOX genes on a range 
of different ovarian cancer cell lines together with previous observations from other 
studies, we aimed to further investigate HOXB 13 expression and its specificity for 
ovarian cancer.
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5.2.2 PCR analysis of a range of different normal tissues for the expression of 
HOXB13
In order to determine the expression pattern of HOXB 13 genes at the 
molecular level in normal tissues, RNA was extracted from a range of different 
normal tissues and cDNA was synthesised to perform qRT-PCR analysis (Figure 5.2).
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Figure 5.2 Expression of H0XB13 in a range of different normal tissues and Caov4 
ovarian cancer cell line. RNA was extracted from a range of different normal tissues and 
cDNA was synthesised. Then, qRT-PCR analysis was performed to determine the expression 
of HOXBl 3 gene in various types of normal tissues. Values were normalized to the co­
amplification reaction of the house-keeping gene, P-actin.
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The results of the qRT-PCR analysis on a range of different normal tissues 
showed very low level or no expression of HOXB 13 in all tissues with the exception 
of prostate tissue in which HOXB 13 was highly expressed. For comparison purposes, 
ovarian cancer cell line, Caov4, was included which showed high level of HOXB 13 
expression. These results are consistent with the data reported in other studies (Jung et 
al, 2004a&b; Okuda et al, 2006; Huang et al, 2007). However, normal ovarian tissue 
was not included in this panel of tissues, therefore, we performed further investigation 
to confirm that HOXB 13 is not expressed in the majority of normal tissues, including 
normal ovarian tissue, but its expression is up-regulated in ovarian cancer.
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5.2.3 Immunohistochemical analysis of ovarian cancer tissue array for the 
expression of HOXB13
In order to assess the expression pattern of HOXB 13 at the protein level in 
ovarian cancer, immunohistochemical analysis was performed. A multiple ovarian 
carcinoma and normal tissue microarray including 70 cases of ovarian carcinoma plus 
5 cases of tumour adjacent normal and 5 normal ovarian tissue biopsies was used. 
Figure 5.3 shows the tissue array panel display and Figure 5.4 demonstrates the 
representative examples of immunohistochemical staining of ovarian cancer tissue 
array for the expression of HOXB 13. (The specific information regarding each 
individual core within the tissue array is summarised in Appendix 5.1 and the total 
results of HOXB 13 immunohistochemical staining is shown in Appendix 5.2).
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Figure 5.3 T issue array panel display used  for im m unohistochem ical analysis of 
H0XB13 expression  (Biomax, US).
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Figure 5.4 Representative examples of enzymatic staining of ovarian cancer tissue 
array for the expression of H0XB13. A) Paraffin-embedded ovarian cancer tissue array 
was deparaffinised and rehydrated followed by a microwave heat-mediated antigen retrieval 
method. Slides were blocked and then incubated overnight with anti-H0XB13 primary 
antibody followed by incubation with ABC detection kit. Peroxidase activity was detected 
using DAB kit followed by counterstaining with Hematoxylin.
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Figure 5.4 Representative examples of enzymatic staining of ovarian cancer tissue 
array for the expression of H0XB13. B) Images showing higher magnifications (x20) of 
different ovarian cancer cores.
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The immunohistochemical study on the ovarian cancer tissue array showed 
that 92.85% (65 out of 70) of ovarian cancers over-expressing HOXB 13 compared to 
normal ovarian tissues and tumour adjacent normal tissues (Appendix 5.2). Although 
different levels of expression were observed, all ovarian tumours stained positive for 
HOXB 13 in comparison to the normal ovarian tissues analysed. Therefore, 
considering the expression data, both at molecular and protein level (Figure 5.2 and 
5.4 respectively), in addition to the results obtained from previous studies (Zhao et al, 
2005; Lopez et al, 2006), we suggest that HOXB 13 might be a potential promising 
candidate to be targeted in ovarian cancer. Table 5.1 summarizes the results of scoring 
that was performed for the expression of HOXB 13 on the ovarian cancer tissue array.
HOXBl 3 score Frequency Percent Valid Percent
Cumulative
Percent
Valid -VE 5 7.1 7.1 7.1
+ 22 31.4 31.4 38.6
++ 29 41.4 41.4 80.0
+++ 14 20.0 20.0 100.0
Total 70 100.0 100.0
Table 5.1 Summary of the HOXBl 3 scoring performed on ovarian cancer tissues.
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In addition, we also performed nonparametric spearman’s rank correlation 
coefficient to determine whether there was an association between the expression 
pattern of HOXB 13 with the age of ovarian cancer patients and the grade of tumour 
(see Appendix 5.1). The results showed that there was a statistically significant 
positive correlation between the over expression of HOXB 13 and tumour grade (P = 
0.009). Additionally, there was a strong indication of a positive correlation with age 
o f cancer patients (P = 0.089). Table 5.2 summarizes the results obtained from 
statistical analysis (nonparametric spearman’s rank correlation coefficient). 
Highlighted value in green demonstrates significant correlation between HOXB 13 and 
tumour grade, for patients’ age, where 0.10>p>0.05, the value is shown in yellow.
C orrelations HOXBl 3 sco re
Spearman's rho Age Correlation Coefficient .205
Sig. (2-tailed) .089
N 70
3 rade scord Correlation Coefficient sod
Sig. (2-tailed) ood
N
Table 5.2 sum m ary of the statistical analysis perform ed on ovarian can cer tis su e s .
Nonparametric spearm an’s rank correlation test was applied to determine the correlation 
between HOXB 13 expression with cancer patients’ age and tumour stage.
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5.2.4 HOXB13 humoral response in ovarian cancer patients
It was shown previously (chapter 4) that HOXAl has the characteristics of a 
potential target for immunotherapy. This was suggested due to antibody response to 
HOXAl in 32% of breast cancer patients compared to 3.5% of aged-matched 
controls. Therefore, in order to assess the auto-antibody response in ovarian cancer 
patients to HOXB 13 as well, an ELISA was performed on patient’s plasma. This was 
compared to plasma obtained from female age-matched controls with no known 
history of cancer. Figure 5.5 shows the humoral response to HOXB 13 in each 
individual group tested.
HOX B13 humoral response
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Figure 5.5 Levels of H0XB13 auto-antibodies in the plasma of ovarian cancer patients.
ELISA plates were coated overnight with H0XB13 recombinant protein diluted in 0.1 M 
carbonate buffer. Plates were then incubated with patient or control plasma for 1 hour 
followed by incubation with anti-human IgG conjugated to horseradish peroxidase. Plates 
were washed and developed with TMB. The optical density was analysed at 450nm on a  DTX 
880 Multimode Detector ELISA plate reader. The humoral response in ovarian cancer 
patients was not significant compared to age-matched controls. A positive HOXBl 3 IgG 
antibody result was defined as H0XB13 IgG antibody levels equal to or greater that the mean 
value plus 2 standard deviations obtained in the total healthy control group. The smallest 
observation (minimum), lower quartile, median, upper quartile, and largest observation 
(maximum) are respresentative of the whisker plots.
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We tested the plasma of 58 ovarian cancer patients and 45 age-matched 
controls. The ELISA results showed that only 1.7% of ovarian cancer patients (one 
out of 58 ovarian cancer patients) had an antibody response to HOXB 13 compared to 
4.4% of aged-matched controls (2 out of 45 controls). Individual plasma were scored 
as positive which had an OD value equal to or greater than two standard deviations 
from the mean of control subjects. This observation suggests that unlike having 
humoral response to HOXAl in breast cancer patients, ovarian cancer patients had no 
significant HOXB 13 auto-antibody response.
5.2.5 HOXB13 cell-mediated immune responses
In order to investigate a cell-mediated response to HOXB 13, potentially 
immunogenic HLA-A2 restricted epitopes from the HOXB 13 protein sequence were 
selected using the computer algorithm SYFPEITHI. This predicts HLA class 1 and 11 
specific epitopes according to specific factors including anchor residues and 
proteasomal cleavage sites (Schirle et al, 2001) (Table 5.3). Following this, high 
binding epitopes (H0XB13.1, B13.2, B13.3, B13.4, B13.5, B13.6 and B13.7) were 
synthetically generated and tested against healthy donor PBMCs.
Protein
code Peptide Amino acid position
SYFPEITHI
sco re
H0XB13.1 SLSERQITI 254-262 24
HOXB13.2 TLMPAVNYA 41-49 22
HOX B13.3 YLDVSWQT 143-151 22
HOX B13.4 TLAAYPAET 105-113 21
HOXB13.5 ALAGGWNSQ 173-181 21
HOXB13.6 GAGGGRNLV 20-28 20
HOXB13.7 VLAKVKNSA 274-282 20
Table 5.3 H0XB13 peptides with SYFPEiTHI sco res .
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The target cells used were the T2 cell line which is a B lymphoblastoid, TAP 
deficient cell line expressing HLA class-I A2. T2 cells pulsed with irrelevant peptide 
(HIV peptide: SLYNTVATL) were used as a negative control for the assay. Four out 
of the 7 selected HOXAl epitopes tested (HOX B13.2, HOXBl3.4, HOXB 13.5 and 
HOX B13.7) generated specific responses in preliminary experiments against T2 
target cells loaded with the relevant peptide and therefore were shown to be 
immunogenic (Figure 5.6).
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Figure 5.6 H0XB13-reactive T cell lines can be generated from the blood of healthy 
donors. T cells were stimulated with peptide five times before testing their specificity in an 
IFN-gamma ELISpot assay. Targets were T2 cells pulsed with H0XB13 peptides (reI) or a 
control peptide, HIV (irrelevant). Representative examples are shown here from four different 
healthy donors (but only one experiment on each). Number of spots is per 2x10® cells/well.
As the results of IFN-gamma ELISpot assay show in Figure 5.6, peptide- 
specific immune responses were generated from the peripheral blood of healthy 
controls. Specific immune responses were generated against peptide HOXB 13.2 in 
donor 1, against HOXB 13.4 in donors 2, 3 and 4, against HOX B13.5 in all donors 
and also donors 2, 3 and 4 showed specific immune responses against peptide 
HOXB13.7.
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5.3 DISCUSSION
There is an urgent need for novel treatments for ovarian cancer. 
Immunotherapy is a potential strategy with an evolving scientific basis. Ovarian 
cancers, in a similar manner to other cancers, are known to over express a number of 
genes involved in early development (Morgan et al, 2010). One of the homeobox 
genes, H0XB13, has been shown to be over expressed in human ovarian, endometrial 
and cervical carcinomas and that also over expression of H0XB13 is correlated with 
the invasiveness of endometrial and ovarian cancer cells (Zhao et al, 2005; Lopez et 
al, 2006). In addition, the potential importance and common role of H0XB13 gene in 
the development of ovarian cancer is strongly suggested by Yamashita et al (2006) 
and Jung et al (2004b). Consequently, in this project we assessed the immunogenicity 
of H0XBI3 in ovarian cancer (versus healthy controls) and its potential as a target for 
immunotherapy.
Initially, we screened the expression patterns of the whole HOX gene network 
(39 genes) in a range of different ovarian cancer cell lines using quantitative RT-PCR 
analysis. The results demonstrated that in general, the pattern of expression of each 
individual HOX gene cluster was different from each other among various ovarian 
cell lines analysed. Over expression of paralogs of H0X3, H0X4, H0X5, H0X7 and 
H0X9 were observed in cluster A and B, and of HOX 13 in all paralogs. Yamashita et 
al. reported similar results to our data in their study with the exception of H0X5 and 
H0X9 which was not expressed. In addition, in a study by Cheng et al. in 2005, HOX 
gene expression in normal human ovarian tissue was analysed. Immunohistochemical 
analysis of H0XA7 and H0XA9 in fallopian tube, of HOXAIO in endometrium and 
of HOXAl 1 in endocervix showed little or no staining of HOX proteins in normal 
human ovarian surface epithelium (OSE).
Our gene of interest, H0XB13 gene, in particular was shown to be expressed 
in all cell lines tested. Consistant with our data, Miao et al. carried out a similar study 
in 2007 to determine the prevalence of H0XB13 gene expression in ovarian cancer 
using 10 different primary ovarian tumours and 10 human ovarian cell lines. Their 
results demonstrated that H0XB13 was expressed in 5 of 9 ovarian carcinomas and 
all but one ovarian cancer cell line that were examined.
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Next, we assessed a range of normal tissues for the expression of H0XB13 at 
the molecular level using qRT-PCR. The results showed very low level or no 
expression of H0XB13 in all normal tissues with the exception of prostate tissue in 
which H0XB13 was highly expressed. Our observations are consistent with the data 
reported in other studies. It has been shown that a marked difference between ovary 
and organs such as kidney and prostate is that H0XB13 is absent in the normal ovary, 
while it is highly expressed in the normal kidney and prostate (Jung et al, 2004a&b; 
Okuda et al, 2006; Huang et al, 2007), where it is involved in epithelial cell 
differentiation (Economides and Capecchi, 2003; Huang et al, 2007). The H0XB13 
expression pattern is up-regulated in ovarian cancers (Yamashita et al, 2006) and 
down-regulated in renal and prostate carcinoma cell lines (Jung et al, 2004b; Okuda et 
al, 2006). Therefore, it is implicated that in one tissue type H0XB13 may function as 
a tumour suppressor (Jung et al, 2004b) that is required for development of normal 
organ (Economides and Capecchi, 2003) and in another tissue type (Wang et al, 2007) 
is associated with tumorigenesis and aggressive disease(Shah and Sukumar, 2010).
Further investigation at the protein level, using immunohistochemical analysis 
on an ovarian cancer tissue array also confirmed expression of H0XB13 in 92.85% 
(65 out of 70) of cancer sections compared to normal ovarian tissues and tumour 
adjacent normal tissues. Alongside this, we correlated the expression of H0XB13 
with patients’ age and tumour grade. H0XBI3 was found to have a statistically 
significant positive correlation with tumour grade (P = 0.009). Additionally, there was 
a strong indication of a positive correlation with age of cancer patients (P = 0.089). 
Taking together the findings at both the molecular and protein level, in addition to the 
results obtained from previous studies (Zhao et al, 2005; Lopez et al, 2006), we 
confirm that H0XB13 expression is specific to ovarian cancer compared to normal 
ovarian tissue.
Having determined the expression pattern of H0XB13 in normal and ovarian 
cancer tissues as well as ovarian cancer cell lines, we next assessed the IgG auto­
antibody response in ovarian cancer patients to H0XB13. Neither ovarian cancer 
patients nor healthy female controls gave a significant auto-antibody response to 
H0XB13 (1/58 vs. 2/45 respectively). Thus, this observation suggests that ovarian 
cancer patients had no significant auto-antibody response to H0XB13. One
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explanation for this finding may be due to poor antigen presentation and/or perhaps 
tolerance to H0XB13.
In a similar study, McNeel et al. evaluated the inherent humoral immune 
response against known prostate cancer associated proteins (prostate specific antigen 
(PSA), prostatic acid phosphatase (PAP), p53 and HER-2/neu) in 200 prostate cancer 
patients with various stages of disease and male controls. Their results showed no 
cancer specific humoral responses to PAP or p53, while significant antibody 
responses were detected to PSA and Her-2/neu. They suggested these findings could 
be a reflection of expression levels of these proteins and consequently greater uptake 
and antigen presentation of PSA compared to PAP. In addition, they suggested the 
inherent humoral immunogenicity of these specific proteins with perhaps higher 
tolerance to PAP as another explanation for not producing humoral response (McNeel 
et al, 2000). However, there are cases that humoral responses against known CTL- 
defined tumour antigens have been detected (i.e. tyrosinase and MAGE-1). Moreover, 
in a similar study by Jager et al. in 1998 on cancer-testis antigen NY-ESO-1, it was 
reported that antigen-specific humoral and cellular immune responses against human 
tumour antigens may occur simultaneously.
These observations showed that a humoral response was not generated against 
H0XB13; therefore, we further investigated whether cell-mediated responses against 
H0XBI3 could be generated. From these initial studies four potentially immunogenic 
H0XBI3 epitopes (B13.2, B13.4, B13.5 and B13.7) were identified which were 
observed to generate peptide specific immune responses in the majority of donors 
tested. In all donors tested, specific immune responses generated against each 
individual peptide in preliminary experiments (T2 + relevant H0XB13 peptide) were 
different compared to negative controls (T2 + irrelevant HIV peptide).
In conclusion, based on all expression data obtained from qRT-PCR and 
immunohistochemical analysis plus reports from other studies (both at RNA and 
protein level respectively), it was shown in this study that H0XB13 is expressed in 
ovarian cancer. Furthermore, we showed that specific immune responses against 
H0XB13 epitopes were generated in peripheral blood of healthy donors. However, 
we will need to carry out further studies to investigate whether these peptide-specific
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immune responses against H0XB13 can be generated in ovarian cancer patients in 
comparison to healthy donors. Additionally, we will test these peptide-specific lines 
against ovarian cancer cell lines to assess whether these lines are able to recognize 
and kill specifically HLA-A2-restricted cancer cell lines.
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Chapter 6
Targeting modulatory T cells 
to enhance cancer vaccine
efficacy
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6. TARGETING REGULATORY T CELLS TO ENHANCE CANCER 
VACCINE EFFICACY
6.1 INTRODUCTION
Recent studies have provided considerable evidence that inhibitory regulatory 
T cells (Tregs) at tumour sites may pose major obstacles to effective cancer 
immunotherapy, as these cells have a potent ability to suppress host immune 
responses (Wang et al, 2004; Baecher-Allan and Anderson, 2006; Kondelkova et al, 
2010). Increased proportions of Tregs both in the tumour microenvironment and in the 
peripheral blood have been reported in patients with different types of cancers (Woo 
et al, 2001; Curiel et a/, 2004; Javia and Rosenberg, 2003; Liyanage et al., 2002; 
Schaefer et al, 2005). Indeed, the central role of Tregs in suppressing anti-tumour 
immune responses has been shown by numerous preclinical and clinical studies. In 
one study, using mice injected with syngeneic tumour cells, removal of CD4+CD25+ 
Tregs induced anti-tumour immunity (Onizuka et al, 1999). In another murine study, 
administration of anti-CD25 monoclonal antibody abrogated immune tolerance and 
induced the spontaneous development of tumour-specific T cells and natural killer 
cells (Shimizu et al, 1999; Tang et al, 2010).
Furthermore, clinical studies in patients with melanoma have shown that Tregs 
can inhibit both antigen-specific and non-specific T cell responses and in patients with 
ovarian cancer, a direct correlation has been shown between tumour infiltrating Tregs 
and decrease in overall survival rate (Curiel et al, 2004). Treatment of ovarian cancer 
patients with the recombinant interleukin 2 diphtheria toxin conjugate DAB389IL-2  
(denileukin diftitox; ONTAK) resulted in the depletion of Tregs and improved anti­
tumour responses (Barnett et al, 2005). Furthermore, denileukin diftitox has also been 
shown to significantly reduce the number of Tregs in the peripheral blood of 
metastatic renal cell carcinoma patients and to abrogate Treg mediated 
immunosuppression in vivo (Dannull J et al, 2005).
Thus, taken together these studies have shown that in some malignancies 
Tregs could reduce the efficacy of immunotherapeutic protocols and that depletion of
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these cells could enhance vaccine-mediated anti-tumour immune responses (Liu et al, 
2009). However, to date there are few clinical options for specifically targeting Tregs. 
One approach, low dose cyclophosphamide, does not exclusively target T-cells, and 
may result in serious toxicities including the development of secondary malignancies, 
most notably acute myeloid leukaemia. A second, indirect option involves the use of 
antibodies directed against the extracellular protein CTLA4 that is involved in 
blocking T effector cell activation by other immune cells (Mitsui et al, 2010). 
Although anti-CTLA4 antibodies administered for this purpose have resulted in anti­
tumour effects in some types of cancer, its use is associated with a number of severe 
autoimmune events. Thus, there is still a critical need for more specific strategies to 
modulate Treg function.
Regulatory T cells, depending on their type, mediate immunological tolerance 
through cytokine release and direct interaction with other immune cells (Sakaguchi, 
2005). In common with all other cell lineages their identity is conferred by specific 
transcription factors, although those involved in Treg development are exceptionally 
well defined. Most prominent amongst them is F0XP3 (Sakaguchi et al, 2010). 
Mutations in this gene are linked to autoimmune disease (Ziegler, 2006). Naturally 
occurring F0XP3 null mouse mutants die soon after birth as a result of aggressive 
autoimmunity in multiple organs (Brunkow et al, 2001), and humans with F0XP3 
mutations develop a similar syndrome called ‘IPEX’ characterised by insulin- 
dependent diabetes, thyroiditis, massive T-cell infiltration and chronic wasting 
(Bennett et al, 2001; Wildin et al, 2001). Subsequent studies demonstrated that 
F0XP3 serves as a lineage specification factor for Tregs (Chatenoud, 2011), as 
primary T cells transduced with F0XP3 and T cells from F0XP3 transgenic mice 
acquire many of the phenotypic and functional characteristics of Tregs (Fontenot et al, 
2003; Hori gf al, 2003; Khattri et al, 2003).
Unlike F0XP3, which is expressed almost exclusively in Tregs, the NFAT 
transcription factors (NFAT 1-4) are expressed in a wide range of tissue types 
(Hermann-Kleiter and Baier, 2010) and have multiple functions, including the 
differentiation of osteoclasts, slow twitch muscle fibres and T effector cells (Crabtree 
and Olson, 2002; Hogan et al, 2003). NFAT proteins interact with different factors in 
different cell types to regulate transcription in a cell specific manner. In cardiac.
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skeletal and smooth muscle cells the key interaction is with GATA transcription 
factor (Hogan et al, 2003), whereas in activated T effector cells NFAT complexes 
with AP-1 (Fos-Jun) proteins (Rao et al, 1997; Kretschmer et al, 2008). In Tregs 
however NFAT interacts with F0XP3, regulating a distinct set of target genes and 
switching T cell activity to repression rather than activation (Wu et al, 2006; Hu et al, 
2007). Hence F0XP3 and NFAT specifically repress the transcription of IL-2, whilst 
up regulating the Treg markers CTLA4 and CD25.
6.1.1 Hypothesis
Based on the published data outlined in the previous section, we hypothesised 
that disrupting the F0XP3/NFAT interaction in Tregs would result in the down 
regulation of these genes, and ablate or modify Treg function. Therefore, employment 
of an agent which would modulate regulatory T cells in combination with a vaccinate 
might be an effective way to overcome immunosuppression and enhance immune 
responses in cancer patients.
6.1.2 Aims and objectives
The goal of this project was to develop a clinically relevant T-regulatory cell 
(Treg) selective biologic (termed HWFT) to abrogate the immunosuppressive function 
of cancer associated Tregs. Thus, we set out to evaluate:
>  The in vitro apoptotic effects of HWFT on human and murine Treg compared 
to non-Treg immune cells
> Identify the most potent and specific Treg targeting peptide sequence of 
HWFT by specific amino acid substitutions and deletions
>  The effect of HWFT on the production of cytokines by Tregs
>  The efficacy of HWFT to enhance human recall antigen responses in vitro
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Design of the HWFT peptide:
In order to antagonise the interaction between F0XP3 and NFAT, Dr Morgan 
in our group designed a peptide that combines with the two sequences in the F0XP3 
protein that mediate this interaction (Wu et al, 2006). To facilitate uptake into cells 
nine arginine residues were added to the C-terminal end of the peptide. This motif is 
known to facilitate peptide uptake by endocytosis (Jiang et al, 2004), and has 
previously been used in peptide based inhibitors of other protein / protein interactions 
(Morgan et al, 2007). The resulting peptide was 23 amino acids long and was 
subsequently referred to as ‘HWFT’ (Figure 3.1).
F0XP3 sequence:
iPPF[ryATLIRWAILEAPEKQRYl|lll7HWFgRMFAFFRNHPA-rVVKNAllHNL^ HKCFVlvfsgGAW^ 0ELEFRKi 
O  DNA binding HWFT = TLMEIYHWFTÈSEKRRRRRRRRR
Figure 6.1 Protein-Protein Interactions between NFAT and F0XP3: Sequence alignment 
of F0XP3. Residues interacting with DNA are shaded in magenta; residues interacting with 
NFAT are shaded in green.
The control peptide, WHINE, was designed based on randomised sequence of the 
HWFT peptide, but include the same nine argenine cellular uptake sequence.
WHINE peptide sequence = SEFEYKTWHINETLRRRRRRRRR
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6.2 RESULTS
Transcriptional targeting of regulatory T cells
6.2.1 Murine Studies
6.2.1.1 HWFT triggers apoptosis in murine Tregs but not other CD4+ cells
In order to assess whether HWFT had specific biological effects on murine 
Tregs in comparison to non-Tregs, FACS staining for the apoptotic marker, Annexin 
V was performed. This showed that exposure to HWFT resulted in a large reduction 
in Treg viability. The IC50 of HWFT on murine CD4^CD25^ Tregs was 5pM, whilst 
relatively little toxicity was exhibited against other T cells (i.e. CD4^CD25’ and non- 
CD4 cells) at the same dose. Annexin V staining of HWFT treated CD4^CD25^ Tregs 
revealed that the majority were in late phases of apoptosis, whilst only a smaller 
proportion of CD4^CD25' T cells and non-CD4 cells underwent apoptosis when 
subjected to an identical treatment. The use of a control peptide (WHINE) in the same 
assays showed no selective induction of apoptosis (Fig 6.2 A and B).
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Figure 6.2 HWFT induces selective apoptosis in murine CD4"^CD25^ Tregs. A)
Representative FACS plots of murine CD4''CD25''Tregs (Treg), CD4''CD25'T cells (CD4) and 
the non-CD4 cell population (rest) treated with the HWFT or the control peptide (WHINE) at 
5pM or untreated and analysed for the proportion of apoptotic cells by annexinV/7AAD 
staining. The percentage of apoptotic cells (top right quadrant of FACS plots) for each 
population and each treatment is shown.
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Figure 6.2 HWFT induces selective apoptosis in murine 004^^0025^ Tregs. B) Murine 
CD4‘"CD25'' Tregs (Treg), CD4^CD25' T cells (CD4) and the non-CD4 cell population (rest) 
were treated with HWFT or a control peptide (WHINE) at various concentrations for 2 hours 
and then analysed for the proportion of apoptotic cells by annexinV/7AAD FACS analysis. 
The mean proportion of apoptotic cells for each population and each treatment is shown (+/- 
SD). The figure is representative of 5 individual experiments. ** p = 0.0018 (a): HWFT-treated 
Tregs compared to untreated cells. ** p = 0.0071 (b); HWFT-treated Tregs compared to 
WHINE-treatment.
The apoptotic effect of HWFT within a whole, unsorted murine splenocyte 
population was tested. Murine splenocytes were treated with HWFT peptide at 5uM 
for 2 hours followed by subsequent staining for different cell populations including 
CD4^CD25^ Tregs, CD4^CD25' T cells, CD8^ T cells, CD49b NK cells and CDl lc
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dendritic cells. Cells were then analysed for the proportion of apoptotic cells by 
annexinV/7AAD FACS analysis. The proportion of apoptotic cells for each 
population and each treatment is shown (Fig 6.3). HWFT was shown to have a 
selective apoptotic effect on Tregs compared to other cell populations. As before, no 
effect of WHINE treatment was observed on any of the cell populations studied.
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Figure 6.3 Selective apoptosis of Tregs within a mixed murine splenocyte population 
treated with HWFT peptide (5uM). Murine splenocytes were treated with HWFT peptide at 
5uM for 2 hours followed by subsequent staining for different cell populations including 
CDACD25^ Tregs, CDACD25‘ T cells, CDS"^  T cells, CD49b NK cells and CD11c dendritic 
cells. Cells were then analysed for the proportion of apoptotic cells by annexinV/7AAD FACS 
analysis. Background values for untreated splenocytes were subtracted. The figure is 
representative of minimum 2 experiments.
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6.2.1.2 HWFT inhibits the suppressive function of murine Tregs
In order to investigate whether HWFT can inhibit murine Treg suppressive 
function, a stimulation/proliferation assay was performed. Murine CD4^CD25^ 
MACS isolated Tregs were co-cultured with CD4 T cells (T resp) at different ratios (I 
:I and 1 : 2) in the presence and absence of the HWFT peptide at different 
concentrations (0.625pM-5pM) along with the eontrol peptide (WHINE) and 
stimulated with anti-CD3 (Fig 6.4). The results showed an increase in proliferation of 
CD4 resp cells at 2 : 1, Tresp : Treg ratio when treated with the HWFT peptide at 
5pM eompared to the control peptide or absence of HWFT.
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Figure 6.4 HWFT inhibits Treg suppressive  function. Murine Tregs were isolated by 
mouse regulatory T cell isolation kit (Miltenyi Biotec) and cocultured with CD4''CD25' 
responder T cells (‘CD4 resp’) at different ratios. For T cell stimulation, the Treg anti-CD3 
antibody was added to the culture. Proliferation of T cells was determined by 3H-thymidine 
incorporation. The figure is representative of 2 individual experiments.
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6.2.1.3 HWFT reduces the production of IL-10 by Tregs
In order to investigate whether HWFT can inhibit production of IL-IO, one of 
the characteristic immunosuppressive cytokines produced by Tregs, an ELISA was 
performed. Murine CD4^CD25^ MACS isolated Tregs and CD4^ T cells were treated 
with the HWFT peptide at different concentrations (0.156pM-10pM) and stimulated 
with CD3 and CD28 feeders (Fig 6.5). After 48 hours, the supernatant was then 
harvested and analysed. There was a decrease in production of IL-IO by Tregs when 
treated with the HWFT peptide at 5pM compared to untreated Tregs or HWFT-treated 
CD4 T cells.
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Figure 6.5 HWFT selectively reduces the production of IL-10 by murine Tregs 
compared to CD4 cells. Murine CD4"'CD25'' MACS isolated Tregs and CD4"^CD25' T cells 
were treated with the HWFT peptide at different concentrations (0.156pM-10pM). Following 
stimulation with CDS, CD28 and feeders, an ELISA was performed after 48 hours on Tregs 
and CD4 cells supernatant. The figure is representative of minimum 2 experiments.
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6.2.1.4 Identification of the most potent and specific Treg targeting peptide 
sequence of HWFT by specific amino acid substitution
In order to investigate the minimal peptide sequence required for the most 
selective and potent anti-Treg effect, deletions (Table 6.1) and alanine substitutions 
(Table 6.2) were introduced into the HWFT peptide sequence. Alanine which is a 
short, non-polar/charged amino acid was used for these point mutations. These variant 
peptides were then used to treat sorted Treg (CD4^CD25^), CD4^CD25" and non- 
CD4^ murine splenocyte populations. Again we used the Annexin-V/7AAD staining 
as a read-out for the induction of apoptosis.
The results showed that deletion of the 9-amino acid residues required for the 
uptake of the peptide into the cells, caused no apoptosis (A7). Also double amino acid 
deletions in positions 1/2 (A8), 5/6 (B2) and 7/8 (B3) as well as just the HWFT 
sequence only (B6), did not induce apoptosis. However, deletion in positions 2/3 (Bl) 
and 9/10 (B4) induced apoptosis, whereas deleting the four amino acid sequence 
ESEK (B5) resulted in a non-selective apoptotic effect when compared to the wild 
type HWFT sequence. 88% apoptosis was defined as target for significant and 
effective killing; hence, the apoptotic effect of these variant peptides was considered 
accordingly (Table 6.2) (Fig 6.6).
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Peptide Sequence Result
WHINE SEFEYKTWHINETLRRRRRRRRR 43%
HWFT TLNEIYHWFTESEKRRRRRRRRR 100%
A7 TLNEIYHWFTESEKXXXXXXXXX 63%
A8 XXNEIYHWFTESEKRRRRRRRRR 65%
B1 TLXXIYHWFTESEKRRRRRRRRR 100%
B2 TLNEXXHWFTESEKRRRRRRRRR 65%
B3 TLNEIYXXFTESEKRRRRRRRRR 68%
B4 TLNEIYHWXXESEKRRRRRRRRR 75%
B5 TLNEIYHWFTXXXXRRRRRRRRR 100% (non-selective)
B6 XXXXXXHWFTXXXXXXXXXXXXX 61%
Table 6.1 Effects of the  altered peptides on Treg and non-Treg populations by 
introducing am ino acid deletions into the  HWFT peptide. CD4^CD25^ Treg (Treg ) and 
CD4'’CD25' T cell (‘CD4’) populations were treated with the wild type HWFT peptide, WHINE 
or altered sequences of this peptide (A7, A8, B1, B2, B3, B4, B5, and B6) for 2 hours and 
then analysed for the proportion of apoptotic cells by annexinV/7AAD FACS analysis.
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Figure 6.6 Removal of pairs of amino acid residues alters the apoptotic effect of the 
HWFT peptide. CDACD25’'Treg (Treg’) and CDACD25'T cell populations were treated with 
the wild type HWFT peptide or altered sequences of this peptide (A7, A8, B1, B2, B3, B4, B5, 
and B6) at different concentrations for 2 hours and then analysed for the proportion of 
apoptotic cells by annexinV/7AAD FACS analysis. The proportion of apoptotic cells for each 
population and each treatment is shown.
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Due to the observed non-specific apoptotic effects of deleting the ESEK part 
of the HWFT sequence, we wanted to further investigate changes in the amino acids 
in this part of the sequence. Therefore, we substituted alanine at each amino acid 
position of the ESEK region, as well as deleting individually in turn each amino acid 
over the ESEK region (C8, D l, D2 and D3). The ESEK region was also completely 
substituted by 4 alanines (C l) .  These altered peptides revealed that the final position 
of the ESEK region (C6 and D3) was essential to retain the function of the peptide. 
75% apoptosis was defined as target for significant and effective killing; hence, the 
apoptotic effect of these variant peptides was considered accordingly (Table 6.2) (Fig 
6.7).
Peptide S eq u en ce Result
WHINE SEFEYKTWHINETLRRRRRRRRR 43%
HWFT TLNEIYHWFTESEKRRRRRRRRR 100%
0 3 TLNEIYHWFTASEKRRRRRRRRR 100%
0 4 TLNEIYHWFTEAEKRRRRRRRRR 70%
0 5 TLNEIYHWFTESAKRRRRRRRRR 100%
0 6 TLNEIYHWFTESEARRRRRRRRR 48%
0 7 TLNEIYHWFTAAAARRRRRRRRR 100%
0 8 TLNEIYHWFTXSEKRRRRRRRRR 100% (non-specific)
D1 TLNEIYHWFTEXEKRRRRRRRRR 100%
D2 TLNEIYHWFTESXKRRRRRRRRR 100%
D3 TLNEIYHWFTESEXRRRRRRRRR 51%
Table 6.2 Effects of the altered peptides on Tregs, non-Tregs and non-CD4^ cell 
populations by introducing aianine substitu tions into the HWFT peptide. Murine 
CD4^CD25^ Tregs (Treg’), CD4'^CD25' T cells (‘CD4’) and the non-CD4^ cell population 
(‘rest’) were treated with the wild type HWFT peptide or altered sequences of this peptide (C3, 
C4, C5, C6, Cl,  C8, D1, D2, and D3) at various concentrations for 2 hours and then analysed 
for the proportion of apoptotic cells by annexinV/7AAD FACS analysis.
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Figure 6.7 Alanine substitution of pairs of amino acid residues alters the apoptotic 
effect of the HWFT peptide in Tregs and CD4 cells. Murine CD4^CD25^ Tregs (Treg ), 
CD4"^CD25' T cells (‘CD4’) and the non-CD4^ cell population (‘rest’) were treated with the wild 
type HWFT peptide or altered sequences of this peptide (03, 04, 05, 06, 07, 08, D1, D2, 
and D3) at various concentrations for 2 hours and then analysed for the proportion of 
apoptotic cells by annexinV/7AAD FAOS analysis. The proportion of apoptotic cells for each 
population and each treatment is shown.
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Having observed in the first set of experiments (Table 6.1 and Figure 6.4; 
peptide Bl*) that the 2"  ^ and 3*^  ^ amino acid positions (NE) of the HWFT peptide 
sequence were not needed to retain the apoptotic effect, we combined these amino 
acid deletions with those in the ESEK region which had also appeared not to affect the 
function of the peptide. Comparing the specific apoptotic effects of these altered 
peptides on Tregs and other T cell subsets with wild type HWFT, we concluded that 
the M1832-B2 peptide can be regarded as the minimal sequence that induces efficient 
selective apoptosis in Tregs. It may also be a more effective (Treg killing) peptide due 
to induction of apoptosis at a lower dose (0.625 jiM) than the wild type HWFT 
peptide. Therefore, further studies using M1832-B2 peptide are suggested in future. 
None of the other altered peptides displayed a similar effect (Fig 6.8).
HWFT = TLNEIYHWFTESEKRRRRRRRRR 
M1832-A8 = TLXXIYHWFTESXKRRRRRRRRR 
M1832-B1 = TLXXIYHWFTEXEKRRRRRRRRR 
M1832-82 = TLXXIYHWFTEXXKRRRRRRRRR
200
HWFT
100
90
80
70
60
50
40
30
20
10
0
0 0.625 1.25 2.5 105
OTREG 
■ CD4
□ THE REST
Concentration of peptide
M1832-A8
Concentration of peptide
100
(A
5a
i
I
S0
0.
0 0.625 1.25 2.5 105
OTREG 
■ CD4 
□ THE REST
IVI1832-B1
100
OTREG 
■ CD4
□ THE REST40 -
0 0.625 1.25
Concentration of peptide
M1832-B2
100
Ia0
an0I
I
Q.
0 0.625 1.25 2.5 105
Concentration of peptide
OTREG 
■ CD4 
□ THE REST
Figure 6.8 Increased efficacy of altered HWFT peptide sequence. Murine CD4^CD25^ 
Tregs (Treg’), CD4‘"CD25‘ T cells (‘CD4’) and the non-CD4^ cell population (‘rest’) were 
treated with the wild type HWFT peptide or altered sequences of this peptide (A8, B1 and B2) 
for 2 hours and then analysed for the proportion of apoptotic cells by annexinV/7AAD FACS 
analysis. The proportion of apoptotic cells for each population and each treatment is shown.
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6.2.2 Human Studies
A distinction between Tregs in murine and human systems has been reported. 
Indeed, several differences between F0XP3 in humans and mice have been reported 
in recent studies. Human F0XP3 has two known isoforms: one encodes the full length 
of F0XP3, whilst the other encodes a short version of the protein that lacks exon 2 
(amino acids 71-105) (Ziegler, 2006; Allan et al, 2005). In murine CD4+ Treg cells 
there is no short form of Foxp3. In humans, over-expression of F0XP3 alone or 
together with the short isoform is not effective in generating Treg cells (Allan et al,
2005). Another major difference between humans and mice is that F0XP3 expression 
in human CD4+ T cells is tightly linked to T-cell receptor (TCR)-mediated activation 
(Ziegler, 2006).
In mice, all CD4'^/CD25^ T cells possess immunosuppressive action, whereas, 
in humans, only CD4^ T cells with the highest level of CD25 expression are 
characterised by T cell suppressive activity. More recently, it has been found that in 
humans, CD 127 expression (a-chain of the interleukin-7 receptor) inversely correlates 
with F0XP3 expression and the suppressive function of CD4+ Treg cells (Liu et al, 
2006; Seddiki et al, 2006). CD 127 expression on effector T cells is down regulated 
after T cell activation. Thus, in human the combination of markers including CD25+, 
F0XP3+ and CD 127— better define the Treg cell population with suppressive 
function (Wang HY and Wang RF, 2007).
In order to investigate the immunomodulatory effects of HWFT on Tregs in 
humans the following experiments were performed. HWFT was used as a universal 
peptide in both murine and human system.
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6.2.2.1 Biological effects of HWFT on human T cells
FACS-sorted human CD4^CD25^CD127'"^‘ Tregs, CD4^CD25 CD127^ non- 
Tregs and non-CD4’^ T cell (The rest) populations were treated with the HWFT 
peptide and control peptide WHINE at various concentrations (1.25 pM-10 pM) for 2 
hours. In contrast to the effect of HWFT on murine Tregs, FACS analysis after 
Annexin V/7AAD staining showed no selective apoptosis of human Tregs compared 
with other T cell populations (Fig 6.9).
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Figure 6.9 HWFT does not Induce selective apoptosis In human CD4"^CD25"^CD127'°'' 
Tregs. CD4'’CD25'^ Tregs (Treg), CD4^CD25 T cells (CD4) and the non-CD4’" cell population 
(rest) were treated with HWFT or a control peptide (WHINE) for 2 hours and then analysed for 
the proportion of apoptotic cells by annexinV/7AAD FACS analysis. The proportion of 
apoptotic cells for each population and each treatment is shown. The figure is representative 
of 4 individual experiments (mean +/- SD shown).
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6.2.2.2 HWFT inhibits human Treg suppressive function
Since HWFT did not have any specific apoptotic effect on human Tregs, we 
investigated whether our peptide could inhibit Treg suppressive function. Using a 
stimulation/proliferation assay, co-culturing FACS sorted (CD4^CD25^'CD 127^ °^ ') 
human Treg and Tresp populations in the presence and absence of HWFT and the 
control peptide WHINE, HWFT was shown to indeed reduee Treg suppressive 
function by increasing the proliferation of Tresp cells at 2 : 1 Tresp : Treg ratio. The 
control peptide (WHINE) did not produce this effect (Fig 6.10).
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Figure 6.10 HWFT inhibits Treg su ppressive  function. Human Tregs were isolated by 
FACS sorting (CD4^CD25^‘CD127'°^') and co-cultured with CD4^CD25' responder T cells 
(‘CD4 resp’) at different ratios. For T cell stimulation, the Treg Suppression Inspector (anti­
biotin MACSiBead particles pre-loaded with biotinylated CD2, CD3, and CD28 antibodies) 
was added to the culture. Proliferation of T cells was determined by 3H-thymidine 
incorporation.
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6.2.2.3 Efficacy of HWFT in enhancing human recall antigen responses in vitro
6.2.2.3.1 Optimisation of Elispot assay for testing human immune responses to 
common recall-antigens
Specific responses to tumour associated antigens have been detected after 
depletion of Tregs indicating the suppressive function of Tregs towards the tumour- 
specific immune response (Clarke et al, 2006). We wanted to test the ability of HWFT 
to enhance human recall-antigen responses in vitro. For this purpose we started with 
optimisation of the IFN-y Elispot assay to look for antigen-specific T cell responses of 
healthy donors to common recall antigens including Epstein - Barr virus (EBV), 
varicella zoster virus (VZV), Mumps, Tetanus and purified protein derivative (PPD). 
To do this we treated freshly isolated PBMCs (2 x 10  ^ cells/well) at different 
concentrations of each of the antigens (*see below for stock concentration) and used 
cells alone as a negative control and PHA-treated cells as the positive control. Figure 
6.11 shows the results obtained from two of the healthy donors tested.
* Stock concentration of each antigen used:
VZV: 0.2 mg/ml 
PPD: 5000 lU/ml 
Tetanus: 500 pl/ml 
Mumps: 0.61 mg/ml 
EBV: 10 pg/ml
Varicella-Zoster Virus (VZV): products are prepared by the glycine extraction of human 
fibroblast infected with VZV, strain ELLEN. (Meridian, Life Science, UK).
Purified Protein Derivative (PPD): of M. Tuberculosis. (NIBSC, UK).
T etanus: Tetanus toxoid (NIBSC, UK).
Mumps: product is prepared from a glycine extraction of LLC-MK2 cells infected with the 
Mumps virus strain Enders. (Meridian, Life Science, UK).
EBV: EBV peptide (GLOTLVAML) 280-288. BM(F).
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Figure 6.11 Optimisation of the IFN-y Elispot assay using healthy donor peripheral 
blood. PBMCs of healthy donor were cultured with common re-call antigens at various 
concentrations (1:10 -  1:80 in donor A and 1:20 -  1:320 in donor B) along with cells alone 
and PHA as negative and positive controls respectively. The numbers of spots are 
representative of antigen-specific CD4/CD8 T cells.
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Having performed the IFN-y Elispot assay to test immune responses against 
common recall antigens in healthy donors (Figure 6.11), next we further investigated 
whether HWFT peptide could enhance the immune response against the common 
recall antigen compared to CD25-depleted cells. In order to do this, we cultured whole 
PBMCs, CD25-depleted PBMCs, HWFT peptide-treated PBMCs and WHINE 
peptide-treated PBMCs of healthy donors and several different cancer patients with a 
common recall antigen of interest (PPD or the tumour-associated antigen, survivin). 
PHA and cells alone were used as positive and negative controls respectively, in each 
individual types of treatment. Figure 6.12 shows the results obtained from experiment.
As Figure 6.12 demonstrates, the PPD-stimulated PBMC of the healthy 
control (Don 4) showed no alteration in the immune response generated upon HWFT 
treatment compared to depletion of CD25 cells. In contrast, the Elispot results 
obtained from the peripheral blood of cancer patients showed an increased antigen 
specific T cell response when treated with the HWFT peptide compared to CD-25 
depleted cells. This augmentation in immune response upon treatment with the HWFT 
peptide was observed in both of the ovarian cancer patients against PPD antigen, as 
well as the renal cancer patients against PPD and survivin.
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Figure 6.12 HWFT enhances the immune response to common recall antigens in cancer 
patients. PBMCs of one healthy donor and 4 cancer patients were cultured with common 
recall antigen PPD or tumour antigen survivin and treated with HWFT peptide at various 
concentrations (2 pM and 0.5 pM) along with cells alone and PHA as negative and positive 
controls respectively. The numbers of spots are representative of antigen-specific CD4/CD8 T 
cells.
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6.3 DISCUSSION
Interfering with Treg function is not yet well established as a potential therapy 
in cancer. The use of anti-CTLA4 antibodies has achieved some significant successes 
in clinical trials for malignancies including melanoma, renal and colon cancer (Peggs 
et al, 2006; Weber, 2007). The attenuation of Treg function by our HWFT peptide 
may be an alternative or complementary approach in this area of immunotherapy. 
Although effective, anti CTLA4 antibodies have a very long clearance time leading to 
aggressive autoimmune responses. Peptides tend to be cleared very swiftly in vivo so 
less severe side effects might be expected. Therefore, we hypothesise that by ablating 
Tregs or modulating their suppressive function using our F0XP3 (HWFT) peptide in 
combination with other interventions, we might be able to achieve a good therapeutic 
immune response in immunocompromised cancer patients.
In murine Tregs, the results obtained from treatment of MACS-sorted Treg, 
CD4+ non-Treg and non-CD4+ T cell populations with our F0XP3 modulatory agent, 
HWFT peptide, showed a selective and specific apoptotic effect in vitro. In addition, 
introducing the HWFT peptide into a standard suppression assay demonstrated that 
HWFT was indeed specifically affecting the Tregs as we observed a recovery of T 
responder cell proliferation in the presence of HWFT.
In order to investigate the most potent and specific version of the HWFT 
peptide, deletions and alanine substitutions were introduced to the wild-type HWFT 
peptide sequence. The results showed that a shortened/altered peptide still retained the 
same selective effect on Tregs as the wild type HWFT peptide and induced efficient 
selective apoptotic effects in Tregs at a lower dose (0.625 pM) compared to the 
original HWFT peptide (5 pM). However, further experiments need to be performed 
to confirm this.
In contrast to the HWFT effect on murine Tregs, the HWFT peptide did not 
induce the same selective apoptotic effect on human Tregs. This finding was not that 
surprising since there are now several reports demonstrating the fact that regulatory T 
cells show different biology and physiology from each other in the murine and human 
system (Sakaguchi et al, 1995; Wing et al, 2002; Dannull et al, 2005). Several
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findings have been confirmed by other groups (Roncador et al, 2005; Allan et al,
2006) and provide evidence that human and mouse F0XP3 are indeed regulated 
differently. Monitoring of F0XP3 expression in the human system using Western 
blotting has shown that the protein actually ran as a closely spaced doublet (Walker et 
al, 2003). RT-PCR analysis has demonstrated that the upper isoform represents the 
ortholog to mouse F0XP3, whereas the lower isoform is encoded from a mRNA 
lacking exon 2 (amino acids 71-105) (Allan et al, 2006). This splicing variant has not 
been reported in mouse CD4+CD25+ Tregs.
In addition, the regulation of F0XP3 expression is different between humans 
and mice as shown by the analysis of F0XP3 expression in stimulated human 
CD4+CD25- T cells. Walker et al. showed that the starting population of human T 
cells lacked detectable F0XP3 expression, but upon stimulation with anti 
CD3+CD28, F0XP3 expression was detected within 24 hour, peaking at 72 hours. 
Up-regulation of F0XP3 was not reported in similar experiments using mouse 
CD4+CD25- T cells. They also showed in their further analysis with human CD4+ T 
cells that the subset of T cells that up-regulated CD25, expressed F0XP3 as well. 
Therefore, F0XP3 in humans acts as an activation-induced gene in CD4+ cells [108].
Furthermore, in a microarray study, comparing the Treg cell specific gene 
signatures from human and mouse Treg cells, 62 genes were differentially expressed 
in Treg cells emphasizing the cross-species differences between mice and humans 
(Pfoertner et al, 2006).
Our results showed that despite the lack of selective apoptotic effects induced 
by HWFT on human Tregs, our peptide did affect Treg suppressive activity in vitro. 
This inhibitory effect of HWFT on the functional activity of Tregs was shown by an 
increase in proliferation of T responder cells when these cells were co-cultured with 
Tregs at 2:1 ratio in the presence of the HWFT peptide. This functional attenuation 
rather than specific deletion of Tregs by our agent HWFT is the preferred strategy for 
abrogating the immunosuppressive effect of Tregs due to the arguments put forward 
by Colombo and Piconese (Colombo and Piconese, 2007). They argued that the 
potential benefit of Treg cell depletion through the interleukin-2 receptor is lost by the 
concurrent elimination of activated effector T lymphocytes and possibly by the de
210
novo induction of Treg cell replenishment. They indicated that the functional 
inactivation of Treg cells will maintain them at high numbers in tumours and avoid 
their replenishment from the peripheral lymphocyte pool, which has the capacity to 
further suppress the effector lymphocyte anti-tumour response. Thus, overcoming the 
tumour-induced expansion of regulatory T cells which is an obstacle to successful 
cancer immunotherapy through Treg functional inactivation appears to be the best 
strategy.
An increased frequency of Tregs in various solid tumours and haematological 
malignancies has now been reported by several studies (Whiteside, 2005; Griffiths et 
al, 2007; Siddiqui et al, 2007; Alhamameh et al, 2008). Results from our own 
preliminary studies enumerating Tregs in the peripheral blood of cancer patients 
showed a slight to significant elevation of Treg numbers compared to healthy 
individuals. Several studies have now shown that these increased levels of Tregs in 
cancer patients do indeed impinge upon anti-tumour immunity. This was 
demonstrated in a study in advanced murine breast cancer by Xu et al where the effect 
of adoptive transfer of Treg-depleted autologous tumour infiltrating lymphocytes in 
enhancement of anti-tumour efficacy was investigated. An increase in the activation 
and proliferation of both CD4+ and CD8+ T cells was observed upon Treg-depleted 
cell transfer. These data indicated that the immune response skewed towards the Thl 
response followed by an elevation in IFN-y and reduction in IL-4 secretion in both 
CD4+ and CD8+ T cells and an increase in release of granzyme B from CTL, all 
leading to delayed tumour growth and reduced tumour burden (Xu et al, 2009).
In another study by Clarke et al. specific responses to the tumour associated 
antigen 5T4 were evaluated in a proportion of healthy controls where the majority of 
these responses were unaltered upon Treg depletion. In contrast, after depletion of 
Tregs, they reported that in more than a third of the Colorectal cancer (CRC) patients, 
a 5T4-specific response was detected indicating the suppressive function of Tregs 
towards the tumour-specific immune response. Their data suggest that Treg cells 
capable of suppressing 5T4-specific responses are induced in response to the tumour 
since in healthy controls 5T4-responses were not unmasked by removal of Treg cells 
(Clarke et al, 2006). Similarly, in our study it was demonstrated that in healthy 
individuals, specific T cell responses to the common recall antigens remained
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unmodified upon HWFT treatment compared to CD25 depletion. However, in cancer 
patients, the HWFT peptide had a potentiating effect on the immune response 
generated against common human recall antigens. We showed that treatment with 
HWFT on peripheral blood of cancer patients cultured with common recall antigen 
PPD or tumour-associated antigen survivin did indeed enhance the induced immune 
response. This effect was compared to the results obtained from depletion of CD25 
cells which revealed less effective outcome. Therefore, it is suggested that our peptide 
has an inhibiting effect on immunosuppressive function of Tregs.
The theory of overcoming immunosupression in cancer by specific focus on 
targeting regulatory T cells as a major and crucial immunosuppressive mechanism, 
led us to the hypothesis that inhibition of Treg function using our HWFT agent can be 
a promising strategy. However, further studies to identify molecular signalling 
pathways of HWFT in addition to comparing its efficacy and specificity in targeting 
Treg with current strategies (anti CTLA4 Ab, anti CD25 Ab, cyclophosphamide) in 
mouse models including intratumoural T-cell/Treg ratios, is needed. Moreover, 
pharmacokinetic and toxicity effects of HWFT in a murine model and evaluation of 
the ability of HWFT compared to other anti Treg treatments to augment the efficacy 
of a murine cancer vaccine, needs to be tested. Consequently, our ultimate goal is to 
investigate whether we can indeed observe increased anti-tumour responses when 
HWFT is used in a vaccination protocol using in vivo animal tumour models. The 
longer term aim would be to develop a small molecule mimic of HWFT for clinical 
use.
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7. DISCUSSION
Immunotherapy aims to stimulate the body’s immune system to target and 
destroy cancer cells and has been shown to be promising as a treatment modality. 
Despite difficulties in prevention and treatment of human cancer, recent advances in 
both molecular biology and immunological aspects of tumour evolution, as well as 
increased understanding of the fundamental mechanisms of the regulation of the 
immune response are leading to the development of a variety of specific and 
nonspecific immunostimulatory strategies for anti-cancer treatment (Hong and Fan, 
2008). The clinical goal of tumour immunotherapy is to elicit either active or passive 
immunity to target tumours and thereby break immune tolerance and improve survival 
in cancer patients (King et al, 2008).
To date, various forms of immunotherapeutic approaches have included 
monoclonal antibodies, immune response modifiers, and vaccines. Vaccines (whole 
tumour cell, viral, peptide and dendritic-based) are regarded as a specific form of 
immunotherapy since they stimulate immune responses directly towards tumour 
antigens compared to nonspecific methods that generally induce the immune system 
to produce cytokines (Adam et al, 2003). The repertoire of tumour antigens is 
increasing across a range of malignancies.
Tumour antigens are mainly non-mutated self-proteins which are abnormally 
expressed in cancer cells due to genomic instability (Stoler et al, 1999). Despite 
extensive research, cancer vaccines to date have had limited efficacy. The reasons for 
this may include the choice of target antigen, delivery of the vaccine, choice of 
adjuvant and the effects of an immunoinhibitory microenvironment. For an effective 
antitumor response to occur, it was reported that 1% antigen-specific CTLs of the 
total effector CD8^ cell pool are needed (Walker and Disis, 2003); levels of less than 
0.01% have been obtained from most vaccine strategies in patients (Tomasi et al,
2006). In a review by Cheever et al, in 2009 characteristics of an ideal tumour antigen 
have been defined. These are as follows: (a) therapeutic function, (b) immunogenicity, 
(c) role of the antigen in oncogenicity, (d) specificity, (e) expression level and percent 
of antigen-positive cells, (f) stem cell expression, (g) number of patients with antigen-
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positive cancers, (h) number of antigenic epitopes, and (i) cellular location of antigen 
expression (Cheever et al, 2009).
The potential immunogenicity of EN2, HOXAl and H0XB13 as 
immunotherapeutic targets was investigated in this project. These are members of 
Homeobox (HOX) genes which are a large group of regulatory genes that encode 
transcription factors involved in developmental processes (Abe et al, 2006). These 
include the control of cell growth, differentiation, programmed cell death (apoptosis) 
and cellular interactions (e.g. cell-cell and cell-extracellular matrix) (Abdel-Fattah et 
al, 2006). The immunogenicity of EN2 in melanoma, HOXAl in breast and H0XB13 
in ovarian cancer was determined. All nominees were found to have strong expression 
both at RNA and protein level in cancer cell lines as well as tumour tissue sections 
compared to normal tissues. The immunohistochemical analysis demonstrated that 
62% of primary and 65% of metastatic malignant melanoma sections, 73% of breast 
cancer sections and 92% of ovarian cancer sections were positive for the expression of 
EN2, HOXAl and H0XB13 respectively.
Additionally, we correlated the over expression of HOXAl with histology, 
stage, grade, Her2/neu status, estrogen and progesterone receptor status and associated 
the over expression of EN2 and H0XB13 with patients’ age and tumour stage/grade. 
HOXAl was found to have a statistically significant positive correlation with AR. 
Moreover, there was a strong indication of a positive correlation with ER, PR and 
Her-2/neu. Therefore, expression of HOXAl can be considered as a potential marker 
in addition to these hormonal receptors in diagnosis of breast cancer. Our further 
analysis also revealed that 71% of the TNBC patients were positive for the expression 
of HOXAl. Hence, expression of HOXAl in TNBC patients can potentially be a 
diagnostic marker. For EN2, statistical analysis demonstrated that there was no 
significant correlation between the expression of EN2 with melanoma patients’ age 
and stage of the tumour. H0XB13 was found to have a statistically significant 
positive correlation with tumour grade. Additionally, there was a strong indication of 
a positive correlation with age of ovarian cancer patients. Thus, H0XB13 over 
expression can be a potential marker in diagnosis of ovarian cancer with 
pathologically defined as high grade tumour.
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There is convincing evidence that cellular and humoral immune recognition is 
elicited by many human tumours (Dranoff, 2009). Most of the antigens that are 
expressed by human cancer cells and are recognized by host antibodies and T cells are 
non-mutated self antigens that are also expressed on the surface of normal cells. 
Studies of spontaneous tumours in mice have also shown the relevance of T cell 
recognition of non-mutated self-antigens (Houghton and Guevara-Patino, 2004). 
However, from another perspective, one explanation for the difficulties in 
immunization against human cancer could be that these antigens are ineffective at 
triggering immune responses against cancer cells which might be due to tolerance. 
Although these tumours are weakly immunogenic, they have been considered as 
representative of most human cancers compared to the strongly immunogenic 
mutagen-induced tumours (Prehn and Main, 1957; Hewitt et al, 1976).
We tested the presence and level of IgG “auto”-antibodies against EN2, 
HOXAl and H0XB13 in the serum and/or plasma of melanoma, breast and ovarian 
cancer patients. The results showed that 37.5% (6/16) of melanoma cancer patients 
had strong significant EN2-humoral response, while none (0/33) of the aged-matched 
controls had auto-antibody response to EN2 according to cut off point. 32% (64/198) 
of breast cancer patients had an antibody response to HOXAl compared to 3.5% 
(3/86) of aged-matched controls while neither ovarian cancer patients nor healthy 
female controls gave a significant auto-antibody response to H0XB13 (1/58 vs. 2/45 
respectively). In a similar study, Reuschenbach et al. in 2009 detected antibodies 
against NY-ESO-1, Her-2/neu, p53, p62, survivin, MUCl and cyclin B1 in median 
14% of analyzed tumour patients with generally very low frequencies in healthy 
individuals. They also reported a high correlation between frequencies of antibody 
responses and antigen (over)-expression for several antigens such as Her2/neu, p53 
and NY-ESO-1. In another study, Zhang et al. demonstrated that 14.6% (weighted 
average) humoral response to survivin was observed in breast cancer patients while 
0.7% of healthy individuals had antibody responses. However, the results we obtained 
from humoral responses to EN2 and HOXAl were higher compared to the antibody 
responses to the tumour antigens assessed in previous studies.
The discovery of tumour antigens, which provide a way to distinguish between 
tumours and normal cells, is the key to development of immunotherapies for cancers.
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Specific immunogenic epitopes can be identified from these tumour antigens to either 
provide a way to measure the presence of specific T cells in the circulation of cancer 
patients or for use as vaccines to activate an immune response against tumour cells 
(Meidenbauer et al, 2003). A number of methods have been described for the 
identification of these immunogenic HLA-restricted epitopes from TAA including 
reverse immunology (Stevanovic, 2002).
Reverse immunology, was selected for use in this project and it relies on the 
specific binding affinities of different HLA alleles for different peptides. The binding 
of peptides to HLA molecules relies on key anchor residues at specific positions. 
Computer based algorithms have been designed using this information, which predict 
potential immunogenic peptides from a protein sequence (Doytchinova and Flower,
2007). Following selection of potential binders peptides can be synthetically made 
and used to test their ability to generate specific T cells in a human PBMC in vitro 
model. After identification of immunogenic epitopes processing of these epitopes 
needs to be investigated, because if these peptides are not generated from the whole 
protein sequence encoding for a tumour antigen they will fail to elicit specific T cells 
that recognise tumour cells. To investigate this, a method including the use of target 
cells expressing both the antigen and MHC molecule of interest was used.
We investigated the specificity and immunogenicity of these candidate 
antigens to generate cell-mediated immune responses. Significant EN2-speciflc CTL 
responses were induced from the peripheral blood of melanoma cancer patients 
stimulated with HLA-A2 restricted EN2 epitopes compared to controls. Furthermore, 
we identified three immunogenic HOXAl epitopes which generated significant 
peptide-specific immune responses in the majority of donors tested. In addition, these 
HOXAl specific responses were also able to recognise HLA-A2 positive breast 
cancer cell lines. Recognition of breast cancer cell lines by these T cells also suggests 
these epitopes are naturally processed and presented. For H0XB13, four potentially 
immunogenic H0XB13 epitopes were identified which generated significant peptide- 
specific immune responses in the majority of donors tested compared to negative 
controls.
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Consequently, considering the characteristics of ideal tumour antigens, both 
EN2 and HOXAl have met these criteria. To summarise, both of these antigens were 
found to show immunogenicity and specificity, a role in oncogenicity, high level of 
expression and percentage of antigen-positive cells, patients with antigen-positive 
cancers, antigenic epitopes and cellular location of antigen expression. Thus, we 
suggest that these antigens could be promising novel candidates in treatment of 
melanoma and breast cancer respectively.
However, in the future the immunogenicity of the selected peptide-derived 
epitopes needs to be investigated in more detail, especially in relation to other HLA- 
alleles other than HLA-A2. This could be carried out using different target cells such 
as a range of cancer cell lines in the ELISpot assay as well as involving a cohort of 
cancer patients with a variety of different HLA-alleles. Further studies could also 
include the use of tetramer analysis, alongside investigating the responses to MHC 
class-II restricted epitopes. The findings of these studies could then be used for 
developing potential vaccine strategies involving both the MHC class-I and II 
epitopes firstly using a mouse model and then human studies leading to clinical trials.
Immunotherapeutic vaccination against tumour-associated antigens represents 
a promising option as viable alternative therapies in certain cancer treatment (Ho et al,
2008) in regard to the possibility of long-lasting immunity against the cancer, its 
efficacy and safety profile (Kruger et al, 2007). However, despite these advances in 
vaccine technology, vaccines designed to evoke specific T cell based anti-tumour 
immunity have obtained partial successes in the clinic (Henderson et al, 2005). The 
key reason possibly stems in part from the ability of tumours to suppress related T cell 
responses (Paul et al, 2007). Recent studies have provided considerable evidence that 
inhibitory regulatory T cells (Tregs) at tumour sites may pose major obstacles to 
effective cancer immunotherapy, as these cells have a potent ability to suppress host 
immune responses (Wang et al, 2004; Baecher-Allan and Anderson, 2006; 
Kondelkova et al, 2010).
Consequently, as the overall goal of this thesis was to look at both arms of the 
immune system (activation and immunosuppression), we also investigated the effects 
of a Treg-selective biologic (HWFT) on abrogating the immunosuppressive function
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of cancer associated Tregs. The attenuation of Treg function by our HWFT peptide 
may be an alternative or complementary approach in the area of immunotherapy to 
increase vaccine efficacy.
In murine Tregs, HWFT peptide showed a selective and specific apoptotic 
effect on Tregs in vitro. In addition, HWFT specifically affected the function of Tregs 
as a recovery of T responder cell proliferation in the presence of HWFT was 
observed. In contrast to the HWFT effect on murine Tregs, the HWFT peptide did not 
induce the same selective apoptotic effect on human Tregs. This finding may be due 
to the fact that Tregs in the murine and human system have different biology and 
physiology from each other (Sakaguchi et al, 1995; Wing et al, 2002; Dannull et al, 
2005). However, HWFT did affect human Treg suppressive activity in vitro. This was 
shown by a significant increase in proliferation of T responder cells when these cells 
were co-cultured with Tregs in the presence of the HWFT peptide. This functional 
attenuation rather than specific deletion of Tregs by HWFT is the preferred strategy 
for abrogating the immunosuppressive effect of Tregs.
Specific responses to the common recall antigens upon HWFT treatment 
were evaluated compared to CD25 depletion in a proportion of healthy controls where 
the majority of these responses were unaltered upon Treg depletion. In contrast, in 
cancer patients, the HWFT peptide had a potentiating effect on the immune response 
generated against common human recall antigens. Additionally, in renal cancer 
patient, HWFT treatment showed to enhance the immune response induced against 
the tumour antigen survivin. Therefore, it is suggested that our peptide has an 
inhibiting effect on immunosuppressive function of Tregs. In a similar study by 
Clarke et al., specific responses to the tumour associated antigen 5T4 were evaluated 
in a proportion of healthy controls where the majority of these responses were 
unaltered upon Treg depletion. In contrast, after depletion of Tregs, they reported that 
in more than a third of the Colorectal cancer (CRC) patients, a 5T4-specific response 
was detected indicating the suppressive function of Tregs towards the tumour-specific 
immune response. Their data suggest that Treg cells capable of suppressing 5T4- 
specific responses are induced in response to the tumour since in healthy controls 
5T4-responses were not unmasked by removal of Treg cells (Clarke et al, 2006).
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Consequently, the theory of overcoming immunosupression in cancer by 
specific focus on targeting regulatory T cells as a major and crucial 
immunosuppressive mechanism, led us to the hypothesis that inhibition of Treg 
function using our HWFT agent can be a promising strategy. Hence, our eventual aim 
is to apply HWFT to interfere with the immunosuppressive processes and to combine 
this with vaccination protocol.
In the future, the efficacy and specificity of HWFT in targeting Treg in mouse 
models needs to be evaluated compared to current strategies (anti CTLA4 Ab, anti 
CD25 Ab, cyclophosphamide). Primary readouts could be tumour size and histology 
of the intratumoural proportions of T cell/Treg ratios. Also, pharmacokinetic (PK) and 
toxicity effects of HWFT in a murine model need to be studied. For PK studies, mice 
with B16F10 flank tumours need to be dosed intravenously with radioactively labelled 
HWFT. The level of peptide/radioactivity in the tumours, the liver, bone marrow, 
brain, kidney, spleen and lungs could be measured. Where significant levels of 
radioactivity are detected, tissues could be sectioned for more detailed analysis. For in 
vitro toxicity studies, the comparisons of HWFT-mediated effects on CD4^CD25^ 
versus CD4^CD25' cells could be extended to include the effects on other murine 
immune cells e.g. CD 19  ^ B cells, CD 14  ^ monocytes and CD 133^ early progenitor 
cells.
Moreover, in order to determine the maximum tolerated dose (MTD), HWFT 
is required to be intravenously administered to mice. Mice treated with 80% of the 
MTD could then be used to determine the IRAE-pathology by histological 
examination of the intestines, liver and skin. Furthermore, the levels of key cytokines 
including anti-inflammatory IL-10 and TGF-P and pro-inflammatory IFN-y, IL-I, and 
IL-6 need to be examined. Neurological effects such as altered behaviour, changes in 
feeding habits and shaking could be monitored. Since NFAT is broadly expressed, 
changes in organ function or structure are possible. Therefore, mice need to be 
monitored for normal cardiac, kidney and liver function during treatment and internal 
organs examined by histology.
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Additionally, as well as assessing the effects of HWFT in murine system, it is 
necessary to investigate the anti-Treg efficacy of HWFT treatment in humans too. As 
was done for murine Treg, peptide optimisation needs to be done for humans in order 
to identify the most potent and specific Treg targeting peptide sequence of HWFT by 
specific amino acid substitution. This is necessary since different species often show 
differences in protein affinities and also human Tregs did not appear to undergo 
apoptosis, hence, necessitating a different readout assay. Furthermore, the molecular 
mechanisms of action of HWFT on Treg intracellular signalling need to be identified 
in comparison with current anti-Treg treatments. This could be done by isolating and 
hybridizing RNA against (human) whole-genome expression microarrays. Expression 
changes could be analysed and lists of specifically affected genes generated. The 
ultimate goal is to investigate anti-tumour responses when HWFT is used in a 
vaccination protocol using in vivo animal tumour models. The longer term aim would 
be to develop a small molecule mimic of HWFT for clinical use.
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Appendix 3.1 Specification sheet (Normal human tissue)
ÆM S U
A1 1 18 Breast Normal breast tissue (fibrofatty tissue) Normal
A2 2 F 18 Breast Normal breast tissue (fibrofatty tissue) Normal
A3 3 F 21 Breast Normal breast tissue Normal
A4 4 F 21 Breast Normal breast tissue Normal
A5 5 F 19 Breast Normal breast tissue Normal
A6 6 F 19 Breast Normal breast tissue (fibrofatty tissue) Normal
A7 7 M 35 Colon Normal colon tissue Normal
A8 8 M 35 Colon Normal colon tissue Normal
B1 9 M 30 Colon Normal colon tissue Normal
B2 10 M 3 Colon Normal colon tissue Normal
B3 11 M 35 Colon Normal colon tissue Normal
B4 12 M 35 Colon Normal colon tissue Normal
B5 13 M 50 Lung Normal colon tissue Normal
B6 14 M 50 Lung Normal lung tissue Normal
B7 15 M 55 Lung Normal lung tissue Normal
B8 16 M 55 Lung Normal lung tissue Normal
C l 17 M 24 Lung Normal lung tissue Normal
C2 18 M 24 Lung Normal lung tissue Normal
C3 19 F 40 Liver Normal lung tissue Normal
C4 20 F 40 Liver Normal hepatic tissue Normal
C5 21 19 Liver Normai hepatic tissue Normal
C6 22 19 Liver Normal hepatic tissue Normal
C7 23 F 40 Liver Normal hepatic tissue Normal
C8 24 F 40 Liver Normal hepatic tissue Normal
D1 25 F 15 Ovary Normal ovarian tissue Normal
D2 26 F 15 Ovary Normal ovarian tissue Normal
D3 27 F 21 Ovary Normal ovarian tissue Normal
D4 28 F 21 Ovary Normai ovarian tissue Normal
D5 29 F 41 Ovary Normal ovarian tissue Normal
D6 30 F 41 Ovary Normal ovarian tissue Normal
D7 31 F 21 Pancreas Normal pancreatic tissue (sparse) Normal
D8 32 F 21 Pancreas Normal pancreatic tissue Normal
E l 33 35 Pancreas Normal pancreatic tissue Normal
E2 34 F 35 Pancreas Normal pancreatic tissue Normal
E3 35 F 35 Pancreas Normal pancreatic tissue Normal
E4 36 F 35 Pancreas Normal pancreatic tissue Normal
E5 37 M 19 Prostate Normal prostate tissue Normal
E6 38 M 19 Prostate Normal prostate tissue Normal
E7 39 M 43 Prostate Normal prostate tissue Normal
E8 40 M 43 Prostate Normal prostate tissue Normal
F I 41 M 28 Prostate Normal prostate tissue Normal
F2 42 M 28 Prostate Normal prostate tissue (sparse) Normal
F3 43 M 47 Skin Normal skin tissue Normal
F4 44 M 47 Skin Normal skin tissue Normal
F5 45 M 40 Skin Normai skin tissue Normal
F6 46 M 40 Skin Normal skin tissue Normal
F7 47 M 19 Skin Normal skin tissue Normal
F8 48 M 19 Skin Normal skin tissue Normal
- - M 58 Skin Malignant melanoma (tissue marker) Malignant
Appendix 3.1 Specification sheet for normal human tissue array (Biomax, US)
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Appendix 3.2 Expression of EN2 in normal tissues
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Appendix 3.2 Expression of EN2 in normal tissues
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Appendix 3.2 Enzymatic staining of a range of different normal tissues for the 
expression of EN2. Paraffin-embedded normal tissue array was deparaffinised and 
rehydrated followed by a microwave heat-mediated antigen retrieval method. Slides were 
blocked and then incubated overnight with anti-EN2 primary antibody followed by 
incubation with ABC detection kit. Peroxidase activity was detected using DAB kit followed 
by counterstaining with Hematoxylin.
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TNM grading:
T - Primary tumour
Tx - Primary tumour cannot be assessed  
TO - No evidence of primary tumour
Tis - Carcinoma in situ; intraepithélial or invasion of lamina propria
T1 - Tumour invades submucosa
T2 - Tumour invades muscularis propria
T3 - Tumour invades through muscularis propria into subserosa or into non-peritonealized 
pericolic or perirectal tissues.
T4 - Tumour directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed  
NO - No regional lymph node metastasis 
N1 - Metastasis in 1 to 3 regional lymph nodes 
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed  
MO - No distant metastasis 
M1 - Distant metastasis
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Appendix 3.4 Expression of EN2 in melanoma
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Appendix 3.4 Enzymatic staining of melanoma tissue array for the expression of EN2.
Paraffin-embedded breast cancer tissue array was deparaffinised and rehydrated followed 
by a microwave heat-mediated antigen retrieval method. Slides were blocked and then 
incubated overnight with anti-EN2 primary antibody followed by incubation with ABC kit. 
Peroxidase activity was detected using DAB kit followed by counterstaining with 
Hematoxylin.
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Appendix 3.5 Enzymatic staining of melanoma biopsy sections for the expression of 
EN2. Paraffin-embedded melanoma biopsy sections were deparaffinised and rehydrated 
followed by a microwave heat-mediated antigen retrieval method. Slides were blocked and 
then incubated overnight with anti-EN2 primary antibody followed by incubation with ABC kit. 
Peroxidase activity was detected using DAB kit followed by counterstaining with Hematoxylin.
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Appendix 4.1 Specification sheet (normal human tissue)
A1 1 M 45 Adrenal gland* Normal Normal
A2 2 F 37 Adrenal gland* Normal Normal
A3 3 F 61 Adrenal gland* Normal Normal
A4 4 F 51 Bladder Normal Normal
A5 5 M 36 Bladder Normal Normal
A6 6 M 61 Bladder Normal Normal
A7 7 M 16 Bone m arrow* Normal Normal
A8 8 F 1 Eye* Normal Normal
A9 9 F 70 Eye* Normal Normal
AlO 10 F 34 Breast Normal Normal
A l l 11 F 43 Breast Normal Normal
A12 12 F 45 Breast Normal Normal
B1 13 M 46 Cerebellum* Normal Normal
B2 14 M 49 Cerebellum* Normal Normal
B3 15 M 3 Cerebellum* Normal Normal
B4 16 M 49 Cerebral cortex* Normal Normal
B5 17 F 5 Cerebral cortex* Normal Normal
B6 18 M 46 Cerebral cortex* Normal Normal
B7 19 F 45 Fallopian tube Normal Normal
B8 20 F 23 Fallopian tube Normal Normal
B9 21 F 48 Fallopian tube Normal Normal
BIO 22 M 62 GI-Esophagus Normal Normal
B l l 23 M 55 GI-Esophagus Normal Normal
B12 24 F 61 GI-Esophagus Normal Normal
C l 25 M 59 Gl-Stomach Normal Normal
C2 26 F 50 Gl-Stomach Normal Normal
C3 27 F 48 Gl-Stomach Normal Normal
C4 28 M 80 Gl-Sm all intestine Normal Normal
C5 29 M 17 Gl-Sm all intestine Normal Normal
C6 30 F 76 Gl-Sm all intestine Normal Normal
C7 31 F 69 Gl-Colon Normal Normal
C8 32 F 27 Gl-Colon Normal Normal
C9 33 M 34 Gl-Colon Normal Normal
CIO 34 M 53 GI-Rectum Normal Normal
C l l 35 M 68 G I-Rectum Normal Normal
C12 36 M 70 GI-Rectum Normal Normal
D1 37 M 46 H eart* Normal Normal
D2 38 F 5 H eart* Normal Normal
D3 39 M 65 H eart* Normal Normal
D4 40 F 51 Kidney Normal Normal
D5 41 M 39 Kidney Normal Normal
D6 42 M 30 Kidney Normal Normal
D7 43 F 51 Kidney Normal Normal
D8 44 M 39 Kidney Normal Normal
D9 45 M 30 Kidney Normal Normal
DIO 46 M 41 Liver Normal Normal
D l l 47 M 42 Liver Normal (cell swelling) Normal
D12 48 M 35 Liver Normal Normal
E l 49 M 19 Lung Normal Normal
E2 50 M 59 Lung Normal Normal
298
E3 51 M 72 Lung Normal Normal
E4 52 F 53 Ovary Normal Normal
E5 53 F 45 Ovary Normal Normal
E6 54 F 35 Ovary Normal Normal
E7 55 5 Pancreas* Normal Normal
E8 56 1 Pancreas* Normal Normal
E9 57 F 58 Pancreas* Normal Normal
ElO 58 62 Parathyroid Adenoma Normal
E ll 59 5 Pituitary gland* Normal Normal
E12 60 46 Pituitary gland* Normal Normal
FI 61 F 23 Placenta Normal Normal
F2 62 F 27 Placenta Normal Normal
F3 63 F 23 Placenta Normal Normal
F4 64 M 68 Prostate Normal Normal
F5 65 M 82 Prostate Normal Normal
F6 66 M 64 Prostate Normal Normal
F7 67 F 47 Skin Normal Normal
F8 68 M 50 Skin Normal Normal
F9 69 M 46 Spinal cord* Normal Normal
FIO 70 M 65 Spinal cord* Normal Normal
F l l 71 F 21 Spleen Normal Normal
F12 72 M 55 Spleen Normal Normal
G1 73 M 44 Striated muscle* Normal Normal
G2 74 M 46 Striated muscle* Normal Normal
G3 75 M 59 Striated muscle* Normal Normal
G4 76 M 77 Testis Normal Normal
G5 77 M 34 Testis Normal Normal
G6 78 M 30 Testis Normal Normal
G7 79 M 13 Thymus* Normal Normal
G8 80 F 2.5 Thymus* Normal Normal
G9 81 F 15 Thymus* Normal Normal
GIO 82 F 64 Thyroid Normal Normal
G ll 83 F 52 Thyroid Normal Normal
G12 84 F 39 Thyroid Normal Normal
- - Unknown Unknown tissue marker Unknown
HI 85 F 12 Tonsil Normal Normal
H2 86 M 6 Tonsil Normal Normal
H3 87 M 20 Tonsil Normal Normal
H4 88 F 51 Ureter Normal Normal
H5 89 M 56 Ureter Normal Normal
H6 90 F 56 Ureter Normal Normal
H7 91 F 48 Uterus-cervix Normal Normal
H8 92 F 48 Uterus-cervix Normal Normal
H9 93 F 51 Uterus-cervix Normal Normal
HIO 94 F 40 Uterus-endometrium Normal Normal
H ll 95 F 50 Uterus-endometrium Normal Normal
H12 96 F 49 Uterus-endometrium Normal Normal
- - Unknown Unknown tissue marker Unknown
Appendix 4.1 Specification sheet for normal human tissue array (Biomax, US)
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Appendix 4.2 Expression of HOXAl in normal tissues
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Appendix 4.2 Expression of HOXAl in normal tissues
HI2
Appendix 4.2 Enzymatic staining of a range of different normal tissues for the 
expression of H0XA1. Paraffin-embedded normal tissue array was deparaffinised and 
rehydrated followed by a microwave heat-mediated antigen retrieval method. Slides were 
blocked and incubated overnight with anti-H0XA1 primary antibody followed by incubation 
with ABC detection kit. Peroxidase activity was then detected using DAB kit followed by 
counterstaining with Hematoxylin.
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Appendix 4.4 Enzymatic staining of breast cancer tissue array for the expression of 
H0XA1. Paraffin-embedded breast cancer tissue array was deparaffinised and rehydrated 
followed by a microwave heat-mediated antigen retrieval method. Slides were blocked and 
incubated overnight with anti-H0XA1 primary antibody followed by incubation with ABC kit. 
Peroxidase activity was detected using DAB kit followed by counterstaining with 
Hematoxylin.
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Appendix 5.2 Enzymatic staining of ovarian cancer tissue array for the expression of 
H0XB13. Paraffin-embedded ovarian cancer tissue array was deparaffinised and 
rehydrated followed by a microwave heat-mediated antigen retrieval method. Slides were 
blocked and then incubated overnight with anti-H0XB13 primary antibody followed by 
incubation with ABC detection kit. Peroxidase activity was detected using DAB kit followed 
by counterstaining with Hematoxylin.
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